{"5bd66f28894ae0b63b146154df95f8f8ea3dcf33": [["IntroductionCOVID-19 (Corona Virus Disease-2019) has emerged as a pandemic factor that has infected more than 26.5 million people, 3.5 million being actively sick, since the first case appeared (1).IntroductionIt caused by Sars-Cov-2 (Severe Acute Respiratory Syndrome Coronavirus 2) virus.", [["Corona Virus Disease", "DISEASE", 22, 42], ["Acute Respiratory Syndrome Coronavirus 2) virus", "DISEASE", 242, 289], ["Corona Virus Disease-2019", "ORGANISM", 22, 47], ["people", "ORGANISM", 123, 129], ["Sars-Cov-2 (", "ORGANISM", 223, 235], ["Severe Acute Respiratory Syndrome Coronavirus", "ORGANISM", 235, 280], ["people", "SPECIES", 123, 129], ["Corona Virus Disease-2019", "SPECIES", 22, 47], ["Sars-Cov-2 (Severe Acute Respiratory Syndrome Coronavirus 2) virus", "SPECIES", 223, 289], ["IntroductionCOVID", "TEST", 0, 17], ["Corona Virus Disease", "PROBLEM", 22, 42], ["a pandemic factor", "PROBLEM", 64, 81], ["Sars-Cov", "TEST", 223, 231], ["Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 235, 280], ["virus", "PROBLEM", 284, 289], ["Severe", "OBSERVATION_MODIFIER", 235, 241], ["Acute", "OBSERVATION_MODIFIER", 242, 247], ["Respiratory Syndrome", "OBSERVATION", 248, 268]]], ["The fatality rate is highest in patients aged \u226565 years or those with certain comorbidities (2) (3) (4) .", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["highest", "OBSERVATION_MODIFIER", 21, 28]]], ["The population of patients with hypertension, chronic respiratory and cardiac diseases, diabetes mellitus, renal failure and malignancy are defined as the most severely affected group (5) .IntroductionIn the studies where the incubation period of the virus is performed, the median reaches from 4 days to 14 days.", [["respiratory", "ANATOMY", 54, 65], ["cardiac", "ANATOMY", 70, 77], ["renal", "ANATOMY", 107, 112], ["hypertension", "DISEASE", 32, 44], ["chronic respiratory and cardiac diseases", "DISEASE", 46, 86], ["diabetes mellitus", "DISEASE", 88, 105], ["renal failure", "DISEASE", 107, 120], ["malignancy", "DISEASE", 125, 135], ["patients", "ORGANISM", 18, 26], ["cardiac", "ORGAN", 70, 77], ["renal", "ORGAN", 107, 112], ["patients", "SPECIES", 18, 26], ["hypertension", "PROBLEM", 32, 44], ["chronic respiratory and cardiac diseases", "PROBLEM", 46, 86], ["diabetes mellitus", "PROBLEM", 88, 105], ["renal failure", "PROBLEM", 107, 120], ["malignancy", "PROBLEM", 125, 135], ["the studies", "TEST", 204, 215], ["the virus", "PROBLEM", 247, 256], ["hypertension", "OBSERVATION", 32, 44], ["chronic", "OBSERVATION_MODIFIER", 46, 53], ["respiratory", "ANATOMY", 54, 65], ["cardiac", "ANATOMY", 70, 77], ["diseases", "OBSERVATION", 78, 86], ["diabetes mellitus", "OBSERVATION", 88, 105], ["renal", "ANATOMY", 107, 112], ["failure", "OBSERVATION", 113, 120], ["malignancy", "OBSERVATION", 125, 135], ["most severely", "OBSERVATION_MODIFIER", 155, 168]]], ["Although there are clinical findings on a wide scale ranging from mild J o u r n a l P r e -p r o o f respiratory symptoms to severe respiratory failure, it is possible to say that severe cases are around 4-5% (7) (8) .", [["respiratory", "ANATOMY", 133, 144], ["respiratory symptoms", "DISEASE", 102, 122], ["respiratory failure", "DISEASE", 133, 152], ["a wide scale", "TEST", 40, 52], ["respiratory symptoms", "PROBLEM", 102, 122], ["severe respiratory failure", "PROBLEM", 126, 152], ["severe cases", "PROBLEM", 181, 193], ["severe", "OBSERVATION_MODIFIER", 126, 132], ["respiratory failure", "OBSERVATION", 133, 152], ["severe", "OBSERVATION_MODIFIER", 181, 187]]], ["It is evident that early diagnosis, treatment and optimal isolation of the patient and his/her environment are vital at the point of treatment due to the spread of the disease.", [["patient", "ORGANISM", 75, 82], ["patient", "SPECIES", 75, 82], ["treatment", "TREATMENT", 36, 45], ["treatment", "TREATMENT", 133, 142], ["the disease", "PROBLEM", 164, 175], ["early", "OBSERVATION_MODIFIER", 19, 24], ["disease", "OBSERVATION", 168, 175]]], ["In the literature, we see that there are many publications on the diagnosis of the disease.", [["the disease", "PROBLEM", 79, 90], ["many", "OBSERVATION_MODIFIER", 41, 45], ["publications", "OBSERVATION", 46, 58], ["disease", "OBSERVATION", 83, 90]]], ["The analysis of various samples based on real-time polymerase chain reaction (RT-PCR), which was used as the gold standard diagnostic method, cannot achieve sufficient speed and sensitivity in the diagnosis of the disease.", [["samples", "ANATOMY", 24, 31], ["The analysis", "TEST", 0, 12], ["various samples", "TEST", 16, 31], ["RT-PCR", "TEST", 78, 84], ["the disease", "PROBLEM", 210, 221], ["disease", "OBSERVATION", 214, 221]]], ["This, in particular, delays the isolation of patients and accelerates disease spread.", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["accelerates disease spread", "PROBLEM", 58, 84]]], ["There are differences in the sensitivity of the PCR samples studied with various samples.", [["samples", "ANATOMY", 81, 88], ["the PCR samples", "TEST", 44, 59], ["various samples", "TEST", 73, 88], ["differences", "OBSERVATION_MODIFIER", 10, 21]]], ["In the most recent study of Wenling Wang et al. (9) , the sensitivity order was as follows: Bronchoalveolar lavage 93%, throat culture 72%, nasal sample 63%, fibrobronchoscopic brush biopsy 46%, pharyngeal sample 32%, faeces 29%, blood% 1 and urine 0%.", [["Bronchoalveolar lavage", "ANATOMY", 92, 114], ["throat", "ANATOMY", 120, 126], ["nasal sample", "ANATOMY", 140, 152], ["brush", "ANATOMY", 177, 182], ["pharyngeal sample", "ANATOMY", 195, 212], ["blood", "ANATOMY", 230, 235], ["urine", "ANATOMY", 243, 248], ["brush biopsy", "MULTI-TISSUE_STRUCTURE", 177, 189], ["pharyngeal", "ORGAN", 195, 205], ["blood", "ORGANISM_SUBSTANCE", 230, 235], ["urine", "ORGANISM_SUBSTANCE", 243, 248], ["Bronchoalveolar lavage", "TEST", 92, 114], ["throat culture", "TEST", 120, 134], ["nasal sample", "TEST", 140, 152], ["fibrobronchoscopic brush biopsy", "TEST", 158, 189], ["pharyngeal sample", "TEST", 195, 212], ["faeces", "TEST", 218, 224], ["blood", "TEST", 230, 235], ["urine", "TEST", 243, 248], ["pharyngeal", "ANATOMY", 195, 205]]], ["Evaluation with bronchoalveolar lavage is quite difficult in emergency conditions and it does not seem possible due to the high risk of transmission.", [["bronchoalveolar lavage", "ANATOMY", 16, 38], ["Evaluation", "TEST", 0, 10], ["bronchoalveolar lavage", "TEST", 16, 38], ["bronchoalveolar lavage", "OBSERVATION", 16, 38]]], ["Therefore, negative results in potential cases lead to different opinions about the approach to patients.", [["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104]]], ["PCR comparison with diagnostic methods based on thorax computed tomography (CT) has also been studied in the literature and the sensitivity appears to be high in favor of CT.", [["thorax", "ORGAN", 48, 54], ["PCR", "TEST", 0, 3], ["diagnostic methods", "TEST", 20, 38], ["thorax computed tomography", "TEST", 48, 74], ["CT", "TEST", 76, 78], ["the sensitivity", "TEST", 124, 139], ["CT", "TEST", 171, 173], ["thorax", "ANATOMY", 48, 54], ["high", "OBSERVATION", 154, 158]]], ["(10) In our study, the data from 2217 patients who were admitted to the emergency room of our hospital between March 2020 and June 2020; diagnosed as COVID-19 and hospitalized or discharged with home isolation were retrospectively analyzed.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["our study", "TEST", 8, 17], ["home isolation", "TREATMENT", 195, 209]]], ["Clinical features, treatments, laboratory and imaging results and mortality data of this patient group were retrospectively examined.", [["patient", "ORGANISM", 89, 96], ["patient", "SPECIES", 89, 96], ["treatments", "TREATMENT", 19, 29], ["imaging", "TEST", 46, 53], ["mortality data", "TEST", 66, 80]]], ["Based on the hypothesis that it could present a new diagnostic method in terms of the early diagnosis and early isolation, it was aimed at providing early diagnosis for especially those patients with typical radiological involvement and clinical findings through the LactateIntroductionThe basis of our study and the starting point of our hypothesis is the other clinical studies based on LDH, which is an important indicator in the early diagnosis of pneumocystis carinii clinic-laboratory, which is an important factor of atypical pneumonia (11) (12) (13) .", [["pneumocystis carinii", "DISEASE", 452, 472], ["pneumonia", "DISEASE", 533, 542], ["patients", "ORGANISM", 186, 194], ["LDH", "GENE_OR_GENE_PRODUCT", 389, 392], ["pneumocystis carinii", "ORGANISM", 452, 472], ["patients", "SPECIES", 186, 194], ["pneumocystis carinii", "SPECIES", 452, 472], ["pneumocystis carinii", "SPECIES", 452, 472], ["typical radiological involvement", "PROBLEM", 200, 232], ["our study", "TEST", 299, 308], ["clinical studies", "TEST", 363, 379], ["LDH", "TEST", 389, 392], ["atypical pneumonia", "PROBLEM", 524, 542], ["new", "OBSERVATION_MODIFIER", 48, 51], ["pneumocystis carinii", "OBSERVATION", 452, 472], ["atypical", "OBSERVATION_MODIFIER", 524, 532], ["pneumonia", "OBSERVATION", 533, 542]]], ["Although LDH is an enzyme originating from many organs and systems, it increases significantly especially in patients with lung involvement.", [["organs", "ANATOMY", 48, 54], ["lung", "ANATOMY", 123, 127], ["LDH", "GENE_OR_GENE_PRODUCT", 9, 12], ["organs", "ORGAN", 48, 54], ["patients", "ORGANISM", 109, 117], ["lung", "ORGAN", 123, 127], ["LDH", "PROTEIN", 9, 12], ["patients", "SPECIES", 109, 117], ["LDH", "TEST", 9, 12], ["an enzyme", "TEST", 16, 25], ["lung involvement", "PROBLEM", 123, 139], ["lung", "ANATOMY", 123, 127], ["involvement", "OBSERVATION", 128, 139]]], ["In addition, we see that lymphopenia, which will occur secondary to viral infections, is also present in COVID-19 cases.", [["lymphopenia", "DISEASE", 25, 36], ["viral infections", "DISEASE", 68, 84], ["lymphopenia", "PROBLEM", 25, 36], ["viral infections", "PROBLEM", 68, 84], ["COVID", "TEST", 105, 110], ["lymphopenia", "OBSERVATION", 25, 36], ["viral", "OBSERVATION_MODIFIER", 68, 73], ["infections", "OBSERVATION", 74, 84]]], ["The study was conducted with J o u r n a l P r e -p r o o f the hypothesis that the combination of these laboratory values would yield a more sensitive result in early diagnosis.Material and MethodsOur study was conducted upon obtaining the approval from the local ethics committee and PCR swab results (first 3 results, positive or negative), initial CT results, initial leukocyte, neutrophil, lymphocyte, hemoglobin, platelet, urea, creatinine, D-Dimer, aspartate aminotransferase (AST), alanine transaminase (ALT), total protein, albumin, creatine kinase (CK), C-reactive protein (CRP), procalcitonin, LDH values, LDH / Lymphocyte ratio, initial treatments (hydroxychloroquine, azithromycin, oseltamivir, additional antibiotherapy, lopinavir/ritonavir, favipiravir usage), follow-up subtypes (inpatient or outpatient) and their last status (alive or exitus) were recorded.", [["leukocyte", "ANATOMY", 372, 381], ["neutrophil", "ANATOMY", 383, 393], ["lymphocyte", "ANATOMY", 395, 405], ["platelet", "ANATOMY", 419, 427], ["Lymphocyte", "ANATOMY", 623, 633], ["urea", "CHEMICAL", 429, 433], ["creatinine", "CHEMICAL", 435, 445], ["D-Dimer", "CHEMICAL", 447, 454], ["aspartate", "CHEMICAL", 456, 465], ["alanine", "CHEMICAL", 490, 497], ["creatine", "CHEMICAL", 542, 550], ["hydroxychloroquine", "CHEMICAL", 661, 679], ["azithromycin", "CHEMICAL", 681, 693], ["oseltamivir", "CHEMICAL", 695, 706], ["lopinavir/ritonavir", "CHEMICAL", 735, 754], ["favipiravir", "CHEMICAL", 756, 767], ["urea", "CHEMICAL", 429, 433], ["creatinine", "CHEMICAL", 435, 445], ["aspartate", "CHEMICAL", 456, 465], ["alanine", "CHEMICAL", 490, 497], ["creatine", "CHEMICAL", 542, 550], ["hydroxychloroquine", "CHEMICAL", 661, 679], ["azithromycin", "CHEMICAL", 681, 693], ["oseltamivir", "CHEMICAL", 695, 706], ["lopinavir", "CHEMICAL", 735, 744], ["ritonavir", "CHEMICAL", 745, 754], ["favipiravir", "CHEMICAL", 756, 767], ["leukocyte", "CELL", 372, 381], ["neutrophil", "CELL", 383, 393], ["lymphocyte", "CELL", 395, 405], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 407, 417], ["platelet", "CELL", 419, 427], ["urea", "SIMPLE_CHEMICAL", 429, 433], ["creatinine", "SIMPLE_CHEMICAL", 435, 445], ["D-Dimer", "SIMPLE_CHEMICAL", 447, 454], ["aspartate aminotransferase", "SIMPLE_CHEMICAL", 456, 482], ["AST", "SIMPLE_CHEMICAL", 484, 487], ["alanine transaminase", "GENE_OR_GENE_PRODUCT", 490, 510], ["ALT", "SIMPLE_CHEMICAL", 512, 515], ["albumin", "GENE_OR_GENE_PRODUCT", 533, 540], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 542, 557], ["CK", "GENE_OR_GENE_PRODUCT", 559, 561], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 564, 582], ["CRP", "GENE_OR_GENE_PRODUCT", 584, 587], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 590, 603], ["LDH", "SIMPLE_CHEMICAL", 605, 608], ["LDH", "SIMPLE_CHEMICAL", 617, 620], ["Lymphocyte", "CELL", 623, 633], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 661, 679], ["azithromycin", "SIMPLE_CHEMICAL", 681, 693], ["oseltamivir", "SIMPLE_CHEMICAL", 695, 706], ["lopinavir", "SIMPLE_CHEMICAL", 735, 744], ["ritonavir", "SIMPLE_CHEMICAL", 745, 754], ["favipiravir", "SIMPLE_CHEMICAL", 756, 767], ["leukocyte, neutrophil, lymphocyte, hemoglobin, platelet, urea, creatinine, D-Dimer", "PROTEIN", 372, 454], ["aspartate aminotransferase", "PROTEIN", 456, 482], ["AST", "PROTEIN", 484, 487], ["alanine transaminase", "PROTEIN", 490, 510], ["ALT", "PROTEIN", 512, 515], ["total protein", "PROTEIN", 518, 531], ["albumin", "PROTEIN", 533, 540], ["creatine kinase", "PROTEIN", 542, 557], ["CK", "PROTEIN", 559, 561], ["C-reactive protein", "PROTEIN", 564, 582], ["CRP", "PROTEIN", 584, 587], ["procalcitonin", "PROTEIN", 590, 603], ["LDH", "PROTEIN", 605, 608], ["LDH", "PROTEIN", 617, 620], ["The study", "TEST", 0, 9], ["the hypothesis", "PROBLEM", 60, 74], ["these laboratory values", "TEST", 99, 122], ["PCR swab", "TEST", 286, 294], ["initial CT", "TEST", 344, 354], ["initial leukocyte", "TEST", 364, 381], ["neutrophil", "TEST", 383, 393], ["lymphocyte", "TEST", 395, 405], ["hemoglobin", "TEST", 407, 417], ["platelet", "TEST", 419, 427], ["urea", "TEST", 429, 433], ["creatinine", "TEST", 435, 445], ["D-Dimer", "TEST", 447, 454], ["aspartate aminotransferase", "TEST", 456, 482], ["AST", "TEST", 484, 487], ["alanine transaminase", "TEST", 490, 510], ["ALT", "TEST", 512, 515], ["total protein", "TEST", 518, 531], ["albumin", "TEST", 533, 540], ["creatine kinase", "TEST", 542, 557], ["CK", "TEST", 559, 561], ["C-reactive protein", "TEST", 564, 582], ["CRP", "TEST", 584, 587], ["procalcitonin", "TEST", 590, 603], ["LDH values", "TEST", 605, 615], ["LDH", "TEST", 617, 620], ["Lymphocyte ratio", "TEST", 623, 639], ["initial treatments", "TREATMENT", 641, 659], ["hydroxychloroquine", "TREATMENT", 661, 679], ["azithromycin", "TREATMENT", 681, 693], ["oseltamivir", "TREATMENT", 695, 706], ["additional antibiotherapy", "TREATMENT", 708, 733], ["lopinavir", "TREATMENT", 735, 744], ["ritonavir", "TREATMENT", 745, 754], ["favipiravir usage", "TREATMENT", 756, 773], ["LDH", "ANATOMY", 617, 620], ["Lymphocyte", "ANATOMY", 623, 633]]], ["CT results were collected under three separate headings as no involvement, unilateral and bilateral involvement.", [["CT", "TEST", 0, 2], ["involvement", "PROBLEM", 62, 73], ["unilateral and bilateral involvement", "PROBLEM", 75, 111], ["no", "UNCERTAINTY", 59, 61], ["unilateral", "OBSERVATION_MODIFIER", 75, 85], ["bilateral", "ANATOMY_MODIFIER", 90, 99], ["involvement", "OBSERVATION", 100, 111]]], ["The relation of the patients' recorded data to individual survival was examined.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28]]], ["In addition, the diagnostic sensitivity of LDH / Lymphocyte ratio, which is the main purpose of the study, was analyzed statistically.", [["Lymphocyte", "ANATOMY", 49, 59], ["LDH", "GENE_OR_GENE_PRODUCT", 43, 46], ["Lymphocyte", "CELL", 49, 59], ["LDH", "PROTEIN", 43, 46], ["the diagnostic sensitivity", "TEST", 13, 39], ["LDH / Lymphocyte ratio", "TEST", 43, 65], ["the study", "TEST", 96, 105], ["Lymphocyte", "ANATOMY", 49, 59]]], ["LDH / Lymphocyte ratio was analyzed in terms of diagnosis and mortality with using specific CT involvement as the gold standard method which was found to be a more sensitive method due to PCR false negativity.Material and MethodsStatistical Analysis: The analysis of the data was carried out using SPSS 25 and Medcalc package programs.", [["Lymphocyte", "ANATOMY", 6, 16], ["LDH", "GENE_OR_GENE_PRODUCT", 0, 3], ["Lymphocyte", "CELL", 6, 16], ["LDH", "PROTEIN", 0, 3], ["LDH", "TEST", 0, 3], ["Lymphocyte ratio", "TEST", 6, 22], ["specific CT involvement", "TEST", 83, 106], ["the gold standard method", "TEST", 110, 134], ["PCR false negativity", "PROBLEM", 188, 208], ["the data", "TEST", 267, 275], ["SPSS", "TEST", 298, 302], ["Medcalc package programs", "TREATMENT", 310, 334], ["Lymphocyte ratio", "OBSERVATION", 6, 22]]], ["Descriptive statistics are presented by giving frequency and percentage tables for categorical variables and arithmetic mean, standard deviation, median, minimum and J o u r n a l P r e -p r o o f maximum values for quantitative variables.", [["categorical variables", "TEST", 83, 104], ["maximum values", "TEST", 197, 211]]], ["Chi-square test was used for comparisons between two categorical variables, and independent sample t-test was used for comparison of categorical variables and quantitative variables since the categorical variable contains two categories.", [["Chi-square test", "TEST", 0, 15], ["independent sample t-test", "TEST", 80, 105], ["categorical variables", "TEST", 133, 154]]], ["The logistic regression analysis was carried out by including the factors determined to have an impact on survival conditions as a result of binary comparisons.", [["The logistic regression analysis", "TEST", 0, 32], ["survival conditions", "TREATMENT", 106, 125]]], ["ROC analysis was applied to test the acceptability of LDH / Lymphocyte ratio as diagnostic test and to determine the predictive values in mortality.Up SubtypesThe data of 2217 patients in total were examined.", [["Lymphocyte", "ANATOMY", 60, 70], ["LDH", "GENE_OR_GENE_PRODUCT", 54, 57], ["Lymphocyte", "CELL", 60, 70], ["patients", "ORGANISM", 176, 184], ["LDH", "PROTEIN", 54, 57], ["patients", "SPECIES", 176, 184], ["ROC analysis", "TEST", 0, 12], ["LDH", "TEST", 54, 57], ["Lymphocyte ratio", "TEST", 60, 76], ["diagnostic test", "TEST", 80, 95], ["The data", "TEST", 159, 167]]], ["53% of the patients were male (n: 1175); 47% were female (n: 1042).", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19]]], ["The mean age was 47.66 \u00b1 17.23.", [["The mean age", "TEST", 0, 12]]], ["60.2% (n: 1334) of the them received inpatient treatment; 39.8% (n: 883) received outpatient treatment.", [["inpatient treatment", "TREATMENT", 37, 56], ["outpatient treatment", "TREATMENT", 82, 102]]], ["The mortality rate of the patients was determined as 3.1% (n: 68).", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["The mortality rate", "TEST", 0, 18]]], ["The most common comorbidity of the patients was hypertension with 20.6% (n: 456).", [["hypertension", "DISEASE", 48, 60], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["hypertension", "PROBLEM", 48, 60], ["hypertension", "OBSERVATION", 48, 60]]], ["Hypertension was followed by diabetes mellitus with 16.2% (n: 360).", [["Hypertension", "DISEASE", 0, 12], ["diabetes mellitus", "DISEASE", 29, 46], ["Hypertension", "PROBLEM", 0, 12], ["diabetes mellitus", "PROBLEM", 29, 46]]], ["The positivity rate of the 1st PCR results of the patients was 69.5% (n = 1541).", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["The positivity rate", "TEST", 0, 19], ["the 1st PCR", "TEST", 23, 34]]], ["PCR result is negative, but 2.", [["PCR", "TEST", 0, 3], ["negative", "OBSERVATION", 14, 22]]], ["PCR result positive patient rate was 4.74% (n = 105).Up SubtypesFirst two negative but the third positive was 1.17 (n = 38) of them.", [["patient", "ORGANISM", 20, 27], ["patient", "SPECIES", 20, 27], ["PCR", "TEST", 0, 3], ["patient rate", "TEST", 20, 32]]], ["9.61 % (n = 213) of patients have 3 negative PCR results.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28]]], ["Initially, typical COVID-19 involvement was detected with CT in 71.9% (n: 1594); while 1387 of them were bilateral; 207 of them were unilateral involvement.", [["COVID-19", "CANCER", 19, 27], ["CT", "TEST", 58, 60], ["unilateral involvement", "PROBLEM", 133, 155], ["bilateral", "ANATOMY_MODIFIER", 105, 114], ["unilateral", "OBSERVATION", 133, 143]]], ["(Table 1. )Drug Usage for COVID-19 TreatmentHydroxychloroquine was used in 82.3% of the patients (n: 1824); this was followed by azithromycin with 44.5% (n: 987).", [["COVID-19", "CHEMICAL", 26, 34], ["Hydroxychloroquine", "CHEMICAL", 44, 62], ["azithromycin", "CHEMICAL", 129, 141], ["COVID-19", "CHEMICAL", 26, 34], ["Hydroxychloroquine", "CHEMICAL", 44, 62], ["azithromycin", "CHEMICAL", 129, 141], ["COVID-19", "SIMPLE_CHEMICAL", 26, 34], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 44, 62], ["patients", "ORGANISM", 88, 96], ["azithromycin", "SIMPLE_CHEMICAL", 129, 141], ["patients", "SPECIES", 88, 96], ["COVID", "TREATMENT", 26, 31], ["Hydroxychloroquine", "TREATMENT", 44, 62], ["azithromycin", "TREATMENT", 129, 141]]], ["Additional antibiotherapy was needed in 14.6% of patients (n: 324).Drug Usage for COVID-19 Treatment2.7% (n: 60) of patients were receiving favipiravir ( Table 2. ).Laboratory ResultsMean absolute lymphocyte count was 1809.66 \u00b1 5146.25; mean LDH 268.56 \u00b1 140.39 and mean LDH / Lymphocyte ratio was 0.17 \u00b1 0.31.", [["lymphocyte", "ANATOMY", 197, 207], ["Lymphocyte", "ANATOMY", 277, 287], ["favipiravir", "CHEMICAL", 140, 151], ["favipiravir", "CHEMICAL", 140, 151], ["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 116, 124], ["favipiravir", "SIMPLE_CHEMICAL", 140, 151], ["lymphocyte", "CELL", 197, 207], ["LDH", "GENE_OR_GENE_PRODUCT", 242, 245], ["LDH", "GENE_OR_GENE_PRODUCT", 271, 274], ["Lymphocyte", "CELL", 277, 287], ["LDH", "PROTEIN", 242, 245], ["LDH", "PROTEIN", 271, 274], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 116, 124], ["Additional antibiotherapy", "TREATMENT", 0, 25], ["COVID", "TEST", 82, 87], ["favipiravir", "TREATMENT", 140, 151], ["Mean absolute lymphocyte count", "TEST", 183, 213], ["mean LDH", "TEST", 237, 245], ["mean LDH", "TEST", 266, 274], ["Lymphocyte ratio", "TEST", 277, 293], ["antibiotherapy", "OBSERVATION", 11, 25]]], ["(Table 3 .)Comorbidity and Drug Usage -Survival AnalysisCOPD, CHF, CAD, HT, DM, CKD and malignancy were found to have a significant statistical relationship with survival (p <0.001).", [["CHF", "DISEASE", 62, 65], ["CAD", "DISEASE", 67, 70], ["HT", "DISEASE", 72, 74], ["DM", "DISEASE", 76, 78], ["CKD", "DISEASE", 80, 83], ["malignancy", "DISEASE", 88, 98], ["Comorbidity", "PROBLEM", 11, 22], ["CHF", "PROBLEM", 62, 65], ["CAD", "PROBLEM", 67, 70], ["HT", "PROBLEM", 72, 74], ["DM", "PROBLEM", 76, 78], ["CKD", "PROBLEM", 80, 83], ["malignancy", "PROBLEM", 88, 98], ["CHF", "OBSERVATION", 62, 65], ["CAD", "OBSERVATION", 67, 70], ["CKD", "OBSERVATION", 80, 83], ["malignancy", "OBSERVATION", 88, 98], ["significant", "OBSERVATION_MODIFIER", 120, 131]]], ["Those with any comorbidity had high mortality than those without comorbidity (p <0.001).", [["any comorbidity", "PROBLEM", 11, 26], ["high mortality", "PROBLEM", 31, 45], ["comorbidity", "PROBLEM", 65, 76]]], ["When the relationship between drug usage and survival was examined, no statistically significant relationship was found for hydroxychloroquine and azithromycin (p = 0.616, p = 0.095).Comorbidity and Drug Usage -Survival AnalysisSignificantly more deaths were observed in patients using oseltamivir (p = 0.031), lopinavir / ritonavir (p = 0.022), supplemental antibiotherapy (p <0.001) and favipiravir (p <0.001).", [["hydroxychloroquine", "CHEMICAL", 124, 142], ["azithromycin", "CHEMICAL", 147, 159], ["deaths", "DISEASE", 247, 253], ["oseltamivir", "CHEMICAL", 286, 297], ["lopinavir / ritonavir", "CHEMICAL", 311, 332], ["favipiravir", "CHEMICAL", 389, 400], ["hydroxychloroquine", "CHEMICAL", 124, 142], ["azithromycin", "CHEMICAL", 147, 159], ["oseltamivir", "CHEMICAL", 286, 297], ["lopinavir", "CHEMICAL", 311, 320], ["ritonavir", "CHEMICAL", 323, 332], ["favipiravir", "CHEMICAL", 389, 400], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 124, 142], ["azithromycin", "SIMPLE_CHEMICAL", 147, 159], ["patients", "ORGANISM", 271, 279], ["oseltamivir", "SIMPLE_CHEMICAL", 286, 297], ["lopinavir", "SIMPLE_CHEMICAL", 311, 320], ["ritonavir", "SIMPLE_CHEMICAL", 323, 332], ["favipiravir", "SIMPLE_CHEMICAL", 389, 400], ["patients", "SPECIES", 271, 279], ["hydroxychloroquine", "TREATMENT", 124, 142], ["azithromycin", "TREATMENT", 147, 159], ["Comorbidity", "PROBLEM", 183, 194], ["oseltamivir", "TREATMENT", 286, 297], ["lopinavir", "TREATMENT", 311, 320], ["ritonavir", "TREATMENT", 323, 332], ["supplemental antibiotherapy", "TREATMENT", 346, 373], ["favipiravir", "TREATMENT", 389, 400]]], ["(Table 5 .)Follow Up Subtype, CT Findings, 1st PCR and Presence of Involvement in CT and Survival AnalysisWhen the effects of involvement subtypes on survival in CT are examined, it was revealed that patients with bilateral CT involvement showed significantly high mortality (p <0.001).", [["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 200, 208], ["CT Findings", "TEST", 30, 41], ["1st PCR", "TEST", 43, 50], ["CT", "TEST", 82, 84], ["Survival", "TREATMENT", 89, 97], ["CT", "TEST", 162, 164], ["bilateral CT involvement", "TEST", 214, 238], ["significantly high mortality", "PROBLEM", 246, 274], ["bilateral", "ANATOMY_MODIFIER", 214, 223], ["significantly", "OBSERVATION_MODIFIER", 246, 259], ["high", "OBSERVATION_MODIFIER", 260, 264]]], ["In patients with CT involvement, there was more statistically deaths than those without CT involvement (p = 0.014).", [["deaths", "DISEASE", 62, 68], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["CT involvement", "TEST", 17, 31], ["CT involvement", "TEST", 88, 102]]], ["(Table 6 .)Laboratory Results, LDH/Lymphocyte Ratio and Age and Survival AnalysisWhen the relationship between laboratory data and survival is examined, high LDH / lymphocyte ratio (p = 0.001), high leukocyte (p = 0.001), high neutrophil (p <0.001), low hemoglobin (p = 0.001), high LDH (p <0.001), high CRP (p < 0.001), high D-Dimer (p = 0.025), high urea (p <0.001), high AST (p = 0.003) and low albumin (p = 0.003) were found to have statistically significant high mortality.", [["lymphocyte", "ANATOMY", 164, 174], ["high leukocyte", "ANATOMY", 194, 208], ["neutrophil", "ANATOMY", 227, 237], ["urea", "CHEMICAL", 352, 356], ["urea", "CHEMICAL", 352, 356], ["Lymphocyte", "CELL", 35, 45], ["lymphocyte", "CELL", 164, 174], ["leukocyte", "CELL", 199, 208], ["neutrophil", "CELL", 227, 237], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 254, 264], ["LDH", "GENE_OR_GENE_PRODUCT", 283, 286], ["CRP", "GENE_OR_GENE_PRODUCT", 304, 307], ["D-Dimer", "SIMPLE_CHEMICAL", 326, 333], ["urea", "SIMPLE_CHEMICAL", 352, 356], ["AST", "SIMPLE_CHEMICAL", 374, 377], ["albumin", "GENE_OR_GENE_PRODUCT", 398, 405], ["LDH", "PROTEIN", 31, 34], ["LDH", "PROTEIN", 158, 161], ["neutrophil", "CELL_TYPE", 227, 237], ["hemoglobin", "PROTEIN", 254, 264], ["LDH", "PROTEIN", 283, 286], ["CRP", "PROTEIN", 304, 307], ["AST", "PROTEIN", 374, 377], ["LDH", "TEST", 31, 34], ["Lymphocyte Ratio", "TEST", 35, 51], ["laboratory data", "TEST", 111, 126], ["survival", "TEST", 131, 139], ["high LDH / lymphocyte ratio", "PROBLEM", 153, 180], ["p", "TEST", 182, 183], ["high leukocyte", "PROBLEM", 194, 208], ["high neutrophil", "PROBLEM", 222, 237], ["low hemoglobin", "PROBLEM", 250, 264], ["high LDH", "PROBLEM", 278, 286], ["high CRP", "PROBLEM", 299, 307], ["high D-Dimer", "PROBLEM", 321, 333], ["high urea", "PROBLEM", 347, 356], ["high AST", "PROBLEM", 369, 377], ["low albumin", "PROBLEM", 394, 405], ["statistically significant high mortality", "PROBLEM", 437, 477], ["high leukocyte", "ANATOMY", 194, 208], ["significant", "OBSERVATION_MODIFIER", 451, 462], ["high mortality", "OBSERVATION", 463, 477]]], ["(Table 7 .)Logistic Regression Analysis of DatasThe p values for step, block and model were less than 0.001 and p = 0.718 at the end of the Hosmer and Lemeshow test.", [["The p values", "TEST", 48, 60], ["step, block and model", "TEST", 65, 86], ["p", "TEST", 112, 113], ["Lemeshow test", "TEST", 151, 164]]], ["The model was found to be feasible and analyses continued.", [["analyses", "TEST", 39, 47]]], ["As a result of logistic regression analysis; 1 unit increase in age was found to increase the mortality risk by 1.034 times, while 1 unit increase in CRP was found to increase the risk 1.007 times.Logistic Regression Analysis of Datas( J o u r n a l P r e -p r o o fROC Analysis: LDH/Lymphocyte Ratio for Diagnosis and SurvivalIn order to test the usability of the LDH / Lymphocyte ratio in diagnosis for COVID-19 disease, individuals who showed unilateral and bilateral specific CT involvement were considered positive due to less false negativity of CT compared to PCR and evaluations were performed by accepting the CT results as a gold standard.", [["Lymphocyte", "ANATOMY", 371, 381], ["CRP", "GENE_OR_GENE_PRODUCT", 150, 153], ["LDH", "GENE_OR_GENE_PRODUCT", 365, 368], ["Lymphocyte", "CELL", 371, 381], ["individuals", "ORGANISM", 423, 434], ["CRP", "PROTEIN", 150, 153], ["LDH", "PROTEIN", 280, 283], ["LDH", "PROTEIN", 365, 368], ["logistic regression analysis", "TEST", 15, 43], ["CRP", "TEST", 150, 153], ["Logistic Regression", "TEST", 197, 216], ["Datas", "TEST", 229, 234], ["a l P r e -p r o o fROC Analysis", "TEST", 246, 278], ["LDH", "TEST", 280, 283], ["Lymphocyte Ratio", "TEST", 284, 300], ["the LDH", "TEST", 361, 368], ["Lymphocyte ratio", "TEST", 371, 387], ["COVID-19 disease", "PROBLEM", 405, 421], ["unilateral", "PROBLEM", 446, 456], ["bilateral specific CT involvement", "PROBLEM", 461, 494], ["CT", "TEST", 552, 554], ["PCR", "TEST", 567, 570], ["evaluations", "TEST", 575, 586], ["the CT", "TEST", 615, 621], ["LDH", "ANATOMY", 280, 283], ["LDH", "ANATOMY", 365, 368], ["Lymphocyte", "ANATOMY", 371, 381], ["bilateral", "ANATOMY_MODIFIER", 461, 470]]], ["As a result of ROC analysis; the area under the curve (AUC) was found to be 0.706 (p <0.001; cut-off> 0.06) and it was concluded that the LDH / Lymphocyte ratio was diagnostic for COVID-19.", [["Lymphocyte", "ANATOMY", 144, 154], ["LDH", "GENE_OR_GENE_PRODUCT", 138, 141], ["Lymphocyte", "CELL", 144, 154], ["LDH", "PROTEIN", 138, 141], ["ROC analysis", "TEST", 15, 27], ["the curve", "TEST", 44, 53], ["AUC", "TEST", 55, 58], ["cut-off", "TEST", 93, 100], ["the LDH / Lymphocyte ratio", "TEST", 134, 160], ["COVID", "TEST", 180, 185], ["Lymphocyte", "ANATOMY", 144, 154]]], ["The sensitivity at the cut-off point is 76.4 and specificity is 59.60.", [["The sensitivity", "TEST", 0, 15], ["specificity", "TEST", 49, 60]]], ["ROC analysis was performed to evaluate the LDH / Lymphocyte ratio in terms of survival conditions and the area under the curve (AUC) was found to be 0.749 (p <0.001; cut-off> 0.21).ROC Analysis: LDH/Lymphocyte Ratio for Diagnosis and SurvivalThe sensitivity at cut-off point is 70.59 and specificity is 73.88.", [["Lymphocyte", "ANATOMY", 49, 59], ["Lymphocyte", "ANATOMY", 199, 209], ["Lymphocyte", "CELL", 49, 59], ["Lymphocyte", "CELL", 199, 209], ["LDH", "PROTEIN", 43, 46], ["LDH", "PROTEIN", 195, 198], ["ROC analysis", "TEST", 0, 12], ["the LDH", "TEST", 39, 46], ["Lymphocyte ratio", "TEST", 49, 65], ["survival conditions", "TREATMENT", 78, 97], ["the curve", "TEST", 117, 126], ["AUC", "TEST", 128, 131], ["cut", "TEST", 166, 169], ["ROC Analysis", "TEST", 181, 193], ["LDH", "TEST", 195, 198], ["Lymphocyte Ratio", "TEST", 199, 215], ["Survival", "TEST", 234, 242], ["The sensitivity", "TEST", 242, 257], ["specificity", "TEST", 288, 299], ["LDH", "ANATOMY", 43, 46], ["Lymphocyte", "ANATOMY", 49, 59], ["Lymphocyte", "ANATOMY", 199, 209]]], ["(Table 10 .)DiscussionOur study contains 3-months data of COVID-19 and has single center homogenization.", [["COVID-19", "CHEMICAL", 58, 66], ["DiscussionOur study", "TEST", 12, 31], ["COVID", "TEST", 58, 63]]], ["It is clear that it will make a significant contribution to the literature not only in terms of revealing the data or determining the survival relationship, but also in terms of the new alternative it offers at the point of diagnosis.DiscussionIt is possible to say that most of the patients who applied for emergency services were isolated by hospitalization.", [["patients", "ORGANISM", 283, 291], ["patients", "SPECIES", 283, 291], ["emergency services", "TREATMENT", 308, 326], ["clear", "OBSERVATION", 6, 11]]], ["This not only provided an advantage in terms of isolation, but also facilitated clinical follow-up and data transfer.", [["isolation", "TREATMENT", 48, 57]]], ["All deaths were among inpatients.", [["deaths", "DISEASE", 4, 10]]], ["Our hospital's mortality rate was 3.1% with 68 patients, which is in line with the literature data.DiscussionThe positive rate of PCR result was 69.5%.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["mortality rate", "TEST", 15, 29], ["PCR", "TEST", 130, 133]]], ["It should be emphasized that all PCR negative cases have CT involvement.", [["all PCR", "TEST", 29, 36], ["CT involvement", "TEST", 57, 71]]], ["This is in line with the discussions carried out in the literature before.J o u r n a l P r e -p r o o fSignificant statistical relationship between LDH / Lymphocyte ratio and survival, which form the basis of our study, has been shown.", [["Lymphocyte", "CELL", 155, 165], ["LDH / Lymphocyte ratio", "TEST", 149, 171], ["our study", "TEST", 210, 219], ["line", "OBSERVATION_MODIFIER", 11, 15], ["LDH", "ANATOMY", 149, 152], ["Lymphocyte", "ANATOMY", 155, 165]]], ["In order to test the usability of the LDH / Lymphocyte ratio in diagnosis for COVID-19, the patients with unilateral and bilateral specific CT involvement were considered positive due to less false negativity than PCR and the evaluations were performed by accepting the CT results as the gold standard.", [["Lymphocyte", "ANATOMY", 44, 54], ["LDH", "GENE_OR_GENE_PRODUCT", 38, 41], ["Lymphocyte", "CELL", 44, 54], ["patients", "ORGANISM", 92, 100], ["LDH", "PROTEIN", 38, 41], ["patients", "SPECIES", 92, 100], ["the LDH / Lymphocyte ratio", "TEST", 34, 60], ["COVID", "TEST", 78, 83], ["unilateral and bilateral specific CT involvement", "PROBLEM", 106, 154], ["less false negativity than PCR", "PROBLEM", 187, 217], ["the evaluations", "TEST", 222, 237], ["the CT", "TEST", 266, 272], ["LDH", "ANATOMY", 38, 41], ["Lymphocyte", "ANATOMY", 44, 54], ["bilateral", "ANATOMY_MODIFIER", 121, 130]]], ["As a result of ROC analysis; the area under the curve (AUC) was found to be 0.706 (p <0.001; cut-off> 0.06) and it was concluded that the LDH / Lymphocyte ratio was diagnostic for COVID-19.", [["Lymphocyte", "ANATOMY", 144, 154], ["LDH", "GENE_OR_GENE_PRODUCT", 138, 141], ["Lymphocyte", "CELL", 144, 154], ["LDH", "PROTEIN", 138, 141], ["ROC analysis", "TEST", 15, 27], ["the curve", "TEST", 44, 53], ["AUC", "TEST", 55, 58], ["cut-off", "TEST", 93, 100], ["the LDH / Lymphocyte ratio", "TEST", 134, 160], ["COVID", "TEST", 180, 185], ["Lymphocyte", "ANATOMY", 144, 154]]], ["The sensitivity at cut-off point is 76.4 and specificity is 59.60.", [["The sensitivity", "TEST", 0, 15], ["specificity", "TEST", 45, 56]]], ["ROC analysis was performed to evaluate the LDH / Lymphocyte ratio for survival and the area under the curve (AUC) was found to be 0.749 (p <0.001; cut-off> 0.21).", [["Lymphocyte", "ANATOMY", 49, 59], ["Lymphocyte", "CELL", 49, 59], ["LDH", "PROTEIN", 43, 46], ["ROC analysis", "TEST", 0, 12], ["the LDH", "TEST", 39, 46], ["Lymphocyte ratio", "TEST", 49, 65], ["the curve", "TEST", 98, 107], ["AUC", "TEST", 109, 112], ["cut", "TEST", 147, 150], ["LDH", "ANATOMY", 43, 46], ["Lymphocyte", "ANATOMY", 49, 59]]], ["The sensitivity at cut-off point is 70.59 and specificity is 73.88.", [["The sensitivity", "TEST", 0, 15], ["specificity", "TEST", 46, 57]]], ["Our LDH/Lymphocyte ratio is usable in terms of mortality and putting cut-off in terms of diagnosis and mortality, they have been a big contribution of our study to the literature.", [["Lymphocyte", "ANATOMY", 8, 18], ["LDH", "GENE_OR_GENE_PRODUCT", 4, 7], ["Lymphocyte", "CELL", 8, 18], ["LDH", "PROTEIN", 4, 7], ["Our LDH/Lymphocyte ratio", "TEST", 0, 24], ["our study", "TEST", 151, 160], ["Lymphocyte ratio", "OBSERVATION", 8, 24]]], ["Our ratio is very impressive in early diagnosis and mortality prediction due to its easy application, especially since COVID-19 has no specific treatment yet and the importance of early isolation is unquestionable.J o u r n a l P r e -p r o o fThe most frequently used treatment is hydroxychloroquine, which is an expected finding.", [["COVID-19", "CHEMICAL", 119, 127], ["hydroxychloroquine", "CHEMICAL", 282, 300], ["hydroxychloroquine", "CHEMICAL", 282, 300], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 282, 300], ["Our ratio", "TEST", 0, 9], ["COVID", "TEST", 119, 124], ["specific treatment", "TREATMENT", 135, 153], ["treatment", "TREATMENT", 269, 278], ["hydroxychloroquine", "TREATMENT", 282, 300], ["very", "OBSERVATION_MODIFIER", 13, 17], ["impressive", "OBSERVATION_MODIFIER", 18, 28]]], ["At this point, when examining the use of favipiravir specifically; we see that it was used for 2.7% of patients.", [["favipiravir", "CHEMICAL", 41, 52], ["favipiravir", "CHEMICAL", 41, 52], ["favipiravir", "SIMPLE_CHEMICAL", 41, 52], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["favipiravir", "TREATMENT", 41, 52]]], ["Due to the rapid increase in case numbers all around the world and the limited and contradictory data from the initial cases, the permission to use favipiravir is subjected to the regulations of Ministry of Health.", [["favipiravir", "CHEMICAL", 148, 159], ["favipiravir", "CHEMICAL", 148, 159], ["favipiravir", "SIMPLE_CHEMICAL", 148, 159], ["the rapid increase in case numbers", "PROBLEM", 7, 41], ["favipiravir", "TREATMENT", 148, 159], ["rapid", "OBSERVATION_MODIFIER", 11, 16], ["increase", "OBSERVATION_MODIFIER", 17, 25]]], ["With the increasing experience in dealing with cases, its scope of usage has broadened.", [["increasing", "OBSERVATION_MODIFIER", 9, 19]]], ["While it was initially only being used in the intensive care unit, lately its application has been extended to other patients.J o u r n a l P r e -p r o o fLooking at the survival data; in parallel with the literature, the relationship between comorbidities such as COPD, HT, DM, CHF, CAD and presence of malignancy and survival has been revealed.", [["COPD", "DISEASE", 266, 270], ["HT", "DISEASE", 272, 274], ["DM", "DISEASE", 276, 278], ["CHF", "DISEASE", 280, 283], ["CAD", "DISEASE", 285, 288], ["malignancy", "DISEASE", 305, 315], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["fLooking", "PROBLEM", 155, 163], ["COPD", "PROBLEM", 266, 270], ["HT", "PROBLEM", 272, 274], ["DM", "PROBLEM", 276, 278], ["CHF", "PROBLEM", 280, 283], ["CAD", "PROBLEM", 285, 288], ["malignancy", "PROBLEM", 305, 315], ["COPD", "OBSERVATION", 266, 270], ["CHF", "OBSERVATION", 280, 283], ["malignancy", "OBSERVATION", 305, 315]]], ["Similarly, statistical significance between any presence of comorbidity and no comorbidity was also shown in our study (16) (17) (18) (19) (20) .", [["comorbidity", "PROBLEM", 60, 71], ["comorbidity", "PROBLEM", 79, 90], ["our study", "TEST", 109, 118], ["comorbidity", "OBSERVATION", 60, 71], ["no", "UNCERTAINTY", 76, 78]]], ["In the data between drug usage and survival, there was no significant relationship between hydroxychloroquine and azithromycin and sur- When it is examined in terms of CT involvement and survival, new data were obtained.", [["hydroxychloroquine", "CHEMICAL", 91, 109], ["azithromycin", "CHEMICAL", 114, 126], ["hydroxychloroquine", "CHEMICAL", 91, 109], ["azithromycin", "CHEMICAL", 114, 126], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 91, 109], ["azithromycin", "SIMPLE_CHEMICAL", 114, 126], ["hydroxychloroquine", "TREATMENT", 91, 109], ["azithromycin", "TREATMENT", 114, 126], ["CT involvement", "TEST", 168, 182], ["new data", "TEST", 197, 205]]], ["Especially it is important to find a significant relationship between bilateral involvement and survival.", [["bilateral", "ANATOMY_MODIFIER", 70, 79], ["involvement", "OBSERVATION", 80, 91]]], ["It should be said that it can be used more easily than the specific findings described in the previous literature data especially regarding the pandemic patient density (25).", [["patient", "ORGANISM", 153, 160], ["patient", "SPECIES", 153, 160], ["the previous literature data", "TEST", 90, 118]]], ["It should be noted that the relationship between laboratory data and survival is parallel to the literature.", [["laboratory data", "TEST", 49, 64]]], ["As a result of logistic regression analysis; 1 unit increase in age was found to increase the mortality risk by 1.034 times, while 1 unit increase in CRP was found to increase the risk 1.007 times.", [["CRP", "GENE_OR_GENE_PRODUCT", 150, 153], ["CRP", "PROTEIN", 150, 153], ["logistic regression analysis", "TEST", 15, 43], ["CRP", "TEST", 150, 153]]], ["These findings seem to be a potentially original contribution to the existing literature.", [["seem to be", "UNCERTAINTY", 15, 25]]], ["(26, 27)LimitationsOur study has some limitations.", [["Our study", "TEST", 19, 28]]], ["The potential relationship between the LDH/Lymphocyte ratio and other infectious diseases is unknown.", [["Lymphocyte", "ANATOMY", 43, 53], ["infectious diseases", "DISEASE", 70, 89], ["LDH", "GENE_OR_GENE_PRODUCT", 39, 42], ["Lymphocyte", "CELL", 43, 53], ["LDH", "PROTEIN", 39, 42], ["the LDH/Lymphocyte ratio", "TEST", 35, 59], ["other infectious diseases", "PROBLEM", 64, 89], ["LDH", "ANATOMY", 39, 42], ["Lymphocyte", "ANATOMY", 43, 53], ["infectious", "OBSERVATION", 70, 80]]], ["For this reason, the relationship between this ratio and mixed infection or other viral pneumonias can lead to confusion as it is not clear.", [["infection", "DISEASE", 63, 72], ["pneumonias", "DISEASE", 88, 98], ["confusion", "DISEASE", 111, 120], ["this ratio", "PROBLEM", 42, 52], ["mixed infection", "PROBLEM", 57, 72], ["other viral pneumonias", "PROBLEM", 76, 98], ["confusion", "PROBLEM", 111, 120], ["mixed", "OBSERVATION_MODIFIER", 57, 62], ["infection", "OBSERVATION", 63, 72], ["viral", "OBSERVATION_MODIFIER", 82, 87], ["pneumonias", "OBSERVATION", 88, 98], ["clear", "OBSERVATION", 134, 139]]], ["Another important limitation point is that new treatment options were not available for the patients included in the study and they were included in the study mostly at the beginning of the pandemic.", [["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["new treatment options", "TREATMENT", 43, 64], ["the study", "TEST", 113, 122], ["the study", "TEST", 149, 158], ["new", "OBSERVATION_MODIFIER", 43, 46]]], ["Therefore, it should be noted that our current treatment approach and guidelines are different.ConclusionAs a result, in our study, we revealed a single center data and examined the LDH / Lymphocyte ratio.", [["Lymphocyte", "ANATOMY", 188, 198], ["LDH", "GENE_OR_GENE_PRODUCT", 182, 185], ["Lymphocyte", "CELL", 188, 198], ["LDH", "PROTEIN", 182, 185], ["our current treatment approach", "TREATMENT", 35, 65], ["our study", "TEST", 121, 130], ["the LDH / Lymphocyte ratio", "TEST", 178, 204], ["LDH", "ANATOMY", 182, 185], ["Lymphocyte", "ANATOMY", 188, 198]]], ["LDH / Lymphocyte ratio was analyzed in terms of diagnosis and mortality with using specific CT involvement as the gold standard method which was found to be a more sensitive method due to PCR false negativity; 0.06 and 0.21 were obtained as cut off values for diagnosis and mortality.Ethics StatementThe study protocol has been approved by Istanbul Training and Research Hospital Ethics Committee and Ministry of Health.", [["Lymphocyte", "ANATOMY", 6, 16], ["LDH", "GENE_OR_GENE_PRODUCT", 0, 3], ["Lymphocyte", "CELL", 6, 16], ["LDH", "PROTEIN", 0, 3], ["LDH", "TEST", 0, 3], ["Lymphocyte ratio", "TEST", 6, 22], ["specific CT involvement", "TEST", 83, 106], ["PCR false negativity", "PROBLEM", 188, 208], ["mortality", "PROBLEM", 274, 283], ["Lymphocyte ratio", "OBSERVATION", 6, 22]]], ["None of the authors have disclosures relevant to this manuscript.Conflict Of InterestNone to declare.Author ContributionsAll authors contributed to the collection of patients data.", [["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["patients data", "TEST", 166, 179]]], ["IS wrote the manuscript and made tables.Data AvailabilityThe authors declare that data supporting the findings of this study are available within the article.", [["this study", "TEST", 114, 124]]]], "PMC7538147": [["Introduction: Early DaysThe field of cell signaling and signal transduction dates back to the late 19th century.", [["cell", "ANATOMY", 37, 41], ["cell", "CELL", 37, 41]]], ["In 1895, epinephrine (adrenaline) was discovered.1 By the 1920s, insulin and glucagon had been discovered.2, 3 Collectively, these discoveries paved the way for researchers to explore how these hormones acted to regulate glucose metabolism in the liver and skeletal muscle.", [["liver", "ANATOMY", 247, 252], ["skeletal muscle", "ANATOMY", 257, 272], ["epinephrine", "CHEMICAL", 9, 20], ["adrenaline", "CHEMICAL", 22, 32], ["glucagon", "CHEMICAL", 77, 85], ["glucose", "CHEMICAL", 221, 228], ["epinephrine", "CHEMICAL", 9, 20], ["adrenaline", "CHEMICAL", 22, 32], ["glucose", "CHEMICAL", 221, 228], ["epinephrine", "SIMPLE_CHEMICAL", 9, 20], ["adrenaline", "SIMPLE_CHEMICAL", 22, 32], ["insulin", "GENE_OR_GENE_PRODUCT", 65, 72], ["glucagon", "GENE_OR_GENE_PRODUCT", 77, 85], ["glucose", "SIMPLE_CHEMICAL", 221, 228], ["liver", "ORGAN", 247, 252], ["skeletal muscle", "TISSUE", 257, 272], ["insulin", "PROTEIN", 65, 72], ["epinephrine (adrenaline", "TREATMENT", 9, 32], ["insulin", "TREATMENT", 65, 72], ["glucagon", "TREATMENT", 77, 85], ["glucose metabolism", "TEST", 221, 239], ["glucose metabolism", "OBSERVATION", 221, 239], ["liver", "ANATOMY", 247, 252], ["skeletal muscle", "ANATOMY", 257, 272]]], ["The laboratory of Dr. Carl Cori played a seminal role in partially unravelling how glycogen could be broken down by glycogen phosphorylase.4 He, his wife Gerty and Bernardo Houssay received the 1947 Nobel Prize in Physiology or Medicine for their work.", [["glycogen", "CHEMICAL", 83, 91], ["glycogen", "CHEMICAL", 116, 124], ["glycogen", "SIMPLE_CHEMICAL", 83, 91], ["glycogen phosphorylase", "GENE_OR_GENE_PRODUCT", 116, 138], ["glycogen phosphorylase", "PROTEIN", 116, 138], ["glycogen phosphorylase", "TEST", 116, 138]]], ["Although the Cori laboratory had discovered and described glycogen phosphorylase, it was not until 1959 that Leloir discovered the enzyme that made glycogen, glycogen synthase.5 During the 1950s, Fischer, Krebs and Sutherland not only discovered and characterized the kinase which regulated glycogen phosphorylase, phosphorylase kinase, but defined for the first time that the phosphorylation of proteins could regulate enzyme activity.6, 7, 8, 9", [["glycogen", "CHEMICAL", 58, 66], ["glycogen", "CHEMICAL", 148, 156], ["glycogen", "CHEMICAL", 158, 166], ["glycogen", "CHEMICAL", 291, 299], ["glycogen phosphorylase", "GENE_OR_GENE_PRODUCT", 58, 80], ["glycogen", "SIMPLE_CHEMICAL", 148, 156], ["glycogen synthase", "GENE_OR_GENE_PRODUCT", 158, 175], ["glycogen phosphorylase", "GENE_OR_GENE_PRODUCT", 291, 313], ["phosphorylase kinase", "GENE_OR_GENE_PRODUCT", 315, 335], ["glycogen phosphorylase", "PROTEIN", 58, 80], ["glycogen synthase", "PROTEIN", 158, 175], ["kinase", "PROTEIN", 268, 274], ["glycogen phosphorylase", "PROTEIN", 291, 313], ["phosphorylase kinase", "PROTEIN", 315, 335], ["the Cori laboratory", "TEST", 9, 28], ["glycogen phosphorylase", "PROBLEM", 58, 80], ["the enzyme", "TEST", 127, 137], ["glycogen, glycogen synthase", "TREATMENT", 148, 175], ["glycogen phosphorylase", "TEST", 291, 313], ["phosphorylase kinase", "TEST", 315, 335], ["the phosphorylation of proteins", "PROBLEM", 373, 404]]]], "19e599ccdaa9e8a034d3126d78e7f18d519a5d3a": [["The schedules provided in this appendix are guidelines for immunization of dogs and cats against major viral and bacterial agents.", [["appendix", "ORGAN", 31, 39], ["dogs", "ORGANISM", 75, 79], ["cats", "ORGANISM", 84, 88], ["dogs", "SPECIES", 75, 79], ["cats", "SPECIES", 84, 88], ["immunization of dogs", "TREATMENT", 59, 79], ["cats", "TREATMENT", 84, 88], ["major viral and bacterial agents", "TREATMENT", 97, 129], ["bacterial agents", "OBSERVATION", 113, 129]]], ["These assume the availability of (1) client resources and (2) suitable products for immunization.", [["suitable products", "TREATMENT", 62, 79], ["immunization", "TREATMENT", 84, 96]]], ["The schedules are based on guidelines written by the WSAVA, AAHA, AAFP, and ABCD 1-11 and on information available at the time of writing.", [["ABCD", "TEST", 76, 80]]], ["These are general guidelines, because the vaccine types recommended and the frequency of immunization vary depending on the lifestyle of the pet being immunized-that is, indoor versus outdoor pets, shelter animals, travel plans, kennel/boarding plans, and underlying disease conditions such as immune-mediated diseases or preexisting infections such as FIV infection.", [["infections", "DISEASE", 334, 344], ["FIV infection", "DISEASE", 353, 366], ["FIV", "ORGANISM", 353, 356], ["FIV", "SPECIES", 353, 356], ["the vaccine types", "TREATMENT", 38, 55], ["immunization", "TREATMENT", 89, 101], ["underlying disease conditions", "PROBLEM", 256, 285], ["immune-mediated diseases", "PROBLEM", 294, 318], ["preexisting infections", "PROBLEM", 322, 344], ["FIV infection", "PROBLEM", 353, 366], ["disease", "OBSERVATION", 267, 274], ["infections", "OBSERVATION", 334, 344], ["FIV", "OBSERVATION_MODIFIER", 353, 356], ["infection", "OBSERVATION", 357, 366]]], ["Because these factors may change over time, the vaccination plan for individual pet animals should be decided by the owner at routine annual examinations, after a discussion between the veterinarian and the client regarding the animal's lifestyle in the year ahead and the advantages and disadvantages of vaccination.", [["the vaccination plan", "TREATMENT", 44, 64], ["individual pet animals", "TREATMENT", 69, 91], ["routine annual examinations", "TEST", 126, 153], ["vaccination", "TREATMENT", 305, 316]]], ["A previous history of vaccine reactions in an individual pet will also affect recommendations for immunization.", [["vaccine reactions", "PROBLEM", 22, 39], ["immunization", "TREATMENT", 98, 110]]], ["Considerable research is still required to generate optimal recommendations for vaccination of dogs and cats.Guidelines for Vaccination of Individual Pet Dogs and CatsGuidelines for vaccination of individual pet dogs and cats are summarized in Tables A-1 and A-2, respectively.", [["dogs", "ORGANISM", 95, 99], ["cats", "ORGANISM", 104, 108], ["dogs", "ORGANISM", 212, 216], ["cats", "ORGANISM", 221, 225], ["A-2", "CELL", 259, 262], ["dogs", "SPECIES", 95, 99], ["cats", "SPECIES", 104, 108], ["dogs", "SPECIES", 212, 216], ["cats", "SPECIES", 221, 225], ["vaccination of dogs", "TREATMENT", 80, 99], ["Vaccination", "TREATMENT", 124, 135], ["Individual Pet Dogs", "TREATMENT", 139, 158], ["CatsGuidelines", "TREATMENT", 163, 177], ["vaccination", "TREATMENT", 182, 193], ["individual pet dogs", "TREATMENT", 197, 216]]], ["Noncore. * Only for FeLV-negative cats.Vaccination Schedules for Dogs and Cats A P P E N D I XFeLV testing before administration mandatory before first administering the vaccine to kittens and if exposure was likely before, booster immunization is required.", [["FeLV", "ORGANISM", 20, 24], ["cats", "ORGANISM", 34, 38], ["kittens", "ORGANISM", 181, 188], ["cats", "SPECIES", 34, 38], ["FeLV", "TEST", 20, 24], ["Vaccination Schedules", "TREATMENT", 39, 60], ["D I XFeLV testing", "TEST", 89, 106], ["the vaccine", "TREATMENT", 166, 177], ["booster immunization", "TREATMENT", 224, 244]]], ["13Guidelines for Immunization of Dogs and Cats in Shelter EnvironmentsFor shelter animals, attenuated live core vaccines apart from rabies should be given before or immediately on entry to the shelter.", [["rabies", "DISEASE", 132, 138], ["Dogs", "ORGANISM", 33, 37], ["rabies", "ORGANISM", 132, 138], ["rabies", "SPECIES", 132, 138], ["Immunization of Dogs", "TREATMENT", 17, 37], ["attenuated live core vaccines", "TREATMENT", 91, 120]]], ["Optimally, immunization for CPV and CDV should occur at least 3 days before entry to a shelter environment, but immunization even hours before entry has the potential to make a difference.", [["CPV", "ORGANISM", 28, 31], ["CDV", "ORGANISM", 36, 39], ["CPV", "SPECIES", 28, 31], ["CDV", "SPECIES", 36, 39], ["immunization", "TREATMENT", 11, 23], ["CPV", "PROBLEM", 28, 31], ["CDV", "TREATMENT", 36, 39], ["immunization", "TREATMENT", 112, 124]]], ["When outbreaks of known parvovirus disease or canine distemper are present, vaccines can be administered as early as 4 to 5 weeks of age, but they should not be administered earlier than this because of the possibility of vaccine-induced disease and immunosuppression.", [["parvovirus disease", "DISEASE", 24, 42], ["canine distemper", "DISEASE", 46, 62], ["parvovirus", "ORGANISM", 24, 34], ["canine distemper", "ORGANISM", 46, 62], ["canine distemper", "SPECIES", 46, 62], ["canine distemper", "SPECIES", 46, 62], ["known parvovirus disease", "PROBLEM", 18, 42], ["canine distemper", "PROBLEM", 46, 62], ["vaccines", "TREATMENT", 76, 84], ["vaccine", "TREATMENT", 222, 229], ["induced disease", "PROBLEM", 230, 245], ["immunosuppression", "TREATMENT", 250, 267], ["parvovirus disease", "OBSERVATION", 24, 42]]], ["In the absence of an outbreak situation, immunization for these pathogens should be performed no earlier than 6 weeks of age.", [["immunization", "TREATMENT", 41, 53], ["these pathogens", "PROBLEM", 58, 73]]], ["In a shelter situation, the benefits and risks of vaccination of individual pregnant animals with attenuated live vaccines must be carefully assessed.", [["vaccination of individual pregnant animals", "TREATMENT", 50, 92], ["attenuated live vaccines", "TREATMENT", 98, 122]]], ["Immunization with an inactivated vaccine is probably better than no vaccine for pregnant animals that enter a shelter, but inactivated vaccines should not be administered to other animals in the shelter environment, because the onset of immunity is slower than with attenuated live vaccines.", [["Immunization", "TREATMENT", 0, 12], ["an inactivated vaccine", "TREATMENT", 18, 40], ["vaccine", "TREATMENT", 68, 75], ["inactivated vaccines", "TREATMENT", 123, 143], ["attenuated live vaccines", "TREATMENT", 266, 290]]], ["Attenuated live vaccines should be administered if ovariohysterectomy is to be performed during pregnancy.", [["Attenuated live vaccines", "TREATMENT", 0, 24], ["ovariohysterectomy", "TREATMENT", 51, 69], ["pregnancy", "PROBLEM", 96, 105]]], ["If pregnant animals are not immunized, they should be strictly isolated from the rest of the shelter animal population.", [["animals", "ORGANISM", 12, 19], ["pregnant animals", "PROBLEM", 3, 19]]], ["The use of rapid in-house serologic tests that determine the immune status of pregnant animals may be helpful in this situation (see Chapter 12) .Guidelines for Immunization of Dogs and Cats in Shelter EnvironmentsRevaccination should be performed no more frequently than at intervals of 2 to 3 weeks, because vaccine administration that occurs within 3 to 14 days of another immunization attempt with attenuated live vaccines can interfere with development of immune responses.", [["Dogs", "ORGANISM", 177, 181], ["serologic tests", "TEST", 26, 41], ["Immunization of Dogs", "TREATMENT", 161, 181], ["Revaccination", "TREATMENT", 214, 227], ["vaccine administration", "TREATMENT", 310, 332], ["another immunization attempt", "TREATMENT", 368, 396], ["attenuated live vaccines", "TREATMENT", 402, 426], ["immune responses", "PROBLEM", 461, 477]]], ["Further study is required to determine optimum revaccination intervals in shelter environments.", [["Further study", "TEST", 0, 13]]], ["Revaccination is most important for pups and kittens younger than 16 weeks of age and is performed to maximize the chance of immunization as soon as possible after the disappearance of maternal antibody interference.", [["pups", "ORGANISM_SUBDIVISION", 36, 40], ["Revaccination", "TREATMENT", 0, 13], ["immunization", "TREATMENT", 125, 137], ["maternal antibody interference", "PROBLEM", 185, 215], ["antibody interference", "OBSERVATION", 194, 215]]], ["Puppies and kittens should also be physically separated from the rest of the shelter animal population and handled with strict attention to quarantine protocols.Guidelines for Immunization of Dogs and Cats in Shelter EnvironmentsIntranasal vaccines are preferred for management of upper respiratory tract disease in shelter environments because of the potential for improved local immunity, the possibility of administration to very young animals, more rapid onset of protection, and improved protection in the face of maternal antibody.", [["upper respiratory tract", "ANATOMY", 281, 304], ["respiratory tract disease", "DISEASE", 287, 312], ["kittens", "ORGANISM", 12, 19], ["Dogs", "ORGANISM", 192, 196], ["upper", "ORGANISM_SUBDIVISION", 281, 286], ["respiratory tract", "ORGANISM_SUBDIVISION", 287, 304], ["maternal antibody", "PROTEIN", 519, 536], ["quarantine protocols", "TREATMENT", 140, 160], ["Immunization of Dogs", "TREATMENT", 176, 196], ["Intranasal vaccines", "TREATMENT", 229, 248], ["management", "TREATMENT", 267, 277], ["upper respiratory tract disease", "PROBLEM", 281, 312], ["maternal antibody", "PROBLEM", 519, 536], ["upper", "ANATOMY_MODIFIER", 281, 286], ["respiratory tract", "ANATOMY", 287, 304]]], ["However, they also have been associated with vaccine-induced upper respiratory disease, which may be more severe in debilitated animals and can be difficult to distinguish from natural infection.", [["respiratory", "ANATOMY", 67, 78], ["upper respiratory disease", "DISEASE", 61, 86], ["infection", "DISEASE", 185, 194], ["vaccine", "TREATMENT", 45, 52], ["upper respiratory disease", "PROBLEM", 61, 86], ["natural infection", "PROBLEM", 177, 194], ["upper", "ANATOMY_MODIFIER", 61, 66], ["respiratory disease", "OBSERVATION", 67, 86], ["may be", "UNCERTAINTY", 94, 100], ["more severe", "OBSERVATION_MODIFIER", 101, 112], ["natural", "OBSERVATION_MODIFIER", 177, 184], ["infection", "OBSERVATION", 185, 194]]], ["In addition, field studies have yet not shown benefit of intranasal over parenteral vaccines for prevention of respiratory disease.", [["respiratory", "ANATOMY", 111, 122], ["respiratory disease", "DISEASE", 111, 130], ["field studies", "TEST", 13, 26], ["intranasal over parenteral vaccines", "TREATMENT", 57, 92], ["respiratory disease", "PROBLEM", 111, 130], ["respiratory disease", "OBSERVATION", 111, 130]]], ["14 Intranasal Bordetella bronchiseptica vaccines should never be given parenterally.", [["Bordetella bronchiseptica", "DISEASE", 14, 39], ["Bordetella bronchiseptica", "ORGANISM", 14, 39], ["Bordetella bronchiseptica", "SPECIES", 14, 39], ["Bordetella bronchiseptica", "SPECIES", 14, 39], ["Intranasal Bordetella bronchiseptica vaccines", "TREATMENT", 3, 48]]], ["This is an emergency situation that requires immediate treatment.", [["immediate treatment", "TREATMENT", 45, 64]]], ["See Chapter 12 for specific instructions for how to manage accidental parenteral administration of these vaccines.Guidelines for Immunization of Dogs and Cats in Shelter EnvironmentsIn endemic areas, if possible, a rabies vaccine could be administered at the time of discharge from the facility.", [["parenteral", "ANATOMY", 70, 80], ["parenteral", "ORGANISM_SUBDIVISION", 70, 80], ["rabies", "ORGANISM", 215, 221], ["rabies", "SPECIES", 215, 221], ["accidental parenteral administration", "TREATMENT", 59, 95], ["these vaccines", "TREATMENT", 99, 113], ["Immunization of Dogs", "TREATMENT", 129, 149], ["a rabies vaccine", "TREATMENT", 213, 229], ["endemic", "OBSERVATION_MODIFIER", 185, 192]]], ["1 Administration of a 3-year product is preferred, but regardless of the product used, booster immunization must be performed no later than 1 year after the initial immunization.", [["booster immunization", "TREATMENT", 87, 107], ["the initial immunization", "TREATMENT", 153, 177]]], ["Rabies immunization must be properly documented, and a veterinarian must usually be present at the time of immunization.", [["Rabies", "DISEASE", 0, 6], ["Rabies", "ORGANISM", 0, 6], ["Rabies", "SPECIES", 0, 6], ["Rabies immunization", "TREATMENT", 0, 19], ["immunization", "TREATMENT", 107, 119]]], ["Otherwise, the number of vaccines should be limited to those that can assist control of disease that is confirmed to exist within the shelter.", [["vaccines", "TREATMENT", 25, 33], ["disease", "PROBLEM", 88, 95]]], ["This will avoid excessive immune suppression that may worsen the severity of illness due to other pathogens in the shelter for which vaccines are nonexistent.", [["illness", "DISEASE", 77, 84], ["excessive immune suppression", "PROBLEM", 16, 44], ["illness", "PROBLEM", 77, 84]]]], "778ff70d89b114048875aef5222d83e2e156d39a": [["INTRODUCTIONExosomes are a type of 60-90-nm small vesicles secreted by many types of cells, including dendritic cells (DCs) and tumor cells.", [["vesicles", "ANATOMY", 50, 58], ["cells", "ANATOMY", 85, 90], ["dendritic cells", "ANATOMY", 102, 117], ["DCs", "ANATOMY", 119, 122], ["tumor cells", "ANATOMY", 128, 139], ["tumor", "DISEASE", 128, 133], ["cells", "CELL", 85, 90], ["dendritic cells", "CELL", 102, 117], ["DCs", "CELL", 119, 122], ["tumor cells", "CELL", 128, 139], ["dendritic cells", "CELL_TYPE", 102, 117], ["DCs", "CELL_TYPE", 119, 122], ["tumor cells", "CELL_TYPE", 128, 139], ["small vesicles", "PROBLEM", 44, 58], ["dendritic cells", "PROBLEM", 102, 117], ["tumor cells", "PROBLEM", 128, 139], ["many types", "OBSERVATION_MODIFIER", 71, 81], ["of cells", "OBSERVATION", 82, 90], ["dendritic cells", "OBSERVATION", 102, 117], ["tumor cells", "OBSERVATION", 128, 139]]], ["[1] [2] [3] [4] [5] [6] It has been shown that exosomes are highly enriched in major histocompatibility complex (MHC) class II molecules, MHC class I, heat shock proteins (HSPs), adhesion molecules, and other functional cellular components.", [["exosomes", "ANATOMY", 47, 55], ["cellular", "ANATOMY", 220, 228], ["[1] [2] [3] [4] [5] [6]", "SIMPLE_CHEMICAL", 0, 23], ["exosomes", "CELL", 47, 55], ["MHC class I", "GENE_OR_GENE_PRODUCT", 138, 149], ["heat shock proteins", "GENE_OR_GENE_PRODUCT", 151, 170], ["HSPs", "GENE_OR_GENE_PRODUCT", 172, 176], ["cellular", "CELL", 220, 228], ["major histocompatibility complex (MHC) class II molecules", "PROTEIN", 79, 136], ["MHC class I", "PROTEIN", 138, 149], ["heat shock proteins", "PROTEIN", 151, 170], ["HSPs", "PROTEIN", 172, 176], ["adhesion molecules", "PROTEIN", 179, 197], ["heat shock proteins (HSPs)", "PROBLEM", 151, 177], ["adhesion molecules", "PROBLEM", 179, 197], ["other functional cellular components", "PROBLEM", 203, 239], ["adhesion molecules", "OBSERVATION", 179, 197], ["functional", "OBSERVATION_MODIFIER", 209, 219], ["cellular components", "OBSERVATION", 220, 239]]], ["7, 8 Exosomes produced by numerous cell types can be defined by three major criteria: a size of 60-90 nm in diameter, a density of 1.13-1.21 g/dl in a sucrose gradient and an endocytic origin.", [["Exosomes", "ANATOMY", 5, 13], ["cell", "ANATOMY", 35, 39], ["sucrose", "CHEMICAL", 151, 158], ["sucrose", "CHEMICAL", 151, 158], ["Exosomes", "CELL", 5, 13], ["cell", "CELL", 35, 39], ["sucrose", "SIMPLE_CHEMICAL", 151, 158], ["a density", "TEST", 118, 127], ["a sucrose gradient", "TREATMENT", 149, 167], ["numerous cell types", "OBSERVATION", 26, 45], ["size", "OBSERVATION_MODIFIER", 88, 92], ["diameter", "OBSERVATION_MODIFIER", 108, 116], ["density", "OBSERVATION_MODIFIER", 120, 127], ["endocytic origin", "OBSERVATION", 175, 191]]], ["[1] [2] [3] [4] It has been demonstrated previously that exosomes play functional roles in eradication of obsolete proteins, antigen presentation, or act as \"Trojan horses\" for viruses or prions.", [["exosomes", "ANATOMY", 57, 65], ["[1] [2] [3] [4", "SIMPLE_CHEMICAL", 0, 14], ["exosomes", "CELL", 57, 65], ["antigen", "GENE_OR_GENE_PRODUCT", 125, 132], ["obsolete proteins", "PROTEIN", 106, 123], ["obsolete proteins", "PROBLEM", 106, 123], ["viruses", "PROBLEM", 177, 184], ["prions", "PROBLEM", 188, 194]]], ["[1] [2] [3] [4] Recently, exosomes have been the focus of immunologists because exosomes derived from either DC (Dex) or tumor cells (Tex) can serve as a kind of cell-free vaccine and can induce potent antitumor immunity in animal models.", [["exosomes", "ANATOMY", 26, 34], ["exosomes", "ANATOMY", 80, 88], ["DC", "ANATOMY", 109, 111], ["tumor cells", "ANATOMY", 121, 132], ["cell", "ANATOMY", 162, 166], ["antitumor", "ANATOMY", 202, 211], ["Dex", "CHEMICAL", 113, 116], ["tumor", "DISEASE", 121, 126], ["[1] [2] [3] [4", "SIMPLE_CHEMICAL", 0, 14], ["exosomes", "CELL", 26, 34], ["exosomes", "CELL", 80, 88], ["DC", "CELL", 109, 111], ["Dex", "CELL", 113, 116], ["tumor cells", "CELL", 121, 132], ["Tex", "CELL", 134, 137], ["cell", "CELL", 162, 166], ["antitumor", "CANCER", 202, 211], ["exosomes", "CELL_TYPE", 80, 88], ["DC", "CELL_TYPE", 109, 111], ["tumor cells", "CELL_TYPE", 121, 132], ["DC (Dex", "TREATMENT", 109, 116], ["tumor cells", "PROBLEM", 121, 132], ["cell-free vaccine", "TREATMENT", 162, 179]]], ["5, 6 Dex are able to present antigens to T cells (directly and indirectly) and stimulate antigen-specific T-cell responses.", [["T cells", "ANATOMY", 41, 48], ["T-cell", "ANATOMY", 106, 112], ["Dex", "CHEMICAL", 5, 8], ["Dex", "SIMPLE_CHEMICAL", 5, 8], ["T cells", "CELL", 41, 48], ["antigen", "GENE_OR_GENE_PRODUCT", 89, 96], ["T-cell", "CELL", 106, 112], ["T cells", "CELL_TYPE", 41, 48], ["antigen", "TEST", 89, 96]]], ["5, [9] [10] [11] [12] [13] [14] [15] When used as a tumor vaccine, Dex loaded with acid-eluted tumor peptides can eradicate established tumors in mice.", [["tumor", "ANATOMY", 52, 57], ["tumor", "ANATOMY", 95, 100], ["tumors", "ANATOMY", 136, 142], ["5, [9] [10] [11] [12] [13] [14", "CHEMICAL", 0, 30], ["tumor", "DISEASE", 52, 57], ["Dex", "CHEMICAL", 67, 70], ["tumor", "DISEASE", 95, 100], ["tumors", "DISEASE", 136, 142], ["Dex", "CHEMICAL", 67, 70], ["[9] [10] [11] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 3, 36], ["tumor", "CANCER", 52, 57], ["Dex", "SIMPLE_CHEMICAL", 67, 70], ["tumor", "CANCER", 95, 100], ["tumors", "CANCER", 136, 142], ["mice", "ORGANISM", 146, 150], ["mice", "SPECIES", 146, 150], ["mice", "SPECIES", 146, 150], ["a tumor vaccine", "TREATMENT", 50, 65], ["Dex", "TREATMENT", 67, 70], ["acid-eluted tumor peptides", "TREATMENT", 83, 109], ["tumor", "OBSERVATION", 52, 57], ["tumors", "OBSERVATION", 136, 142]]], ["5 Most tumor cells constitutively release exosomes (Tex) in the extracellular milieu.", [["tumor cells", "ANATOMY", 7, 18], ["exosomes", "ANATOMY", 42, 50], ["extracellular", "ANATOMY", 64, 77], ["tumor", "DISEASE", 7, 12], ["tumor cells", "CELL", 7, 18], ["exosomes", "CELL", 42, 50], ["Tex", "GENE_OR_GENE_PRODUCT", 52, 55], ["extracellular milieu", "CELLULAR_COMPONENT", 64, 84], ["tumor cells", "CELL_TYPE", 7, 18], ["exosomes", "CELL_TYPE", 42, 50], ["Tex", "PROTEIN", 52, 55], ["Most tumor cells", "PROBLEM", 2, 18], ["tumor cells", "OBSERVATION", 7, 18], ["extracellular milieu", "ANATOMY", 64, 84]]], ["In mice, it has been revealed that Tex can also serve as antigen delivery systems and can prevent autologous tumor development in a CD4 + and CD8 + T cell-dependent manner.", [["tumor", "ANATOMY", 109, 114], ["CD4 +", "ANATOMY", 132, 137], ["CD8 + T cell", "ANATOMY", 142, 154], ["tumor", "DISEASE", 109, 114], ["mice", "ORGANISM", 3, 7], ["Tex", "GENE_OR_GENE_PRODUCT", 35, 38], ["tumor", "CANCER", 109, 114], ["CD4", "GENE_OR_GENE_PRODUCT", 132, 135], ["CD8", "GENE_OR_GENE_PRODUCT", 142, 145], ["Tex", "PROTEIN", 35, 38], ["CD4", "PROTEIN", 132, 135], ["CD8", "PROTEIN", 142, 145], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["antigen delivery systems", "TREATMENT", 57, 81], ["autologous tumor development", "PROBLEM", 98, 126], ["a CD4", "TEST", 130, 135], ["tumor", "OBSERVATION", 109, 114]]], ["3, 6 However, the isolation of autologous Tex may require the in vitro culture of primary tumor cells derived from cancer patients, which may be inconvenient in clinical trials.", [["primary tumor cells", "ANATOMY", 82, 101], ["cancer", "ANATOMY", 115, 121], ["tumor", "DISEASE", 90, 95], ["cancer", "DISEASE", 115, 121], ["tumor cells", "CELL", 90, 101], ["cancer", "CANCER", 115, 121], ["patients", "ORGANISM", 122, 130], ["primary tumor cells", "CELL_TYPE", 82, 101], ["patients", "SPECIES", 122, 130], ["autologous", "TREATMENT", 31, 41], ["the in vitro culture", "TEST", 58, 78], ["primary tumor cells", "PROBLEM", 82, 101], ["cancer", "PROBLEM", 115, 121], ["autologous", "OBSERVATION", 31, 41]]], ["The findings by Andre et al. suggest that exosomes can be isolated from malignant effusions of melanoma patients and can deliver melanoma antigen recognized by T cells 1 (Mart-1) and tumor antigens to DC for cross presentation to specific cytotoxic T lymphocytes (CTLs).", [["exosomes", "ANATOMY", 42, 50], ["malignant effusions", "ANATOMY", 72, 91], ["melanoma", "ANATOMY", 95, 103], ["melanoma", "ANATOMY", 129, 137], ["T cells", "ANATOMY", 160, 167], ["tumor", "ANATOMY", 183, 188], ["DC", "ANATOMY", 201, 203], ["cytotoxic T lymphocytes", "ANATOMY", 239, 262], ["CTLs", "ANATOMY", 264, 268], ["malignant effusions", "DISEASE", 72, 91], ["melanoma", "DISEASE", 95, 103], ["melanoma", "DISEASE", 129, 137], ["tumor", "DISEASE", 183, 188], ["exosomes", "CELL", 42, 50], ["malignant effusions", "CANCER", 72, 91], ["melanoma", "CANCER", 95, 103], ["patients", "ORGANISM", 104, 112], ["melanoma antigen", "GENE_OR_GENE_PRODUCT", 129, 145], ["T cells 1", "CELL", 160, 169], ["Mart-1", "GENE_OR_GENE_PRODUCT", 171, 177], ["tumor antigens", "GENE_OR_GENE_PRODUCT", 183, 197], ["DC", "CELL", 201, 203], ["cytotoxic T lymphocytes", "CELL", 239, 262], ["CTLs", "CELL", 264, 268], ["exosomes", "CELL_TYPE", 42, 50], ["melanoma antigen", "PROTEIN", 129, 145], ["T cells 1", "CELL_TYPE", 160, 169], ["tumor antigens", "PROTEIN", 183, 197], ["DC", "CELL_TYPE", 201, 203], ["cytotoxic T lymphocytes", "CELL_TYPE", 239, 262], ["CTLs", "CELL_TYPE", 264, 268], ["patients", "SPECIES", 104, 112], ["malignant effusions", "PROBLEM", 72, 91], ["melanoma", "PROBLEM", 95, 103], ["melanoma antigen", "PROBLEM", 129, 145], ["T cells", "TEST", 160, 167], ["Mart", "TEST", 171, 175], ["tumor antigens", "PROBLEM", 183, 197], ["malignant", "OBSERVATION_MODIFIER", 72, 81], ["effusions", "OBSERVATION", 82, 91], ["melanoma", "OBSERVATION", 95, 103]]], ["16 Most recently, the exosomes derived from malignant effusions of cancer patients have also been prepared and are ready for clinical trial.", [["exosomes", "ANATOMY", 22, 30], ["malignant effusions", "ANATOMY", 44, 63], ["cancer", "ANATOMY", 67, 73], ["malignant effusions", "DISEASE", 44, 63], ["cancer", "DISEASE", 67, 73], ["exosomes", "CELL", 22, 30], ["malignant effusions", "CANCER", 44, 63], ["cancer", "CANCER", 67, 73], ["patients", "ORGANISM", 74, 82], ["exosomes", "CELL_TYPE", 22, 30], ["patients", "SPECIES", 74, 82], ["malignant effusions of cancer", "PROBLEM", 44, 73], ["malignant", "OBSERVATION_MODIFIER", 44, 53], ["effusions", "OBSERVATION", 54, 63], ["cancer", "OBSERVATION", 67, 73]]], ["[17] [18] [19] Thus, Aex may be used as cellfree tumor vaccine in the immunotherapy of cancer.INTRODUCTIONDex have been tested for their safety and efficiency in clinical trials of patients with metastatic melanoma and advanced nonsmall cell lung cancer, which suggests that Dex derived from good manufacturing procedures (GMPs) grade are safe, feasible, and efficient in induction of antigen-specific T-cell responses.", [["tumor", "ANATOMY", 49, 54], ["cancer", "ANATOMY", 87, 93], ["metastatic melanoma", "ANATOMY", 195, 214], ["nonsmall cell lung cancer", "ANATOMY", 228, 253], ["T-cell", "ANATOMY", 402, 408], ["Aex", "CHEMICAL", 21, 24], ["tumor", "DISEASE", 49, 54], ["cancer", "DISEASE", 87, 93], ["melanoma", "DISEASE", 206, 214], ["nonsmall cell lung cancer", "DISEASE", 228, 253], ["Dex", "CHEMICAL", 275, 278], ["Dex", "CHEMICAL", 275, 278], ["[17] [18] [19]", "SIMPLE_CHEMICAL", 0, 14], ["Aex", "SIMPLE_CHEMICAL", 21, 24], ["cellfree tumor", "CANCER", 40, 54], ["cancer", "CANCER", 87, 93], ["patients", "ORGANISM", 181, 189], ["metastatic melanoma", "CANCER", 195, 214], ["nonsmall cell lung cancer", "CANCER", 228, 253], ["Dex", "SIMPLE_CHEMICAL", 275, 278], ["antigen", "GENE_OR_GENE_PRODUCT", 385, 392], ["T-cell", "CELL", 402, 408], ["patients", "SPECIES", 181, 189], ["cellfree tumor vaccine", "TREATMENT", 40, 62], ["cancer", "PROBLEM", 87, 93], ["INTRODUCTIONDex", "TREATMENT", 94, 109], ["metastatic melanoma", "PROBLEM", 195, 214], ["advanced nonsmall cell lung cancer", "PROBLEM", 219, 253], ["antigen", "TEST", 385, 392], ["cancer", "OBSERVATION", 87, 93], ["metastatic", "OBSERVATION_MODIFIER", 195, 205], ["melanoma", "OBSERVATION", 206, 214], ["advanced", "OBSERVATION_MODIFIER", 219, 227], ["nonsmall cell", "OBSERVATION", 228, 241], ["lung", "ANATOMY", 242, 246], ["cancer", "OBSERVATION", 247, 253]]], ["20, 21 Moreover, the oligodeoxynucleotide CpG, double-stranded RNA, and lipopolysaccharide have been used as adjuvants in the Dex-mediated immunotherapy.", [["oligodeoxynucleotide", "CHEMICAL", 21, 41], ["lipopolysaccharide", "CHEMICAL", 72, 90], ["CpG", "CHEMICAL", 42, 45], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 72, 90], ["oligodeoxynucleotide CpG", "DNA", 21, 45], ["the oligodeoxynucleotide CpG", "TREATMENT", 17, 45], ["double-stranded RNA", "TREATMENT", 47, 66], ["lipopolysaccharide", "TREATMENT", 72, 90], ["adjuvants", "TREATMENT", 109, 118], ["the Dex-mediated immunotherapy", "TREATMENT", 122, 152]]], ["15, 22, 23 Previously we, and others, have demonstrated that Tex modified with interleukin-18 (IL-18), IL-2, or superantigen, and Tex isolated after heat stress can elicit potent antitumor immunity in mice models.", [["antitumor", "ANATOMY", 179, 188], ["Tex", "GENE_OR_GENE_PRODUCT", 61, 64], ["interleukin-18", "GENE_OR_GENE_PRODUCT", 79, 93], ["IL-18", "GENE_OR_GENE_PRODUCT", 95, 100], ["IL-2", "GENE_OR_GENE_PRODUCT", 103, 107], ["superantigen", "GENE_OR_GENE_PRODUCT", 112, 124], ["Tex", "GENE_OR_GENE_PRODUCT", 130, 133], ["antitumor", "CANCER", 179, 188], ["mice", "ORGANISM", 201, 205], ["Tex", "PROTEIN", 61, 64], ["interleukin-18 (IL-18", "PROTEIN", 79, 100], ["IL", "PROTEIN", 103, 105], ["superantigen", "PROTEIN", 112, 124], ["Tex", "PROTEIN", 130, 133], ["mice", "SPECIES", 201, 205], ["mice", "SPECIES", 201, 205], ["interleukin", "TEST", 79, 90], ["IL", "TEST", 95, 97], ["IL", "TEST", 103, 105], ["superantigen", "TREATMENT", 112, 124], ["Tex", "TREATMENT", 130, 133], ["heat stress", "PROBLEM", 149, 160]]], ["[24] [25] [26] [27] [28] It has been extensively demonstrated that the granulocyte-macrophage \u00a9 The American Society of Gene Therapy Phase I Clinical Trial of Aex Plus GM-CSF colony-stimulating factor (GM-CSF), when used as adjuvant, can significantly increase the efficiency of antitumor immunity induction.", [["antitumor", "ANATOMY", 279, 288], ["GM", "CHEMICAL", 168, 170], ["GM-CSF", "CHEMICAL", 202, 208], ["[24] [25] [26] [27] [28", "SIMPLE_CHEMICAL", 0, 23], ["granulocyte", "CELL", 71, 82], ["macrophage", "CELL", 83, 93], ["GM-CSF colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 168, 200], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 202, 208], ["antitumor", "CANCER", 279, 288], ["CSF colony-stimulating factor", "PROTEIN", 171, 200], ["GM", "PROTEIN", 202, 204], ["CSF", "PROTEIN", 205, 208], ["the granulocyte", "TEST", 67, 82], ["Gene Therapy", "TREATMENT", 120, 132], ["Aex", "TEST", 159, 162], ["GM", "TEST", 168, 170], ["CSF colony", "TEST", 171, 181], ["stimulating factor", "PROBLEM", 182, 200], ["adjuvant", "TREATMENT", 224, 232], ["antitumor immunity induction", "TREATMENT", 279, 307]]], ["29, 30 Therefore, we evaluated whether ascites-derived exosomes (Aex) combined with GM-CSF (Aex plus GM-CSF) can be considered as a promising vaccine for cancer immunotherapy.", [["ascites", "ANATOMY", 39, 46], ["exosomes", "ANATOMY", 55, 63], ["cancer", "ANATOMY", 154, 160], ["ascites", "DISEASE", 39, 46], ["Aex", "CHEMICAL", 65, 68], ["GM", "CHEMICAL", 84, 86], ["Aex", "CHEMICAL", 92, 95], ["GM", "CHEMICAL", 101, 103], ["cancer", "DISEASE", 154, 160], ["exosomes", "CELL", 55, 63], ["Aex", "SIMPLE_CHEMICAL", 65, 68], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 84, 90], ["Aex", "SIMPLE_CHEMICAL", 92, 95], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 101, 107], ["cancer", "CANCER", 154, 160], ["exosomes", "CELL_TYPE", 55, 63], ["CSF", "PROTEIN", 87, 90], ["Aex", "PROTEIN", 92, 95], ["GM", "PROTEIN", 101, 103], ["CSF", "PROTEIN", 104, 107], ["ascites", "PROBLEM", 39, 46], ["GM-CSF", "TEST", 84, 90], ["a promising vaccine", "TREATMENT", 130, 149], ["cancer immunotherapy", "TREATMENT", 154, 174], ["ascites", "OBSERVATION", 39, 46]]], ["We find that the Aex derived from colorectal cancer (CRC) patients in combination with GM-CSF can efficiently induce potent carcinoembryonic antigen (CEA)-specific antitumor immunity in advanced CRC patients, suggesting that Aex plus GM-CSF can serve as a choice in clinical immunotherapy of CRC.Patient characteristics and treatment scheduleFrom January 2006 to February 2007, totally 54 CRC patients were eligible according to the enrollment criteria.", [["colorectal cancer", "ANATOMY", 34, 51], ["CRC", "ANATOMY", 53, 56], ["antitumor", "ANATOMY", 164, 173], ["CRC", "ANATOMY", 195, 198], ["CRC", "ANATOMY", 292, 295], ["CRC", "ANATOMY", 389, 392], ["Aex", "CHEMICAL", 17, 20], ["colorectal cancer", "DISEASE", 34, 51], ["CRC", "DISEASE", 53, 56], ["GM", "CHEMICAL", 87, 89], ["CRC", "DISEASE", 195, 198], ["Aex", "CHEMICAL", 225, 228], ["GM", "CHEMICAL", 234, 236], ["CRC", "DISEASE", 292, 295], ["CRC", "DISEASE", 389, 392], ["Aex", "GENE_OR_GENE_PRODUCT", 17, 20], ["colorectal cancer", "CANCER", 34, 51], ["CRC", "CANCER", 53, 56], ["patients", "ORGANISM", 58, 66], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 87, 93], ["carcinoembryonic antigen", "GENE_OR_GENE_PRODUCT", 124, 148], ["CEA", "GENE_OR_GENE_PRODUCT", 150, 153], ["antitumor", "CANCER", 164, 173], ["CRC", "CANCER", 195, 198], ["patients", "ORGANISM", 199, 207], ["Aex", "SIMPLE_CHEMICAL", 225, 228], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 234, 240], ["CRC", "CANCER", 292, 295], ["CRC", "CANCER", 389, 392], ["patients", "ORGANISM", 393, 401], ["Aex", "DNA", 17, 20], ["CSF", "PROTEIN", 90, 93], ["carcinoembryonic antigen", "PROTEIN", 124, 148], ["CEA", "PROTEIN", 150, 153], ["Aex", "PROTEIN", 225, 228], ["patients", "SPECIES", 58, 66], ["patients", "SPECIES", 199, 207], ["Patient", "SPECIES", 296, 303], ["patients", "SPECIES", 393, 401], ["colorectal cancer", "PROBLEM", 34, 51], ["GM-CSF", "TEST", 87, 93], ["potent carcinoembryonic antigen", "PROBLEM", 117, 148], ["CEA", "TEST", 150, 153], ["Aex", "TEST", 225, 228], ["CRC", "PROBLEM", 292, 295], ["treatment schedule", "TREATMENT", 324, 342], ["colorectal", "ANATOMY", 34, 44], ["cancer", "OBSERVATION", 45, 51], ["CRC", "OBSERVATION", 292, 295]]], ["Forty patients (seventeen females and twenty-three males), who had assessable advanced CRC (pathologically diagnosed as stage III or IV as per the American Joint Committee on Cancer) and matched all the criteria (e.g., HLA-A0201 + CEA + ) by sucrose/D 2 O gradient ultracentrifugation.", [["CRC", "ANATOMY", 87, 90], ["Cancer", "ANATOMY", 175, 181], ["CRC", "DISEASE", 87, 90], ["Cancer", "DISEASE", 175, 181], ["sucrose", "CHEMICAL", 242, 249], ["sucrose", "CHEMICAL", 242, 249], ["patients", "ORGANISM", 6, 14], ["CRC", "CANCER", 87, 90], ["Cancer", "CANCER", 175, 181], ["sucrose/D 2 O", "SIMPLE_CHEMICAL", 242, 255], ["CEA", "PROTEIN", 231, 234], ["patients", "SPECIES", 6, 14], ["assessable advanced CRC", "PROBLEM", 67, 90], ["HLA", "TEST", 219, 222], ["gradient ultracentrifugation", "TREATMENT", 256, 284], ["CRC", "OBSERVATION", 87, 90], ["Joint", "ANATOMY", 156, 161], ["Cancer", "OBSERVATION", 175, 181]]], ["16, 18 To examine the isolated products, we performed electron microscopy and Western blot to confirm the morphology and protein components.", [["electron microscopy", "TEST", 54, 73], ["Western blot", "TEST", 78, 90]]], ["We found that the isolated Aex were universal membrane vesicles with the diameter ~60-100 nm (Figure 1a) .", [["membrane vesicles", "ANATOMY", 46, 63], ["Aex", "SIMPLE_CHEMICAL", 27, 30], ["membrane vesicles", "CELLULAR_COMPONENT", 46, 63], ["the isolated Aex", "PROBLEM", 14, 30], ["the diameter", "TEST", 69, 81], ["isolated", "OBSERVATION_MODIFIER", 18, 26], ["Aex", "OBSERVATION", 27, 30], ["membrane vesicles", "OBSERVATION", 46, 63], ["diameter", "OBSERVATION_MODIFIER", 73, 81]]], ["Western blotting analysis demonstrated that Aex were enriched in MHC molecules (MHC-I and MHC-II), HSPs (including HSC70, HSP70, and HSP90), CD80, ICAM-1, CD71, and LAMP-3 (Figure 1b) .", [["Aex", "GENE_OR_GENE_PRODUCT", 44, 47], ["MHC-I", "GENE_OR_GENE_PRODUCT", 80, 85], ["MHC-II", "GENE_OR_GENE_PRODUCT", 90, 96], ["HSPs", "GENE_OR_GENE_PRODUCT", 99, 103], ["HSC70", "GENE_OR_GENE_PRODUCT", 115, 120], ["HSP70", "GENE_OR_GENE_PRODUCT", 122, 127], ["HSP90", "GENE_OR_GENE_PRODUCT", 133, 138], ["CD80", "GENE_OR_GENE_PRODUCT", 141, 145], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 147, 153], ["CD71", "GENE_OR_GENE_PRODUCT", 155, 159], ["LAMP-3", "GENE_OR_GENE_PRODUCT", 165, 171], ["Figure 1b", "GENE_OR_GENE_PRODUCT", 173, 182], ["Aex", "PROTEIN", 44, 47], ["MHC molecules", "PROTEIN", 65, 78], ["MHC", "PROTEIN", 80, 83], ["MHC", "PROTEIN", 90, 93], ["HSPs", "PROTEIN", 99, 103], ["HSC70", "PROTEIN", 115, 120], ["HSP70", "PROTEIN", 122, 127], ["HSP90", "PROTEIN", 133, 138], ["CD80", "PROTEIN", 141, 145], ["ICAM", "PROTEIN", 147, 151], ["CD71", "PROTEIN", 155, 159], ["LAMP-3", "DNA", 165, 171], ["Western blotting analysis", "TEST", 0, 25], ["Aex", "TEST", 44, 47], ["MHC", "TEST", 80, 83], ["HSPs", "TEST", 99, 103], ["HSC70", "TEST", 115, 120], ["HSP70", "TEST", 122, 127], ["HSP90", "TEST", 133, 138], ["CD80", "TEST", 141, 145], ["ICAM", "TEST", 147, 151], ["CD71", "TEST", 155, 159], ["LAMP", "TEST", 165, 169]]], ["Notably, the typical CEA of CRC was also detected in the Aex.", [["CRC", "ANATOMY", 28, 31], ["CRC", "DISEASE", 28, 31], ["CEA", "GENE_OR_GENE_PRODUCT", 21, 24], ["CRC", "CANCER", 28, 31], ["CEA", "PROTEIN", 21, 24], ["the typical CEA of CRC", "PROBLEM", 9, 31], ["typical", "OBSERVATION_MODIFIER", 13, 20], ["CEA", "OBSERVATION", 21, 24], ["CRC", "OBSERVATION", 28, 31]]], ["Because the capacity of exosomes in stimulating antitumor immune responses is largely dependent on the levels of MHC molecules and HSPs, 3, 4 we examined the expression of MHC-I and HSC70 as quality control standards for all the Aex preparations.", [["exosomes", "ANATOMY", 24, 32], ["antitumor", "ANATOMY", 48, 57], ["exosomes", "CELL", 24, 32], ["antitumor", "CANCER", 48, 57], ["HSPs", "GENE_OR_GENE_PRODUCT", 131, 135], ["MHC-I", "GENE_OR_GENE_PRODUCT", 172, 177], ["HSC70", "GENE_OR_GENE_PRODUCT", 182, 187], ["exosomes", "CELL_TYPE", 24, 32], ["MHC molecules", "PROTEIN", 113, 126], ["HSPs", "PROTEIN", 131, 135], ["MHC", "PROTEIN", 172, 175], ["HSC70", "PROTEIN", 182, 187], ["the capacity of exosomes", "PROBLEM", 8, 32], ["largely dependent", "PROBLEM", 78, 95], ["HSPs", "TEST", 131, 135], ["all the Aex preparations", "TREATMENT", 221, 245], ["dependent", "OBSERVATION_MODIFIER", 86, 95]]], ["Most of the prepared autologous Aex contained high levels of MHC-I and HSC70 (Figure 1c) .", [["Aex", "CANCER", 32, 35], ["MHC-I", "GENE_OR_GENE_PRODUCT", 61, 66], ["HSC70", "GENE_OR_GENE_PRODUCT", 71, 76], ["MHC", "PROTEIN", 61, 64], ["I", "PROTEIN", 65, 66], ["HSC70", "PROTEIN", 71, 76], ["Figure 1c", "PROTEIN", 78, 87]]], ["These results (morphology, density, and protein components) suggested that the Aex prepared by us were exosomes.Safety and early clinical outcomeGenerally, both the therapies were safe and well tolerated.", [["exosomes", "ANATOMY", 103, 111], ["Aex", "GENE_OR_GENE_PRODUCT", 79, 82], ["exosomes", "CELL", 103, 111], ["Aex", "PROTEIN", 79, 82], ["exosomes", "CELL_TYPE", 103, 111]]], ["A total of 79 adverse events were recorded throughout the treatments in all the groups ( Table 2) .", [["79 adverse events", "PROBLEM", 11, 28], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["The most frequently reported adverse events causally related to the use of Aex or Aex plus GM-CSF were mild (grade 1-2) in severity and included injection site reactions (37 events in groups A-D and 42 events in groups E-H) including erythema, pruritus, or pain, fever (patient H2), nausea (patient H4), fatigue (patients D1, G2, and H5) ( Table 2 ).", [["Aex", "CHEMICAL", 75, 78], ["Aex", "CHEMICAL", 82, 85], ["GM", "CHEMICAL", 91, 93], ["erythema", "DISEASE", 234, 242], ["pruritus", "DISEASE", 244, 252], ["pain", "DISEASE", 257, 261], ["fever", "DISEASE", 263, 268], ["nausea", "DISEASE", 283, 289], ["fatigue", "DISEASE", 304, 311], ["Aex", "SIMPLE_CHEMICAL", 75, 78], ["Aex", "SIMPLE_CHEMICAL", 82, 85], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 91, 97], ["patient", "ORGANISM", 270, 277], ["patient", "ORGANISM", 291, 298], ["patients", "ORGANISM", 313, 321], ["patient", "SPECIES", 270, 277], ["patient", "SPECIES", 291, 298], ["patients", "SPECIES", 313, 321], ["adverse events", "PROBLEM", 29, 43], ["Aex", "TREATMENT", 75, 78], ["GM-CSF", "TEST", 91, 97], ["mild (grade 1", "PROBLEM", 103, 116], ["injection site reactions", "PROBLEM", 145, 169], ["erythema", "PROBLEM", 234, 242], ["pruritus", "PROBLEM", 244, 252], ["pain", "PROBLEM", 257, 261], ["fever", "PROBLEM", 263, 268], ["patient H2)", "PROBLEM", 270, 281], ["nausea (patient H4)", "PROBLEM", 283, 302], ["fatigue", "PROBLEM", 304, 311], ["mild", "OBSERVATION_MODIFIER", 103, 107], ["erythema", "OBSERVATION", 234, 242], ["pruritus", "OBSERVATION", 244, 252]]], ["There were no significant hepatic, renal, pulmonary, cardiac, hematologic, or neurologic toxicities attributable to the treatments.", [["hepatic", "ANATOMY", 26, 33], ["renal", "ANATOMY", 35, 40], ["pulmonary", "ANATOMY", 42, 51], ["cardiac", "ANATOMY", 53, 60], ["neurologic", "ANATOMY", 78, 88], ["hepatic, renal, pulmonary, cardiac, hematologic, or neurologic toxicities", "DISEASE", 26, 99], ["hepatic", "MULTI-TISSUE_STRUCTURE", 26, 33], ["renal", "ORGAN", 35, 40], ["pulmonary", "ORGAN", 42, 51], ["cardiac", "ORGAN", 53, 60], ["significant hepatic, renal, pulmonary, cardiac, hematologic", "PROBLEM", 14, 73], ["neurologic toxicities", "PROBLEM", 78, 99], ["the treatments", "TREATMENT", 116, 130], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["hepatic", "ANATOMY", 26, 33], ["renal", "ANATOMY", 35, 40], ["pulmonary", "ANATOMY", 42, 51], ["cardiac", "ANATOMY", 53, 60], ["hematologic", "OBSERVATION", 62, 73]]], ["No clinical manifestations of autoimmune reactions were observed.", [["autoimmune reactions", "PROBLEM", 30, 50], ["autoimmune", "OBSERVATION", 30, 40]]], ["No significant changes in temperature and blood pressure were recorded.", [["blood", "ANATOMY", 42, 47], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["significant changes in temperature", "PROBLEM", 3, 37], ["blood pressure", "TEST", 42, 56], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["changes", "OBSERVATION", 15, 22], ["temperature", "OBSERVATION_MODIFIER", 26, 37]]], ["After the last immunization, the status of CRC patients was followed.", [["CRC", "ANATOMY", 43, 46], ["CRC", "DISEASE", 43, 46], ["CRC", "CANCER", 43, 46], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["the last immunization", "TREATMENT", 6, 27], ["CRC", "OBSERVATION", 43, 46]]], ["No detectable therapeutic response was observed in groups A-D, which were treated with Aex (100-500 \u03bcg per vaccination) alone.", [["Aex", "CHEMICAL", 87, 90], ["Aex", "CHEMICAL", 87, 90], ["A-D", "SIMPLE_CHEMICAL", 58, 61], ["Aex", "SIMPLE_CHEMICAL", 87, 90], ["Aex", "TREATMENT", 87, 90], ["detectable", "OBSERVATION_MODIFIER", 3, 13], ["therapeutic", "OBSERVATION_MODIFIER", 14, 25], ["response", "OBSERVATION", 26, 34]]], ["However, one case with a stable disease (patient G1 who was treated with 300 \u03bcg Aex plus 50 \u03bcg GM-CSF) and one case with a minor response (patient H3 who was treated with 500 \u03bcg Aex plus 50 \u03bcg GM-CSF) were observed in the Aex plus GM-CSF group (data not shown).Antitumor immune responses elicited by the treatmentsPreviously it has been shown that Dex, Tex, and Aex can induce antigen-specific T-cell responses and tumor growth regression.", [["T-cell", "ANATOMY", 394, 400], ["tumor", "ANATOMY", 415, 420], ["Aex", "CHEMICAL", 80, 83], ["GM", "CHEMICAL", 95, 97], ["Aex", "CHEMICAL", 178, 181], ["GM", "CHEMICAL", 193, 195], ["GM", "CHEMICAL", 231, 233], ["Dex", "CHEMICAL", 348, 351], ["Aex", "CHEMICAL", 362, 365], ["tumor", "DISEASE", 415, 420], ["Dex", "CHEMICAL", 348, 351], ["patient", "ORGANISM", 41, 48], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 95, 101], ["patient", "ORGANISM", 139, 146], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 193, 199], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 231, 237], ["Antitumor", "CANCER", 261, 270], ["Dex", "SIMPLE_CHEMICAL", 348, 351], ["Tex", "GENE_OR_GENE_PRODUCT", 353, 356], ["Aex", "GENE_OR_GENE_PRODUCT", 362, 365], ["antigen", "GENE_OR_GENE_PRODUCT", 377, 384], ["T-cell", "CELL", 394, 400], ["tumor", "CANCER", 415, 420], ["patient", "SPECIES", 41, 48], ["patient", "SPECIES", 139, 146], ["a stable disease", "PROBLEM", 23, 39], ["CSF group (data", "TEST", 234, 249], ["Antitumor immune responses", "TREATMENT", 261, 287], ["the treatments", "TREATMENT", 300, 314], ["antigen", "TEST", 377, 384], ["tumor growth regression", "PROBLEM", 415, 438], ["stable", "OBSERVATION_MODIFIER", 25, 31], ["disease", "OBSERVATION", 32, 39], ["tumor", "OBSERVATION", 415, 420]]], ["5, 6, [9] [10] [11] [12] [13] [14] [15] [16] The above results indicated that Aex contained plenty of immune molecules as well as CEA, and the Aex plus GM-CSF treatments could improve the clinical outcomes of CRC patients to some extent.", [["CRC", "ANATOMY", 209, 212], ["5, 6, [9] [10] [11] [12] [13] [14] [15", "CHEMICAL", 0, 38], ["Aex", "CHEMICAL", 78, 81], ["Aex", "CHEMICAL", 143, 146], ["GM", "CHEMICAL", 152, 154], ["CRC", "DISEASE", 209, 212], ["5, 6, [9] [10] [11] [12] [13] [14] [15] [16", "SIMPLE_CHEMICAL", 0, 43], ["Aex", "SIMPLE_CHEMICAL", 78, 81], ["CEA", "GENE_OR_GENE_PRODUCT", 130, 133], ["Aex", "SIMPLE_CHEMICAL", 143, 146], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 152, 158], ["CRC", "CANCER", 209, 212], ["patients", "ORGANISM", 213, 221], ["immune molecules", "PROTEIN", 102, 118], ["CEA", "PROTEIN", 130, 133], ["patients", "SPECIES", 213, 221], ["Aex", "TEST", 78, 81], ["immune molecules", "PROBLEM", 102, 118], ["CEA", "TEST", 130, 133], ["the Aex", "TEST", 139, 146], ["CSF treatments", "TREATMENT", 155, 169], ["immune molecules", "OBSERVATION", 102, 118], ["CEA", "ANATOMY", 130, 133], ["CRC", "OBSERVATION", 209, 212], ["some extent", "OBSERVATION_MODIFIER", 225, 236]]], ["Therefore, we went further to examine whether the immunotherapies with Aex or Aex plus GM-CSF induced systemic antigen-specific antitumor immunity both in vitro and in vivo.", [["antitumor", "ANATOMY", 128, 137], ["Aex", "CHEMICAL", 71, 74], ["Aex", "CHEMICAL", 78, 81], ["GM", "CHEMICAL", 87, 89], ["Aex", "SIMPLE_CHEMICAL", 71, 74], ["Aex", "SIMPLE_CHEMICAL", 78, 81], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 87, 93], ["antigen", "GENE_OR_GENE_PRODUCT", 111, 118], ["antitumor", "CANCER", 128, 137], ["CSF", "PROTEIN", 90, 93], ["the immunotherapies", "TREATMENT", 46, 65], ["Aex", "TEST", 71, 74], ["Aex", "TEST", 78, 81], ["GM", "TEST", 87, 89], ["systemic antigen", "TEST", 102, 118], ["specific antitumor immunity", "TREATMENT", 119, 146]]], ["First we performed the antigen recall experiments by examining the delayed-type hypersensitivity (DTH) response in CRC patients 2 weeks after the last immunization.", [["CRC", "ANATOMY", 115, 118], ["delayed-type hypersensitivity", "DISEASE", 67, 96], ["CRC", "DISEASE", 115, 118], ["CRC", "CANCER", 115, 118], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["the delayed-type hypersensitivity", "PROBLEM", 63, 96], ["the last immunization", "TREATMENT", 142, 163]]], ["We found that Aex immunization at a dose of 300 or 500 \u03bcg could efficiently induce DTH responses [100% in groups C (4/4), D (5/5), G (5/5), and H (4/4)] in the presence or absence of GM-CSF adjuvants ( Table 3) .", [["Aex", "CHEMICAL", 14, 17], ["GM", "CHEMICAL", 183, 185], ["Aex", "SIMPLE_CHEMICAL", 14, 17], ["DTH", "GENE_OR_GENE_PRODUCT", 83, 86], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 183, 189], ["DTH", "PROTEIN", 83, 86], ["Aex immunization", "TREATMENT", 14, 30], ["DTH responses", "TEST", 83, 96], ["C", "TEST", 113, 114], ["G", "TEST", 131, 132], ["CSF adjuvants", "TREATMENT", 186, 199]]], ["However, when lower doses of Aex (200 \u03bcg per immunization) were used, GM-CSF could significantly increase the efficiency of Aex in the induction of DTH, as evidenced by the differences between the DTH response rate of group B (1/5, 20%) and that of group F (3/5, 60%) ( To further determine whether the antitumor immune response was specific for CRC, we examined the CTL response by tetramer staining, interferon-\u03b3 (IFN-\u03b3) release assay, and cytotoxicity assay after isolating CD8 + T cells from the DTH response sites.", [["antitumor", "ANATOMY", 303, 312], ["CRC", "ANATOMY", 346, 349], ["CD8 + T cells", "ANATOMY", 477, 490], ["Aex", "CHEMICAL", 29, 32], ["GM", "CHEMICAL", 70, 72], ["Aex", "CHEMICAL", 124, 127], ["CRC", "DISEASE", 346, 349], ["Aex", "CHEMICAL", 29, 32], ["Aex", "SIMPLE_CHEMICAL", 29, 32], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 70, 76], ["Aex", "SIMPLE_CHEMICAL", 124, 127], ["DTH", "GENE_OR_GENE_PRODUCT", 148, 151], ["antitumor", "CANCER", 303, 312], ["CRC", "CANCER", 346, 349], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 402, 414], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 416, 421], ["CD8", "GENE_OR_GENE_PRODUCT", 477, 480], ["interferon", "PROTEIN", 402, 412], ["IFN", "PROTEIN", 416, 419], ["CD8 + T cells", "CELL_TYPE", 477, 490], ["DTH response sites", "DNA", 500, 518], ["Aex", "TREATMENT", 29, 32], ["GM-CSF", "TEST", 70, 76], ["CRC", "PROBLEM", 346, 349], ["the CTL response", "TEST", 363, 379], ["tetramer staining", "TEST", 383, 400], ["interferon", "TEST", 402, 412], ["cytotoxicity assay", "TEST", 442, 460], ["isolating CD8 + T cells", "PROBLEM", 467, 490], ["efficiency", "OBSERVATION_MODIFIER", 110, 120]]], ["The HLA-A0201-restricted coronavirus SARS-CoV spike protein peptide SSp-1 (RLNEVAKNL) were used in these assays.", [["HLA-A0201", "GENE_OR_GENE_PRODUCT", 4, 13], ["coronavirus", "ORGANISM", 25, 36], ["SSp-1", "GENE_OR_GENE_PRODUCT", 68, 73], ["A0201", "PROTEIN", 8, 13], ["coronavirus SARS-CoV spike protein", "PROTEIN", 25, 59], ["RLNEVAKNL", "PROTEIN", 75, 84], ["coronavirus SARS-CoV", "SPECIES", 25, 45], ["SARS-CoV", "SPECIES", 37, 45], ["The HLA", "TEST", 0, 7], ["A0201", "TEST", 8, 13], ["restricted coronavirus SARS", "PROBLEM", 14, 41], ["CoV spike protein peptide SSp", "TEST", 42, 71]]], ["For the evaluation of the tetramer tests, we established a ratio of percentages (of CD8 + tetramer + cells specific to CAP-1 to that specific to SSp-1) of more than twofold as a positive one.", [["CD8 + tetramer + cells", "ANATOMY", 84, 106], ["CD8", "GENE_OR_GENE_PRODUCT", 84, 87], ["CAP-1", "GENE_OR_GENE_PRODUCT", 119, 124], ["SSp-1", "GENE_OR_GENE_PRODUCT", 145, 150], ["CD8", "PROTEIN", 84, 87], ["tetramer", "PROTEIN", 90, 98], ["CAP", "PROTEIN", 119, 122], ["SSp", "PROTEIN", 145, 148], ["the evaluation", "TEST", 4, 18], ["the tetramer tests", "TEST", 22, 40], ["percentages", "TEST", 68, 79], ["CD8", "TEST", 84, 87], ["CAP", "TEST", 119, 122], ["SSp", "TEST", 145, 148]]], ["Abbreviations: Aex, ascites-derived exosomes; AJCC, American Joint Committee on Cancer; F, female; GM-CSF, granulocyte-macrophage colony-stimulating factor; LN, lymph node; M, male; Surg, surgery. a F4 stands for FOLFOX4 regimen; oxaliplatin (85 mg/m 2 , IV on day 1); leucovorin (200 mg/m 2 , IV on days 1 and 2); 5-fluorouracil (400 mg/m 2 , IV on days 1 and 2); and 5-fluorouracil (600 mg/m 2 , continuous infusion (CI on days 1 and 2).", [["ascites", "ANATOMY", 20, 27], ["exosomes", "ANATOMY", 36, 44], ["AJCC", "ANATOMY", 46, 50], ["Cancer", "ANATOMY", 80, 86], ["LN", "ANATOMY", 157, 159], ["lymph node", "ANATOMY", 161, 171], ["ascites", "DISEASE", 20, 27], ["Cancer", "DISEASE", 80, 86], ["FOLFOX4", "CHEMICAL", 213, 220], ["oxaliplatin", "CHEMICAL", 230, 241], ["leucovorin", "CHEMICAL", 269, 279], ["5-fluorouracil", "CHEMICAL", 315, 329], ["5-fluorouracil", "CHEMICAL", 369, 383], ["oxaliplatin", "CHEMICAL", 230, 241], ["leucovorin", "CHEMICAL", 269, 279], ["5-fluorouracil", "CHEMICAL", 315, 329], ["5-fluorouracil", "CHEMICAL", 369, 383], ["Aex", "SIMPLE_CHEMICAL", 15, 18], ["exosomes", "CELL", 36, 44], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 99, 105], ["granulocyte-macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 107, 155], ["LN", "MULTI-TISSUE_STRUCTURE", 157, 159], ["lymph node", "MULTI-TISSUE_STRUCTURE", 161, 171], ["FOLFOX4", "SIMPLE_CHEMICAL", 213, 220], ["oxaliplatin", "SIMPLE_CHEMICAL", 230, 241], ["leucovorin", "SIMPLE_CHEMICAL", 269, 279], ["5-fluorouracil", "SIMPLE_CHEMICAL", 315, 329], ["5-fluorouracil", "SIMPLE_CHEMICAL", 369, 383], ["granulocyte-macrophage colony-stimulating factor", "PROTEIN", 107, 155], ["ascites", "PROBLEM", 20, 27], ["GM", "TEST", 99, 101], ["CSF", "TEST", 102, 105], ["granulocyte", "TEST", 107, 118], ["stimulating factor", "PROBLEM", 137, 155], ["surgery", "TREATMENT", 188, 195], ["a F4 stands", "TREATMENT", 197, 208], ["FOLFOX4 regimen", "TREATMENT", 213, 228], ["oxaliplatin", "TREATMENT", 230, 241], ["leucovorin", "TREATMENT", 269, 279], ["fluorouracil", "TREATMENT", 317, 329], ["fluorouracil", "TREATMENT", 371, 383], ["ascites", "OBSERVATION", 20, 27], ["Joint", "ANATOMY", 61, 66], ["Cancer", "OBSERVATION", 80, 86], ["CSF", "ANATOMY", 102, 105], ["granulocyte", "ANATOMY", 107, 118], ["macrophage colony", "OBSERVATION", 119, 136], ["LN", "ANATOMY", 157, 159], ["lymph node", "OBSERVATION", 161, 171]]], ["The regimen was repeated every 2 weeks. b De-G stands for De-Gramont regimen; leucovorin (400 mg/m 2 IV on days 1 and 2) and 5-fluorouracil (400 mg/m 2 , IV on days 1 and 2, plus 600 mg/m 2 5-fluorouracil via CI on days 1 and 2).", [["leucovorin", "CHEMICAL", 78, 88], ["5-fluorouracil", "CHEMICAL", 125, 139], ["5-fluorouracil", "CHEMICAL", 190, 204], ["leucovorin", "CHEMICAL", 78, 88], ["5-fluorouracil", "CHEMICAL", 125, 139], ["5-fluorouracil", "CHEMICAL", 190, 204], ["De-Gramont", "SIMPLE_CHEMICAL", 58, 68], ["leucovorin", "SIMPLE_CHEMICAL", 78, 88], ["5-fluorouracil", "SIMPLE_CHEMICAL", 125, 139], ["5-fluorouracil", "SIMPLE_CHEMICAL", 190, 204], ["The regimen", "TREATMENT", 0, 11], ["b De-G stands", "TREATMENT", 40, 53], ["De-Gramont regimen", "TREATMENT", 58, 76], ["leucovorin", "TREATMENT", 78, 88], ["fluorouracil", "TREATMENT", 127, 139]]], ["The regimen was repeated every 2 weeks. c F6 stands for FOLFOX6 regimen: oxaliplatin (100 mg/m 2 , IV on day 1); leucovorin (400 mg/m 2 , IV on day 1) and 5-fluorouracil (400 mg/m 2 (IV) plus 600 mg/m 2 5-fluorouracil bolus on days 1 and 2,400-3,000 mg/m 2 5-fluorouracil via CI over 46 hours).", [["FOLFOX6 regimen", "CHEMICAL", 56, 71], ["oxaliplatin", "CHEMICAL", 73, 84], ["leucovorin", "CHEMICAL", 113, 123], ["5-fluorouracil", "CHEMICAL", 155, 169], ["5-fluorouracil", "CHEMICAL", 203, 217], ["5-fluorouracil", "CHEMICAL", 257, 271], ["oxaliplatin", "CHEMICAL", 73, 84], ["leucovorin", "CHEMICAL", 113, 123], ["5-fluorouracil", "CHEMICAL", 155, 169], ["5-fluorouracil", "CHEMICAL", 203, 217], ["5-fluorouracil", "CHEMICAL", 257, 271], ["FOLFOX6", "SIMPLE_CHEMICAL", 56, 63], ["oxaliplatin", "SIMPLE_CHEMICAL", 73, 84], ["leucovorin", "SIMPLE_CHEMICAL", 113, 123], ["5-fluorouracil", "SIMPLE_CHEMICAL", 155, 169], ["5-fluorouracil", "SIMPLE_CHEMICAL", 203, 217], ["5-fluorouracil", "SIMPLE_CHEMICAL", 257, 271], ["The regimen", "TREATMENT", 0, 11], ["FOLFOX6 regimen", "TREATMENT", 56, 71], ["oxaliplatin", "TREATMENT", 73, 84], ["leucovorin", "TREATMENT", 113, 123], ["fluorouracil", "TREATMENT", 157, 169]]], ["The regimen was repeated every 2 weeks. d F stands for FOLFIRI regimen (Douillard); irinotecan (180 mg/m 2, IV on day 1); leucovorin (200 mg/m 2 IV on days 1 and 2); and 5-fluorouracil (400 mg/m 2 , IV on days 1 and 2, plus 600 mg/m 2 5-fluorouracil via CI >22 hours on days 1 and 2).", [["FOLFIRI regimen", "CHEMICAL", 55, 70], ["irinotecan", "CHEMICAL", 84, 94], ["leucovorin", "CHEMICAL", 122, 132], ["5-fluorouracil", "CHEMICAL", 170, 184], ["5-fluorouracil", "CHEMICAL", 235, 249], ["FOLFIRI", "CHEMICAL", 55, 62], ["irinotecan", "CHEMICAL", 84, 94], ["leucovorin", "CHEMICAL", 122, 132], ["5-fluorouracil", "CHEMICAL", 170, 184], ["5-fluorouracil", "CHEMICAL", 235, 249], ["FOLFIRI", "SIMPLE_CHEMICAL", 55, 62], ["Douillard", "SIMPLE_CHEMICAL", 72, 81], ["irinotecan", "SIMPLE_CHEMICAL", 84, 94], ["leucovorin", "SIMPLE_CHEMICAL", 122, 132], ["5-fluorouracil", "SIMPLE_CHEMICAL", 170, 184], ["5-fluorouracil", "SIMPLE_CHEMICAL", 235, 249], ["The regimen", "TREATMENT", 0, 11], ["FOLFIRI regimen (Douillard)", "TREATMENT", 55, 82], ["irinotecan", "TREATMENT", 84, 94], ["leucovorin", "TREATMENT", 122, 132], ["fluorouracil", "TREATMENT", 172, 184], ["fluorouracil via CI", "TREATMENT", 237, 256]]], ["This regimen was repeated every 2 weeks. e XELOX regimen: oxaliplatin (130 mg/m 2 , IV on day 1); capecitabine (1,000 mg/m 2 , PO (bid, total dose was ~2,000 mg/m 2 /day) on days [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] .", [["oxaliplatin", "CHEMICAL", 58, 69], ["capecitabine", "CHEMICAL", 98, 110], ["oxaliplatin", "CHEMICAL", 58, 69], ["capecitabine", "CHEMICAL", 98, 110], ["oxaliplatin", "SIMPLE_CHEMICAL", 58, 69], ["capecitabine", "SIMPLE_CHEMICAL", 98, 110], ["PO", "SIMPLE_CHEMICAL", 127, 129], ["[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14]", "SIMPLE_CHEMICAL", 179, 239], ["This regimen", "TREATMENT", 0, 12], ["e XELOX regimen", "TREATMENT", 41, 56], ["oxaliplatin", "TREATMENT", 58, 69], ["capecitabine", "TREATMENT", 98, 110]]], ["This regimen was repeated every 3 weeks. f Capecitabine regimen: capecitabine (1,000 mg/m 2 , PO (bid, total dose was ~2,000 mg/m 2 /day) on days 1-14).", [["Capecitabine", "CHEMICAL", 43, 55], ["capecitabine", "CHEMICAL", 65, 77], ["Capecitabine", "CHEMICAL", 43, 55], ["capecitabine", "CHEMICAL", 65, 77], ["Capecitabine", "SIMPLE_CHEMICAL", 43, 55], ["capecitabine", "SIMPLE_CHEMICAL", 65, 77], ["This regimen", "TREATMENT", 0, 12], ["Capecitabine regimen", "TREATMENT", 43, 63], ["capecitabine", "TREATMENT", 65, 77]]], ["This regimen was repeated every 3 weeks. g AIO regimen. leucovorin (500 mg/m 2 , IV once per week); and 5-fluorouracil (2,000 mg/m 2 , CI once per week).", [["AIO", "CHEMICAL", 43, 46], ["leucovorin", "CHEMICAL", 56, 66], ["5-fluorouracil", "CHEMICAL", 104, 118], ["leucovorin", "CHEMICAL", 56, 66], ["5-fluorouracil", "CHEMICAL", 104, 118], ["leucovorin", "SIMPLE_CHEMICAL", 56, 66], ["5-fluorouracil", "SIMPLE_CHEMICAL", 104, 118], ["This regimen", "TREATMENT", 0, 12], ["g AIO regimen", "TREATMENT", 41, 54], ["leucovorin", "TREATMENT", 56, 66], ["fluorouracil", "TREATMENT", 106, 118]]], ["This regimen was repeated every 3 weeks.Antitumor immune responses elicited by the treatmentsAbbreviations: Aex, ascites-derived exosomes; GM-CSF, granulocyte-macrophage colony-stimulating factor. a The adverse events were recorded from the day of the first immunization of 2 weeks after the last immunization. b Toxicity was assessed throughout the study using the National Cancer Institute Common Toxicity Criteria version 2.0. c The total adverse events in the Aex-treated groups were summarized and presented. d The total adverse events in the Aex + GM-CSF-treated groups were summarized and presented.", [["ascites", "ANATOMY", 113, 120], ["exosomes", "ANATOMY", 129, 137], ["ascites", "DISEASE", 113, 120], ["GM", "CHEMICAL", 139, 141], ["Toxicity", "DISEASE", 313, 321], ["Cancer", "DISEASE", 375, 381], ["Toxicity", "DISEASE", 399, 407], ["Aex", "CHEMICAL", 464, 467], ["Aex", "CHEMICAL", 548, 551], ["GM", "CHEMICAL", 554, 556], ["Aex", "CHEMICAL", 464, 467], ["Antitumor", "CANCER", 40, 49], ["Aex", "SIMPLE_CHEMICAL", 108, 111], ["exosomes", "CELL", 129, 137], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 139, 145], ["granulocyte-macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 147, 195], ["c", "GENE_OR_GENE_PRODUCT", 430, 431], ["Aex", "SIMPLE_CHEMICAL", 464, 467], ["Aex", "SIMPLE_CHEMICAL", 548, 551], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 554, 560], ["GM", "PROTEIN", 139, 141], ["CSF", "PROTEIN", 142, 145], ["granulocyte-macrophage colony-stimulating factor", "PROTEIN", 147, 195], ["CSF", "PROTEIN", 557, 560], ["This regimen", "TREATMENT", 0, 12], ["Antitumor immune responses", "TREATMENT", 40, 66], ["the treatments", "TREATMENT", 79, 93], ["Aex", "TEST", 108, 111], ["ascites", "PROBLEM", 113, 120], ["exosomes", "TEST", 129, 137], ["GM", "TEST", 139, 141], ["CSF", "TEST", 142, 145], ["granulocyte", "TEST", 147, 158], ["stimulating factor", "PROBLEM", 177, 195], ["The adverse events", "PROBLEM", 199, 217], ["the first immunization", "TREATMENT", 248, 270], ["the last immunization", "TREATMENT", 288, 309], ["the study", "TEST", 346, 355], ["the National Cancer", "TREATMENT", 362, 381], ["The total adverse events", "PROBLEM", 432, 456], ["The total adverse events", "PROBLEM", 516, 540], ["the Aex", "TEST", 544, 551], ["ascites", "OBSERVATION", 113, 120], ["CSF", "ANATOMY", 142, 145], ["granulocyte", "ANATOMY", 147, 158], ["macrophage colony", "OBSERVATION", 159, 176], ["total", "OBSERVATION_MODIFIER", 436, 441], ["adverse", "OBSERVATION_MODIFIER", 442, 449], ["total", "OBSERVATION_MODIFIER", 520, 525]]], ["Abbreviations: Aex, ascites-derived exosomes; CTL, cytotoxic T lymphocytes; DTH, delayed-type hypersensitivity; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-\u03b3, interferon \u03b3; ND, not determined. a The results were presented as mean percentage of CD8 + tetramer (CAP-1) + cells to that of total emigrated cells. b The cytotoxicity was evaluated at the effector (DTH site-derived cultured cells) to target (SW480 cells) ratio of 50:1.", [["ascites", "ANATOMY", 20, 27], ["exosomes", "ANATOMY", 36, 44], ["CTL", "ANATOMY", 46, 49], ["cytotoxic T lymphocytes", "ANATOMY", 51, 74], ["CD8 + tetramer (CAP-1) + cells", "ANATOMY", 262, 292], ["cells", "ANATOMY", 320, 325], ["cells", "ANATOMY", 403, 408], ["SW480 cells", "ANATOMY", 421, 432], ["ascites", "DISEASE", 20, 27], ["delayed-type hypersensitivity", "DISEASE", 81, 110], ["Aex", "GENE_OR_GENE_PRODUCT", 15, 18], ["exosomes", "CELL", 36, 44], ["CTL", "CELL", 46, 49], ["cytotoxic T lymphocytes", "CELL", 51, 74], ["DTH", "GENE_OR_GENE_PRODUCT", 76, 79], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 112, 118], ["granulocyte-macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 120, 168], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 170, 175], ["interferon \u03b3", "GENE_OR_GENE_PRODUCT", 177, 189], ["CD8 + tetramer", "GENE_OR_GENE_PRODUCT", 262, 276], ["CAP-1", "GENE_OR_GENE_PRODUCT", 278, 283], ["cells", "CELL", 320, 325], ["cells", "CELL", 403, 408], ["SW480 cells", "CELL", 421, 432], ["ascites-derived exosomes", "CELL_TYPE", 20, 44], ["CTL", "CELL_TYPE", 46, 49], ["cytotoxic T lymphocytes", "CELL_TYPE", 51, 74], ["DTH", "PROTEIN", 76, 79], ["GM", "PROTEIN", 112, 114], ["CSF", "PROTEIN", 115, 118], ["granulocyte-macrophage colony-stimulating factor", "PROTEIN", 120, 168], ["IFN", "PROTEIN", 170, 173], ["\u03b3", "PROTEIN", 174, 175], ["interferon \u03b3", "PROTEIN", 177, 189], ["CD8", "PROTEIN", 262, 265], ["CAP", "PROTEIN", 278, 281], ["total emigrated cells", "CELL_TYPE", 304, 325], ["DTH site-derived cultured cells", "CELL_LINE", 377, 408], ["SW480 cells", "CELL_LINE", 421, 432], ["Aex", "TEST", 15, 18], ["ascites", "PROBLEM", 20, 27], ["CTL", "TEST", 46, 49], ["cytotoxic T lymphocytes", "TEST", 51, 74], ["DTH", "TEST", 76, 79], ["delayed-type hypersensitivity", "PROBLEM", 81, 110], ["GM", "TEST", 112, 114], ["CSF", "TEST", 115, 118], ["granulocyte", "TEST", 120, 131], ["macrophage colony", "TEST", 132, 149], ["stimulating factor", "PROBLEM", 150, 168], ["IFN", "TEST", 170, 173], ["interferon", "TREATMENT", 177, 187], ["ND", "PROBLEM", 191, 193], ["CD8", "TEST", 262, 265], ["CAP", "TEST", 278, 281], ["SW480 cells", "TEST", 421, 432], ["ratio", "TEST", 434, 439], ["ascites", "OBSERVATION", 20, 27], ["CSF", "ANATOMY", 115, 118], ["granulocyte", "ANATOMY", 120, 131], ["macrophage colony", "OBSERVATION", 132, 149], ["emigrated cells", "OBSERVATION", 310, 325]]], ["The results were presented as mean percentage of cell lysis.", [["cell", "ANATOMY", 49, 53], ["cell", "CELL", 49, 53], ["cell lysis", "TREATMENT", 49, 59], ["cell lysis", "OBSERVATION", 49, 59]]], ["The cytotoxicity against LoVo cells were used as control and presented as mean percentage of cell lysis in parentheses. c CD8 + T lymphocytes derived from DTH site-derived cultured cells were cocultured with CAP-1-pulsed T2 cells or Ssp-1-pulsed T2 cells (in parentheses) for 24 hours.", [["LoVo cells", "ANATOMY", 25, 35], ["cell", "ANATOMY", 93, 97], ["c CD8 + T lymphocytes", "ANATOMY", 120, 141], ["cells", "ANATOMY", 181, 186], ["T2 cells", "ANATOMY", 221, 229], ["Ssp-1-pulsed T2 cells", "ANATOMY", 233, 254], ["LoVo cells", "CELL", 25, 35], ["cell", "CELL", 93, 97], ["c CD8", "GENE_OR_GENE_PRODUCT", 120, 125], ["cells", "CELL", 181, 186], ["CAP-1", "CELL", 208, 213], ["T2 cells", "CELL", 221, 229], ["Ssp-1-pulsed T2 cells", "CELL", 233, 254], ["LoVo cells", "CELL_LINE", 25, 35], ["c CD8 + T lymphocytes", "CELL_TYPE", 120, 141], ["DTH site", "DNA", 155, 163], ["cultured cells", "CELL_LINE", 172, 186], ["CAP-1-pulsed T2 cells", "CELL_LINE", 208, 229], ["Ssp-1-pulsed T2 cells", "CELL_LINE", 233, 254], ["The cytotoxicity", "TREATMENT", 0, 16], ["LoVo cells", "TREATMENT", 25, 35], ["cell lysis in parentheses", "PROBLEM", 93, 118], ["CD8", "TEST", 122, 125], ["T lymphocytes", "PROBLEM", 128, 141], ["DTH site", "PROBLEM", 155, 163], ["derived cultured cells", "TEST", 164, 186], ["CAP", "TEST", 208, 211], ["Ssp", "TEST", 233, 236], ["LoVo cells", "OBSERVATION", 25, 35], ["cell lysis", "OBSERVATION", 93, 103]]], ["IFN-\u03b3 in the coculture supernatant was measured by enzyme-linked immunosorbent assay were presented as mean level of IFN-\u03b3. d The DTH responses before the treatments (baseline) and 2 weeks after the treatments (post-treatments) against autologous Aex were evaluated.", [["supernatant", "ANATOMY", 23, 34], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 0, 5], ["Aex", "SIMPLE_CHEMICAL", 247, 250], ["IFN-\u03b3", "PROTEIN", 0, 5], ["IFN", "PROTEIN", 117, 120], ["IFN", "PROBLEM", 0, 3], ["enzyme", "TEST", 51, 57], ["immunosorbent assay", "TEST", 65, 84], ["the treatments", "TREATMENT", 151, 165], ["the treatments (post-treatments", "TREATMENT", 195, 226], ["autologous Aex", "TREATMENT", 236, 250]]], ["The results presented here were for diameter in millimeter of the response sites.Antitumor immune responses elicited by the treatmentsWe found that Aex alone at all the doses (100-500 \u03bcg) could not efficiently induce HLA-A0201-restricted and CEA-specific CTL response in vivo and in vitro because these exosomes accumulate HSPs and MHC-I molecules.", [["exosomes", "ANATOMY", 303, 311], ["Aex", "CHEMICAL", 148, 151], ["Antitumor", "CANCER", 81, 90], ["Aex", "SIMPLE_CHEMICAL", 148, 151], ["HLA-A0201", "GENE_OR_GENE_PRODUCT", 217, 226], ["CEA", "GENE_OR_GENE_PRODUCT", 242, 245], ["CTL", "CELL", 255, 258], ["exosomes", "CELL", 303, 311], ["HSPs", "GENE_OR_GENE_PRODUCT", 323, 327], ["MHC-I molecules", "GENE_OR_GENE_PRODUCT", 332, 347], ["A0201", "PROTEIN", 221, 226], ["CEA", "PROTEIN", 242, 245], ["exosomes", "CELL_TYPE", 303, 311], ["HSPs", "PROTEIN", 323, 327], ["MHC-I molecules", "PROTEIN", 332, 347], ["Antitumor immune responses", "TREATMENT", 81, 107], ["the treatments", "TREATMENT", 120, 134], ["Aex", "TREATMENT", 148, 151], ["HLA", "TEST", 217, 220], ["CEA", "TEST", 242, 245], ["diameter", "OBSERVATION_MODIFIER", 36, 44], ["millimeter", "OBSERVATION_MODIFIER", 48, 58], ["response sites", "OBSERVATION", 66, 80]]], ["24, 26 It has also been demonstrated by the others that an exosome-based cancer vaccine can enhance the host immune responses against tumors in combination with CpG oligodeoxynucleotides or double-stranded RNA.", [["exosome", "ANATOMY", 59, 66], ["cancer", "ANATOMY", 73, 79], ["tumors", "ANATOMY", 134, 140], ["cancer", "DISEASE", 73, 79], ["tumors", "DISEASE", 134, 140], ["CpG oligodeoxynucleotides", "CHEMICAL", 161, 186], ["CpG", "CHEMICAL", 161, 164], ["exosome", "CELLULAR_COMPONENT", 59, 66], ["cancer", "CANCER", 73, 79], ["tumors", "CANCER", 134, 140], ["CpG oligodeoxynucleotides", "SIMPLE_CHEMICAL", 161, 186], ["exosome", "PROTEIN", 59, 66], ["double-stranded RNA", "RNA", 190, 209], ["an exosome-based cancer vaccine", "TREATMENT", 56, 87], ["tumors", "PROBLEM", 134, 140], ["CpG oligodeoxynucleotides", "TREATMENT", 161, 186], ["double-stranded RNA", "TREATMENT", 190, 209], ["cancer", "OBSERVATION", 73, 79], ["stranded RNA", "OBSERVATION_MODIFIER", 197, 209]]], ["22, 23 GM-CSF has potential properties as a vaccine adjuvant and has been widely used as adjuvant in clinical trials of cancer vaccines.", [["cancer", "ANATOMY", 120, 126], ["GM", "CHEMICAL", 7, 9], ["cancer", "DISEASE", 120, 126], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 7, 13], ["cancer", "CANCER", 120, 126], ["a vaccine adjuvant", "TREATMENT", 42, 60], ["adjuvant", "TREATMENT", 89, 97], ["cancer vaccines", "TREATMENT", 120, 135], ["cancer", "OBSERVATION", 120, 126]]], ["29, 30 GM-CSF is a factor that can mediate the maturation and function of DC, and can increase the expression of MHC molecules and costimulators.", [["DC", "ANATOMY", 74, 76], ["GM", "CHEMICAL", 7, 9], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 7, 13], ["DC", "CELL", 74, 76], ["CSF", "PROTEIN", 10, 13], ["DC", "CELL_TYPE", 74, 76], ["MHC molecules", "PROTEIN", 113, 126], ["costimulators", "PROTEIN", 131, 144]]], ["37, 38 Studies have shown that tumor cells either transfected with GM-CSF genes or mixed with GM-CSF biodegradable capsules are able to induce specific immune responses in vitro and in vivo.", [["tumor cells", "ANATOMY", 31, 42], ["tumor", "DISEASE", 31, 36], ["GM", "CHEMICAL", 67, 69], ["GM", "CHEMICAL", 94, 96], ["tumor cells", "CELL", 31, 42], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 67, 73], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 94, 100], ["tumor cells", "CELL_TYPE", 31, 42], ["GM-CSF genes", "DNA", 67, 79], ["tumor cells", "PROBLEM", 31, 42], ["GM", "TEST", 67, 69], ["CSF genes", "TEST", 70, 79], ["GM-CSF biodegradable capsules", "TREATMENT", 94, 123], ["tumor", "OBSERVATION", 31, 36]]], ["39, 40 In this study, we selected a 50 \u03bcg dose of GM-CSF as adjuvant because the GM-CSF may enhance the vaccine-induced immune response at low doses (range 40-80 \u03bcg) but suppress immune function at higher doses (100-500 \u03bcg).", [["GM", "CHEMICAL", 50, 52], ["GM", "CHEMICAL", 81, 83], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 50, 56], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 81, 87], ["this study", "TEST", 10, 20], ["GM-CSF", "TREATMENT", 50, 56], ["adjuvant", "TREATMENT", 60, 68], ["the GM-CSF", "TEST", 77, 87], ["the vaccine", "TREATMENT", 100, 111], ["immune function", "TEST", 179, 194]]], ["41, 42 Therefore, it can be expected that GM-CSF co-administration with Aex may lead to the enhancement of the efficiency of the Aex vaccine by promoting antigen presentation and T-cell activation, which is verified by our findings that the co-administration of Aex with GM-CSF is superior to Aex alone in inducing HLA-A0201 + , (v) CEA + in serum, (vi) malignant peritoneal effusions without hemorrhage and with a protein concentration >30 g/l.", [["T-cell", "ANATOMY", 179, 185], ["serum", "ANATOMY", 342, 347], ["malignant peritoneal effusions", "ANATOMY", 354, 384], ["GM", "CHEMICAL", 42, 44], ["Aex", "CHEMICAL", 72, 75], ["Aex", "CHEMICAL", 129, 132], ["Aex", "CHEMICAL", 262, 265], ["GM", "CHEMICAL", 271, 273], ["Aex", "CHEMICAL", 293, 296], ["malignant peritoneal effusions", "DISEASE", 354, 384], ["hemorrhage", "DISEASE", 393, 403], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 42, 48], ["Aex", "SIMPLE_CHEMICAL", 72, 75], ["Aex", "GENE_OR_GENE_PRODUCT", 129, 132], ["T-cell", "CELL", 179, 185], ["Aex", "SIMPLE_CHEMICAL", 262, 265], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 271, 277], ["Aex", "SIMPLE_CHEMICAL", 293, 296], ["HLA-A0201", "GENE_OR_GENE_PRODUCT", 315, 324], ["(v) CEA", "GENE_OR_GENE_PRODUCT", 329, 336], ["serum", "ORGANISM_SUBSTANCE", 342, 347], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 364, 374], ["A0201", "PROTEIN", 319, 324], ["CEA", "PROTEIN", 333, 336], ["GM-CSF co-administration", "TREATMENT", 42, 66], ["Aex", "TREATMENT", 72, 75], ["the Aex vaccine", "TREATMENT", 125, 140], ["T-cell activation", "PROBLEM", 179, 196], ["HLA", "TEST", 315, 318], ["CEA", "TEST", 333, 336], ["serum", "TEST", 342, 347], ["malignant peritoneal effusions", "PROBLEM", 354, 384], ["hemorrhage", "PROBLEM", 393, 403], ["a protein concentration", "TEST", 413, 436], ["malignant", "OBSERVATION_MODIFIER", 354, 363], ["peritoneal", "ANATOMY", 364, 374], ["effusions", "OBSERVATION", 375, 384], ["without", "UNCERTAINTY", 385, 392], ["hemorrhage", "OBSERVATION", 393, 403]]], ["Exclusion criteria included (i) pregnancy or lactation, (ii) neutrophil count \u22640.5 \u00d7 10 9 /l or a platelet count \u226420 \u00d7 10 9 /l, (iii) anti-HIV antibodies (Abs), (iv) an active infection, (v) contraindications for leukapheresis, and (vi) chemotherapy or radiotherapy undertaken within the last 4 weeks before the first dose.", [["neutrophil", "ANATOMY", 61, 71], ["platelet", "ANATOMY", 98, 106], ["infection", "DISEASE", 176, 185], ["neutrophil", "CELL", 61, 71], ["platelet", "CELL", 98, 106], ["HIV antibodies", "PROTEIN", 139, 153], ["Abs", "PROTEIN", 155, 158], ["HIV", "SPECIES", 139, 142], ["HIV", "SPECIES", 139, 142], ["neutrophil count", "TEST", 61, 77], ["a platelet count", "TEST", 96, 112], ["iii", "TEST", 129, 132], ["anti-HIV antibodies", "TEST", 134, 153], ["Abs", "TEST", 155, 158], ["an active infection", "PROBLEM", 166, 185], ["leukapheresis", "TREATMENT", 213, 226], ["chemotherapy", "TREATMENT", 237, 249], ["radiotherapy", "TREATMENT", 253, 265], ["active", "OBSERVATION_MODIFIER", 169, 175], ["infection", "OBSERVATION", 176, 185]]], ["All the patients with pathologically diagnosed CRC were unresponsive to or reluctant to accept the chemotherapy and radiotherapy.Materials and cell lines.The primary Abs used in this study included the anti-human CEA (BD Biosciences, Becton Dickinson, CA) and the Abs against HSC70, HSP70, HSP90, CD71, LAMP-3, MHC-I, and MHC-II (Santa Cruz Biotechnology, Santa Cruz, CA).", [["CRC", "ANATOMY", 47, 50], ["cell lines", "ANATOMY", 143, 153], ["CRC", "DISEASE", 47, 50], ["patients", "ORGANISM", 8, 16], ["CRC", "CANCER", 47, 50], ["cell lines", "CELL", 143, 153], ["CEA", "GENE_OR_GENE_PRODUCT", 213, 216], ["HSC70", "GENE_OR_GENE_PRODUCT", 276, 281], ["HSP70", "GENE_OR_GENE_PRODUCT", 283, 288], ["HSP90", "GENE_OR_GENE_PRODUCT", 290, 295], ["CD71", "GENE_OR_GENE_PRODUCT", 297, 301], ["LAMP-3", "GENE_OR_GENE_PRODUCT", 303, 309], ["MHC-I", "GENE_OR_GENE_PRODUCT", 311, 316], ["MHC-II", "GENE_OR_GENE_PRODUCT", 322, 328], ["cell lines", "CELL_LINE", 143, 153], ["primary Abs", "PROTEIN", 158, 169], ["anti-human CEA", "PROTEIN", 202, 216], ["BD Biosciences", "PROTEIN", 218, 232], ["CA", "PROTEIN", 252, 254], ["Abs", "PROTEIN", 264, 267], ["HSC70", "PROTEIN", 276, 281], ["HSP70", "PROTEIN", 283, 288], ["HSP90", "PROTEIN", 290, 295], ["CD71", "PROTEIN", 297, 301], ["LAMP", "PROTEIN", 303, 307], ["MHC", "PROTEIN", 311, 314], ["I", "PROTEIN", 315, 316], ["MHC-II", "PROTEIN", 322, 328], ["Santa Cruz Biotechnology", "PROTEIN", 330, 354], ["Santa Cruz, CA", "PROTEIN", 356, 370], ["patients", "SPECIES", 8, 16], ["pathologically diagnosed CRC", "PROBLEM", 22, 50], ["the chemotherapy", "TREATMENT", 95, 111], ["radiotherapy", "TREATMENT", 116, 128], ["cell lines", "TREATMENT", 143, 153], ["this study", "TEST", 178, 188], ["the anti-human CEA", "TREATMENT", 198, 216], ["the Abs", "TEST", 260, 267], ["HSC70", "TEST", 276, 281], ["HSP70", "TEST", 283, 288], ["HSP90", "TEST", 290, 295], ["CD71", "TEST", 297, 301], ["LAMP", "TEST", 303, 307], ["MHC", "TEST", 311, 314], ["CRC", "OBSERVATION", 47, 50], ["cell lines", "OBSERVATION", 143, 153]]], ["The horseradish peroxidasecoupled secondary Abs were from Santa Cruz Biotechnology.", [["horseradish peroxidasecoupled secondary Abs", "PROTEIN", 4, 47], ["Santa Cruz Biotechnology", "PROTEIN", 58, 82], ["horseradish", "SPECIES", 4, 15]]], ["Human GM-CSF was purchased from Schering-Plough China (Shanghai, China).", [["GM", "CHEMICAL", 6, 8], ["Human", "ORGANISM", 0, 5], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 6, 12], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5]]], ["Roswell Park Memorial Institute medium-1640, fetal bovine serum were purchased from Hyclone (Logan, UT).", [["fetal bovine serum", "ANATOMY", 45, 63], ["bovine", "ORGANISM", 51, 57], ["serum", "ORGANISM_SUBSTANCE", 58, 63], ["Hyclone", "ORGANISM_SUBSTANCE", 84, 91], ["bovine", "SPECIES", 51, 57], ["bovine", "SPECIES", 51, 57], ["fetal bovine serum", "TEST", 45, 63]]], ["Recombination human IL-2 was purchased from Sigma (St. Louis, MO).", [["human", "ORGANISM", 14, 19], ["IL-2", "GENE_OR_GENE_PRODUCT", 20, 24], ["Sigma", "ORGANISM_SUBSTANCE", 44, 49], ["St. Louis, MO", "ORGANISM", 51, 64], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 14, 19]]], ["Human IFN-\u03b3 enzyme-linked immunosorbent assay kit was purchased from R&D systems (Minneapolis, MN).", [["Human", "ORGANISM", 0, 5], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 6, 11], ["Human IFN-\u03b3 enzyme", "PROTEIN", 0, 18], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human IFN", "TEST", 0, 9], ["enzyme-linked immunosorbent assay kit", "TEST", 12, 49]]], ["51 Cr sodium chromate was purchased from Amersham Pharmacia Biotech (Arlington Heights, IL).", [["Cr", "CHEMICAL", 3, 5], ["sodium chromate", "CHEMICAL", 6, 21], ["Cr sodium chromate", "CHEMICAL", 3, 21], ["Cr sodium chromate", "SIMPLE_CHEMICAL", 3, 21], ["Cr sodium chromate", "TEST", 3, 21]]], ["The CEA peptide CAP-1 and coronavirus SAS-CoV spike protein peptide SSp-1 were synthesized by GL Biochem (Shanghai, China), the purity of which was >95%.", [["CEA", "GENE_OR_GENE_PRODUCT", 4, 7], ["CAP-1", "GENE_OR_GENE_PRODUCT", 16, 21], ["coronavirus", "ORGANISM", 26, 37], ["SAS-CoV", "GENE_OR_GENE_PRODUCT", 38, 45], ["coronavirus SAS-CoV spike protein", "PROTEIN", 26, 59], ["coronavirus", "SPECIES", 26, 37], ["coronavirus SAS-CoV", "SPECIES", 26, 45], ["The CEA peptide CAP", "TEST", 0, 19], ["coronavirus SAS", "TEST", 26, 41], ["CoV spike protein peptide SSp", "TEST", 42, 71], ["CAP", "OBSERVATION_MODIFIER", 16, 19]]], ["The phycoerythrin-labeled HLA-A0201/SSp-1-tetramers were a kind gift from Dr. X. Cao (Institute of Immunology, Second Military Medical University, P.R. China).", [["phycoerythrin", "GENE_OR_GENE_PRODUCT", 4, 17], ["SSp-1", "GENE_OR_GENE_PRODUCT", 36, 41], ["phycoerythrin-labeled HLA-A0201", "PROTEIN", 4, 35], ["SSp", "PROTEIN", 36, 39], ["The phycoerythrin", "TEST", 0, 17], ["HLA", "TEST", 26, 29], ["SSp", "TEST", 36, 39], ["phycoerythrin", "OBSERVATION", 4, 17]]], ["24 The human colon adenocarcinoma SW480 (HLA-A2 + CEA + ) and LoVo (HLA-A2 -CEA + ) cell lines, and the transporter associated with antigen processing (TAP)-deficient T2 cell lines were obtained from American Type Culture Collection (Manassas, VA) and maintained with defined culture medium according to the supplier's specifications.Preparation of exosomes from ascites of patients.The Aex were prepared according to a modified method previously described under GMP conditions.", [["colon adenocarcinoma SW480", "ANATOMY", 13, 39], ["HLA-A2 + CEA + )", "ANATOMY", 41, 57], ["LoVo (HLA-A2 -CEA + ) cell lines", "ANATOMY", 62, 94], ["T2 cell lines", "ANATOMY", 167, 180], ["exosomes", "ANATOMY", 349, 357], ["ascites", "ANATOMY", 363, 370], ["colon adenocarcinoma", "DISEASE", 13, 33], ["ascites", "DISEASE", 363, 370], ["GMP", "CHEMICAL", 463, 466], ["GMP", "CHEMICAL", 463, 466], ["human", "ORGANISM", 7, 12], ["colon adenocarcinoma SW480", "CANCER", 13, 39], ["HLA-A2", "GENE_OR_GENE_PRODUCT", 41, 47], ["CEA", "GENE_OR_GENE_PRODUCT", 50, 53], ["LoVo", "CELL", 62, 66], ["HLA-A2", "GENE_OR_GENE_PRODUCT", 68, 74], ["TAP", "GENE_OR_GENE_PRODUCT", 152, 155], ["T2 cell lines", "CELL", 167, 180], ["exosomes", "CELL", 349, 357], ["ascites", "CANCER", 363, 370], ["patients", "ORGANISM", 374, 382], ["Aex", "SIMPLE_CHEMICAL", 387, 390], ["human colon adenocarcinoma SW480 (HLA-A2 + CEA + ) and LoVo (HLA-A2 -CEA + ) cell lines", "CELL_LINE", 7, 94], ["antigen processing (TAP)-deficient T2 cell lines", "CELL_LINE", 132, 180], ["exosomes", "CELL_TYPE", 349, 357], ["human", "SPECIES", 7, 12], ["patients", "SPECIES", 374, 382], ["human", "SPECIES", 7, 12], ["The human colon adenocarcinoma", "TEST", 3, 33], ["HLA", "TEST", 41, 44], ["A2", "TEST", 45, 47], ["CEA", "TEST", 50, 53], ["LoVo", "TEST", 62, 66], ["HLA", "TEST", 68, 71], ["A2", "TEST", 72, 74], ["cell lines", "PROBLEM", 84, 94], ["the transporter", "PROBLEM", 100, 115], ["antigen processing", "PROBLEM", 132, 150], ["TAP", "TEST", 152, 155], ["deficient T2 cell lines", "PROBLEM", 157, 180], ["American Type Culture Collection", "TEST", 200, 232], ["defined culture medium", "TREATMENT", 268, 290], ["ascites", "PROBLEM", 363, 370], ["a modified method", "TREATMENT", 418, 435], ["colon", "ANATOMY", 13, 18], ["adenocarcinoma", "OBSERVATION", 19, 33], ["cell lines", "OBSERVATION", 84, 94], ["cell lines", "OBSERVATION", 170, 180], ["exosomes", "OBSERVATION", 349, 357], ["ascites", "OBSERVATION", 363, 370]]], ["16, 18 Briefly, 800 ml of malignant ascites from the enrolled patients were collected in a bag containing anticoagulant.", [["malignant ascites", "ANATOMY", 26, 43], ["malignant ascites", "DISEASE", 26, 43], ["malignant ascites", "CANCER", 26, 43], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["malignant ascites", "PROBLEM", 26, 43], ["a bag containing anticoagulant", "TREATMENT", 89, 119], ["malignant", "OBSERVATION_MODIFIER", 26, 35], ["ascites", "OBSERVATION", 36, 43]]], ["Then, cell debris and protein aggregates of the ascites were removed by preliminary centrifugation at 300g.", [["cell", "ANATOMY", 6, 10], ["ascites", "ANATOMY", 48, 55], ["ascites", "DISEASE", 48, 55], ["cell", "CELL", 6, 10], ["ascites", "CANCER", 48, 55], ["cell debris", "PROBLEM", 6, 17], ["the ascites", "PROBLEM", 44, 55], ["cell debris", "OBSERVATION", 6, 17], ["protein aggregates", "OBSERVATION", 22, 40], ["ascites", "OBSERVATION", 48, 55]]], ["After centrifugations successively at 800g for 30 minutes, 10,000g for 30 minutes, and 100,000g for 1 hour, the pellet was collected, resuspended in phosphate-buffered saline (PBS) and centrifuged at 90,000g for 1.25 hours to remove irrelevent cell debris.", [["pellet", "ANATOMY", 112, 118], ["cell", "ANATOMY", 244, 248], ["phosphate", "CHEMICAL", 149, 158], ["phosphate", "CHEMICAL", 149, 158], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 149, 174], ["cell", "CELL", 244, 248], ["phosphate-buffered saline (PBS", "TREATMENT", 149, 179], ["irrelevent cell debris", "PROBLEM", 233, 255], ["irrelevent cell debris", "OBSERVATION", 233, 255]]], ["After ultracentrifugation on 30% sucrose/D 2 O density gradient at 100,000g for 2 hours, Aex contained in sucrose were collected and resuspended in PBS, then ultracentrifuged at 100,000g for 1 hour.", [["sucrose", "CHEMICAL", 33, 40], ["Aex", "CHEMICAL", 89, 92], ["sucrose", "CHEMICAL", 106, 113], ["sucrose", "CHEMICAL", 33, 40], ["D 2 O", "CHEMICAL", 41, 46], ["sucrose", "CHEMICAL", 106, 113], ["D 2 O", "SIMPLE_CHEMICAL", 41, 46], ["Aex", "SIMPLE_CHEMICAL", 89, 92], ["sucrose", "SIMPLE_CHEMICAL", 106, 113], ["ultracentrifugation", "TREATMENT", 6, 25], ["30% sucrose/D 2 O density gradient", "TREATMENT", 29, 63], ["Aex", "TREATMENT", 89, 92], ["sucrose", "TREATMENT", 106, 113]]], ["Finally, the Aex pellet was resuspended in PBS and \u00a9 The American Society of Gene Therapy Phase I Clinical Trial of Aex Plus GM-CSF stored for use at -80 \u00b0C. All the Aex were determined for protein concentration by Bradford assay (BioRad).", [["GM", "CHEMICAL", 125, 127], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 125, 131], ["Aex", "GENE_OR_GENE_PRODUCT", 166, 169], ["Aex", "DNA", 166, 169], ["the Aex pellet", "TREATMENT", 9, 23], ["Gene Therapy", "TREATMENT", 77, 89], ["Aex", "TEST", 116, 119], ["protein concentration", "TEST", 190, 211]]], ["Endotoxin of all exosomes is free as confirmed by Limulus amebocyte lysate assay.Preparation of exosomes from ascites of patients.Electron microscopy.", [["exosomes", "ANATOMY", 17, 25], ["exosomes", "ANATOMY", 96, 104], ["ascites", "ANATOMY", 110, 117], ["Endotoxin", "CHEMICAL", 0, 9], ["ascites", "DISEASE", 110, 117], ["Endotoxin", "SIMPLE_CHEMICAL", 0, 9], ["exosomes", "CELL", 17, 25], ["exosomes", "CELL", 96, 104], ["ascites", "CANCER", 110, 117], ["patients", "ORGANISM", 121, 129], ["exosomes", "CELL_TYPE", 17, 25], ["exosomes", "CELL_TYPE", 96, 104], ["patients", "SPECIES", 121, 129], ["Limulus amebocyte lysate assay", "TEST", 50, 80], ["ascites", "PROBLEM", 110, 117], ["Electron microscopy", "TEST", 130, 149], ["exosomes", "OBSERVATION", 96, 104], ["ascites", "OBSERVATION", 110, 117]]], ["The purified Aex were fixed for 1 hour in 4% paraformaldehyde and washed once with PBS.", [["paraformaldehyde", "CHEMICAL", 45, 61], ["Aex", "SIMPLE_CHEMICAL", 13, 16], ["paraformaldehyde", "SIMPLE_CHEMICAL", 45, 61], ["The purified Aex", "TREATMENT", 0, 16], ["4% paraformaldehyde", "TREATMENT", 42, 61], ["PBS", "TREATMENT", 83, 86]]], ["Then, the pellets were fixed in 2.5% glutaraldehyde, loaded on Formwar-/carbon-coated EM grids, postfixed in 1% glutaraldehyde, and contrasted successively in 2% methycellulose/0.4% uranyl acetate (pH 4.0) as described previously.", [["glutaraldehyde", "CHEMICAL", 37, 51], ["glutaraldehyde", "CHEMICAL", 112, 126], ["methycellulose", "CHEMICAL", 162, 176], ["uranyl acetate", "CHEMICAL", 182, 196], ["glutaraldehyde", "CHEMICAL", 37, 51], ["carbon", "CHEMICAL", 72, 78], ["glutaraldehyde", "CHEMICAL", 112, 126], ["methycellulose", "CHEMICAL", 162, 176], ["uranyl acetate", "CHEMICAL", 182, 196], ["glutaraldehyde", "SIMPLE_CHEMICAL", 37, 51], ["glutaraldehyde", "SIMPLE_CHEMICAL", 112, 126], ["methycellulose", "SIMPLE_CHEMICAL", 162, 176], ["uranyl acetate", "SIMPLE_CHEMICAL", 182, 196], ["the pellets", "TREATMENT", 6, 17], ["Formwar-/carbon-coated EM grids", "TREATMENT", 63, 94], ["1% glutaraldehyde", "TREATMENT", 109, 126], ["2% methycellulose/0.4% uranyl acetate", "TREATMENT", 159, 196]]], ["24 Observations were made with Philips EM410 electron microscopy (Eindhoven, the Netherlands).Preparation of exosomes from ascites of patients.Western blotting.", [["exosomes", "ANATOMY", 109, 117], ["ascites", "ANATOMY", 123, 130], ["ascites", "DISEASE", 123, 130], ["exosomes", "CELL", 109, 117], ["ascites", "CANCER", 123, 130], ["patients", "ORGANISM", 134, 142], ["exosomes", "CELL_TYPE", 109, 117], ["patients", "SPECIES", 134, 142], ["ascites", "PROBLEM", 123, 130], ["exosomes", "OBSERVATION", 109, 117], ["ascites", "OBSERVATION", 123, 130]]], ["Analysis of Western blotting was done according to the protocol described previously by us.", [["Western blotting", "TEST", 12, 28], ["the protocol", "TEST", 51, 63]]], ["24 Briefly, same amount (30 \u03bcg) of Aex or whole cell lysate was separated on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel, transferred to nitrocellulose membranes, incubated with specific primary Abs at the supplier's recommended dilutions, and finally followed by horseradish peroxidase-coupled secondary Abs and chemiluminescence detection.Preparation of exosomes from ascites of patients.Randomization and treatment plan.", [["cell lysate", "ANATOMY", 48, 59], ["membranes", "ANATOMY", 176, 185], ["exosomes", "ANATOMY", 380, 388], ["ascites", "ANATOMY", 394, 401], ["Aex", "CHEMICAL", 35, 38], ["sodium dodecyl sulfate", "CHEMICAL", 83, 105], ["ascites", "DISEASE", 394, 401], ["sodium dodecyl sulfate", "CHEMICAL", 83, 105], ["polyacrylamide", "CHEMICAL", 106, 120], ["nitrocellulose", "CHEMICAL", 161, 175], ["Aex", "SIMPLE_CHEMICAL", 35, 38], ["cell lysate", "ORGANISM_SUBSTANCE", 48, 59], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 83, 105], ["membranes", "CELLULAR_COMPONENT", 176, 185], ["horseradish", "SIMPLE_CHEMICAL", 288, 299], ["peroxidase", "SIMPLE_CHEMICAL", 300, 310], ["exosomes", "CELL", 380, 388], ["ascites", "CANCER", 394, 401], ["patients", "ORGANISM", 405, 413], ["Abs", "PROTEIN", 219, 222], ["horseradish peroxidase", "PROTEIN", 288, 310], ["coupled secondary Abs", "PROTEIN", 311, 332], ["exosomes", "CELL_TYPE", 380, 388], ["horseradish", "SPECIES", 288, 299], ["patients", "SPECIES", 405, 413], ["Aex or whole cell lysate", "TREATMENT", 35, 59], ["a 10% sodium dodecyl sulfate", "TREATMENT", 77, 105], ["polyacrylamide gel electrophoresis gel", "TREATMENT", 106, 144], ["nitrocellulose membranes", "TREATMENT", 161, 185], ["horseradish peroxidase", "TEST", 288, 310], ["secondary Abs", "PROBLEM", 319, 332], ["chemiluminescence detection", "TEST", 337, 364], ["ascites", "PROBLEM", 394, 401], ["Randomization", "TREATMENT", 414, 427], ["treatment plan", "TREATMENT", 432, 446], ["exosomes", "OBSERVATION", 380, 388], ["ascites", "OBSERVATION", 394, 401]]], ["Forty patients with advanced CRC were enrolled after giving written informed consent.", [["CRC", "ANATOMY", 29, 32], ["CRC", "DISEASE", 29, 32], ["patients", "ORGANISM", 6, 14], ["CRC", "CANCER", 29, 32], ["patients", "SPECIES", 6, 14], ["advanced CRC", "PROBLEM", 20, 32], ["CRC", "OBSERVATION", 29, 32]]], ["These patients were randomly assigned to eight groups.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14]]], ["Patients in groups A-D received 100, 200, 300, and 500 \u03bcg autologous Aex (in 100 \u03bcl PBS) subcutaneous immunization, respectively, in the forearm while patients in groups E-G received 100, 200, 300, and 500 \u03bcg autologous Aex plus 50 \u03bcg GM-CSF (in 100 \u03bcl PBS) subcutaneous immunization, respectively, in the forearm.", [["subcutaneous", "ANATOMY", 89, 101], ["forearm", "ANATOMY", 137, 144], ["subcutaneous", "ANATOMY", 258, 270], ["forearm", "ANATOMY", 306, 313], ["Aex", "CHEMICAL", 69, 72], ["Aex", "CHEMICAL", 220, 223], ["GM", "CHEMICAL", 235, 237], ["Patients", "ORGANISM", 0, 8], ["Aex", "SIMPLE_CHEMICAL", 69, 72], ["forearm", "ORGANISM_SUBDIVISION", 137, 144], ["patients", "ORGANISM", 151, 159], ["Aex", "SIMPLE_CHEMICAL", 220, 223], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 235, 241], ["forearm", "ORGANISM_SUBDIVISION", 306, 313], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 151, 159], ["500 \u03bcg autologous Aex", "TREATMENT", 51, 72], ["subcutaneous immunization", "TREATMENT", 89, 114], ["subcutaneous immunization", "TREATMENT", 258, 283], ["forearm", "ANATOMY", 137, 144], ["forearm", "ANATOMY", 306, 313]]], ["The enrolled patients received a total of four immunizations at weekly intervals.Preparation of exosomes from ascites of patients.Clinical monitoring.", [["exosomes", "ANATOMY", 96, 104], ["ascites", "ANATOMY", 110, 117], ["ascites", "DISEASE", 110, 117], ["patients", "ORGANISM", 13, 21], ["exosomes", "CELL", 96, 104], ["ascites", "CANCER", 110, 117], ["patients", "ORGANISM", 121, 129], ["exosomes", "CELL_TYPE", 96, 104], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 121, 129], ["four immunizations", "TREATMENT", 42, 60], ["ascites", "PROBLEM", 110, 117], ["Clinical monitoring", "TEST", 130, 149], ["exosomes", "OBSERVATION", 96, 104], ["ascites", "OBSERVATION", 110, 117]]], ["In this study, assessment of the CRC patients was performed at baseline and 2 weeks after a course of vaccination (28 days) according to the RECIST criteria.", [["CRC", "ANATOMY", 33, 36], ["CRC", "DISEASE", 33, 36], ["CRC", "CANCER", 33, 36], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["this study", "TEST", 3, 13], ["assessment of the CRC", "TEST", 15, 36], ["vaccination", "TREATMENT", 102, 113], ["the RECIST criteria", "TEST", 137, 156], ["CRC", "OBSERVATION", 33, 36]]], ["Tumor progression (progressive disease): \u226520% increase of target lesions or the appearance of new lesions; partial responses: \u226530% decrease of target lesions; complete responses: the disappearance of target tumor.", [["Tumor", "ANATOMY", 0, 5], ["lesions", "ANATOMY", 65, 72], ["lesions", "ANATOMY", 98, 105], ["lesions", "ANATOMY", 150, 157], ["tumor", "ANATOMY", 207, 212], ["Tumor", "DISEASE", 0, 5], ["tumor", "DISEASE", 207, 212], ["Tumor", "CANCER", 0, 5], ["lesions", "CANCER", 65, 72], ["lesions", "PATHOLOGICAL_FORMATION", 98, 105], ["lesions", "PATHOLOGICAL_FORMATION", 150, 157], ["tumor", "CANCER", 207, 212], ["Tumor progression (progressive disease)", "PROBLEM", 0, 39], ["target lesions", "PROBLEM", 58, 72], ["new lesions", "PROBLEM", 94, 105], ["target lesions", "PROBLEM", 143, 157], ["target tumor", "PROBLEM", 200, 212], ["progressive", "OBSERVATION_MODIFIER", 19, 30], ["disease", "OBSERVATION", 31, 38], ["target", "OBSERVATION_MODIFIER", 58, 64], ["lesions", "OBSERVATION", 65, 72], ["new", "OBSERVATION_MODIFIER", 94, 97], ["lesions", "OBSERVATION", 98, 105], ["partial", "OBSERVATION_MODIFIER", 107, 114], ["target", "OBSERVATION_MODIFIER", 143, 149], ["lesions", "OBSERVATION", 150, 157], ["target", "OBSERVATION_MODIFIER", 200, 206], ["tumor", "OBSERVATION", 207, 212]]], ["On day 28 of the first course of treatment, toxicity was re-evaluated by the treating physician and response to therapy was assessed using the WHO criteria.", [["toxicity", "DISEASE", 44, 52], ["treatment", "TREATMENT", 33, 42], ["toxicity", "PROBLEM", 44, 52], ["therapy", "TREATMENT", 112, 119]]], ["Toxicity was assessed throughout the study using the National Cancer Institute Common Toxicity Criteria version 2.0.DTH responses.Analysis of specific immune response was performed by post-treatment DTH reactions.", [["Toxicity", "DISEASE", 0, 8], ["Cancer", "DISEASE", 62, 68], ["Toxicity", "DISEASE", 86, 94], ["DTH", "GENE_OR_GENE_PRODUCT", 116, 119], ["the study", "TEST", 33, 42], ["the National Cancer", "TREATMENT", 49, 68], ["post-treatment DTH reactions", "TEST", 184, 212]]], ["43 Briefly, 2 weeks after the last vaccination, 100 \u03bcg Aex were injected intradermally in the lateral limb of the vaccine immunization sites.", [["intradermally", "ANATOMY", 73, 86], ["lateral limb", "ANATOMY", 94, 106], ["Aex", "CHEMICAL", 55, 58], ["Aex", "SIMPLE_CHEMICAL", 55, 58], ["lateral limb", "ORGANISM_SUBDIVISION", 94, 106], ["the last vaccination", "TREATMENT", 26, 46], ["Aex", "TREATMENT", 55, 58], ["the vaccine immunization sites", "TREATMENT", 110, 140], ["lateral limb", "ANATOMY", 94, 106]]], ["After 48 hours, the maximum diameter (in millimeter) of induration was measured with a caliper.DTH site-derived tissue culture and CD8 + T cells isolation.This procedure mainly followed a modified protocol described by de Vries et al. 43 Briefly, punch biopsies derived from positive DTH sites (>2 mm) were cut into pieces, and leukocytes emigrating from these tissue pieces (DTH sitederived cells) were cultured in Roswell Park Memorial Institute medium-1640 containing 10% fetal bovine serum and 100 U/ml IL-2.", [["tissue culture", "ANATOMY", 112, 126], ["CD8 + T cells", "ANATOMY", 131, 144], ["punch biopsies", "ANATOMY", 247, 261], ["DTH sites", "ANATOMY", 284, 293], ["pieces", "ANATOMY", 316, 322], ["leukocytes", "ANATOMY", 328, 338], ["tissue pieces", "ANATOMY", 361, 374], ["DTH sitederived cells", "ANATOMY", 376, 397], ["fetal bovine serum", "ANATOMY", 475, 493], ["tissue", "TISSUE", 112, 118], ["CD8", "GENE_OR_GENE_PRODUCT", 131, 134], ["punch biopsies", "CANCER", 247, 261], ["DTH sites", "MULTI-TISSUE_STRUCTURE", 284, 293], ["leukocytes", "CELL", 328, 338], ["tissue", "TISSUE", 361, 367], ["DTH sitederived cells", "CELL", 376, 397], ["bovine", "ORGANISM", 481, 487], ["serum", "ORGANISM_SUBSTANCE", 488, 493], ["IL-2", "GENE_OR_GENE_PRODUCT", 507, 511], ["DTH site", "DNA", 95, 103], ["CD8 + T cells", "CELL_TYPE", 131, 144], ["DTH sites", "DNA", 284, 293], ["leukocytes", "CELL_TYPE", 328, 338], ["DTH sitederived cells", "CELL_LINE", 376, 397], ["bovine", "SPECIES", 481, 487], ["bovine", "SPECIES", 481, 487], ["induration", "PROBLEM", 56, 66], ["tissue culture", "TEST", 112, 126], ["CD8", "TEST", 131, 134], ["T cells isolation", "TREATMENT", 137, 154], ["This procedure", "TREATMENT", 155, 169], ["a modified protocol", "TREATMENT", 186, 205], ["punch biopsies", "TEST", 247, 261], ["positive DTH sites", "PROBLEM", 275, 293], ["leukocytes", "TEST", 328, 338], ["fetal bovine serum", "TREATMENT", 475, 493], ["maximum", "OBSERVATION_MODIFIER", 20, 27], ["diameter", "OBSERVATION_MODIFIER", 28, 36], ["millimeter", "OBSERVATION_MODIFIER", 41, 51], ["induration", "OBSERVATION", 56, 66], ["tissue", "ANATOMY", 112, 118], ["leukocytes", "ANATOMY", 328, 338]]], ["Half of the medium was replaced by fresh IL-2-containing the culture medium every 5 days.", [["IL-2", "SIMPLE_CHEMICAL", 41, 45], ["IL", "PROTEIN", 41, 43], ["fresh IL", "TREATMENT", 35, 43]]], ["After 2 weeks of culture, the cells were examined for CTL response.", [["cells", "ANATOMY", 30, 35], ["cells", "CELL", 30, 35], ["culture", "TEST", 17, 24], ["the cells", "TEST", 26, 35]]], ["In order to test specific IFN-\u03b3 release and evaluate CTL production, CD8 + T lymphocytes were purified by using CD4 + cell-negative depletion.DTH site-derived tissue culture and CD8 + T cells isolation.Tetramer test.", [["CD8 + T lymphocytes", "ANATOMY", 69, 88], ["CD4 + cell", "ANATOMY", 112, 122], ["tissue culture", "ANATOMY", 159, 173], ["CD8 + T cells", "ANATOMY", 178, 191], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 26, 31], ["CTL", "CELL", 53, 56], ["CD8", "GENE_OR_GENE_PRODUCT", 69, 72], ["CD4", "GENE_OR_GENE_PRODUCT", 112, 115], ["tissue", "TISSUE", 159, 165], ["CD8", "GENE_OR_GENE_PRODUCT", 178, 181], ["IFN", "PROTEIN", 26, 29], ["\u03b3", "PROTEIN", 30, 31], ["CD8", "PROTEIN", 69, 72], ["T lymphocytes", "CELL_TYPE", 75, 88], ["CD4", "PROTEIN", 112, 115], ["DTH site", "DNA", 142, 150], ["CD8 + T cells", "CELL_TYPE", 178, 191], ["IFN", "TEST", 26, 29], ["CTL production", "TEST", 53, 67], ["CD8", "TEST", 69, 72], ["CD4", "TEST", 112, 115], ["tissue culture", "TEST", 159, 173], ["CD8", "TEST", 178, 181], ["T cells isolation", "TREATMENT", 184, 201], ["Tetramer test", "TEST", 202, 215], ["negative depletion", "OBSERVATION", 123, 141], ["tissue", "ANATOMY", 159, 165]]], ["The tetramer test was conducted according to our previously described method.", [["The tetramer test", "TEST", 0, 17]]], ["24 DTH site-derived cells were stained with phycoerythrin-labeled HLA-A*0201 tetramers (CAP-1 or SSp-1-specific) and fluorescein isothiocyanate-conjugated anti-CD8 for 40 minutes at room temperature.", [["cells", "ANATOMY", 20, 25], ["fluorescein isothiocyanate", "CHEMICAL", 117, 143], ["fluorescein isothiocyanate", "CHEMICAL", 117, 143], ["cells", "CELL", 20, 25], ["phycoerythrin", "GENE_OR_GENE_PRODUCT", 44, 57], ["CAP-1", "GENE_OR_GENE_PRODUCT", 88, 93], ["SSp-1", "SIMPLE_CHEMICAL", 97, 102], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 117, 143], ["anti-CD8", "SIMPLE_CHEMICAL", 155, 163], ["DTH site", "DNA", 3, 11], ["phycoerythrin-labeled HLA-A*0201 tetramers", "PROTEIN", 44, 86], ["SSp", "PROTEIN", 97, 100], ["conjugated anti-CD8", "PROTEIN", 144, 163], ["phycoerythrin", "TEST", 44, 57], ["HLA", "TEST", 66, 69], ["CAP", "TEST", 88, 91], ["SSp", "TEST", 97, 100], ["fluorescein isothiocyanate", "TREATMENT", 117, 143], ["conjugated anti-CD8", "TREATMENT", 144, 163]]], ["After washing, the samples were analyzed by flow cytometry (Beckman Epics XL).IFN-\u03b3 release assay.Specific IFN-\u03b3 release assay was conducted as described.", [["samples", "ANATOMY", 19, 26], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 78, 83], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 107, 112], ["IFN", "PROTEIN", 78, 81], ["\u03b3", "PROTEIN", 82, 83], ["IFN", "PROTEIN", 107, 110], ["the samples", "TEST", 15, 26], ["flow cytometry", "TEST", 44, 58]]], ["24 Briefly, T2 cells pulsed with the indicated peptide were used as stimulator cells, CD8 + T lymphocytes were prepared as effector cells from the DTH sites-derived cells.", [["T2 cells", "ANATOMY", 12, 20], ["cells", "ANATOMY", 79, 84], ["CD8 + T lymphocytes", "ANATOMY", 86, 105], ["effector cells", "ANATOMY", 123, 137], ["DTH sites", "ANATOMY", 147, 156], ["cells", "ANATOMY", 165, 170], ["T2 cells", "CELL", 12, 20], ["cells", "CELL", 79, 84], ["CD8", "GENE_OR_GENE_PRODUCT", 86, 89], ["cells", "CELL", 132, 137], ["DTH sites-derived cells", "CELL", 147, 170], ["T2 cells", "CELL_LINE", 12, 20], ["stimulator cells", "CELL_TYPE", 68, 84], ["CD8 + T lymphocytes", "CELL_TYPE", 86, 105], ["effector cells", "CELL_TYPE", 123, 137], ["DTH sites", "DNA", 147, 156], ["stimulator cells", "TEST", 68, 84], ["CD8", "TEST", 86, 89], ["T lymphocytes", "PROBLEM", 92, 105], ["the DTH sites", "TEST", 143, 156]]], ["5 \u00d7 10 4 effector cells and 1 \u00d7 10 4 stimulator cells were cocultured in 96-well microplates.", [["cells", "ANATOMY", 18, 23], ["cells", "ANATOMY", 48, 53], ["cells", "CELL", 18, 23], ["cells", "CELL", 48, 53], ["effector cells", "CELL_TYPE", 9, 23], ["1 \u00d7 10 4 stimulator cells", "CELL_LINE", 28, 53], ["4 effector cells", "TREATMENT", 7, 23], ["1 \u00d7 10 4 stimulator cells", "TREATMENT", 28, 53]]], ["After 24 hours, supernatants were collected and tested for IFN-\u03b3 release by enzyme-linked immunosorbent assay according to the manufacturer's protocol.IFN-\u03b3 release assay.Cytotoxicity assessment.", [["supernatants", "ANATOMY", 16, 28], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 59, 64], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 151, 156], ["IFN", "PROTEIN", 59, 62], ["IFN", "PROTEIN", 151, 154], ["\u03b3", "PROTEIN", 155, 156], ["supernatants", "TEST", 16, 28], ["IFN", "TEST", 59, 62], ["enzyme", "TEST", 76, 82], ["immunosorbent assay", "TEST", 90, 109], ["the manufacturer's protocol", "TREATMENT", 123, 150], ["Cytotoxicity assessment", "TEST", 171, 194]]], ["Cytotoxicity assessment was done according to a standard 51 Cr release assay described.", [["Cr", "CHEMICAL", 60, 62], ["Cr", "CHEMICAL", 60, 62], ["Cr", "SIMPLE_CHEMICAL", 60, 62], ["Cytotoxicity assessment", "TEST", 0, 23]]], ["26 T2 cells pulsed with CAP-1 or SSp-1, and SW480 cells or LoVo cells were labeled with 51 Cr sodium chromate in triplicate for 90 minutes at 37 \u00b0C, extensively washed three times, and were used as target cells.", [["T2 cells", "ANATOMY", 3, 11], ["CAP-1", "ANATOMY", 24, 29], ["SSp-1", "ANATOMY", 33, 38], ["SW480 cells", "ANATOMY", 44, 55], ["LoVo cells", "ANATOMY", 59, 69], ["cells", "ANATOMY", 205, 210], ["sodium chromate", "CHEMICAL", 94, 109], ["Cr sodium chromate", "CHEMICAL", 91, 109], ["T2 cells", "CELL", 3, 11], ["CAP-1", "CELL", 24, 29], ["SSp-1", "CELL", 33, 38], ["SW480 cells", "CELL", 44, 55], ["LoVo cells", "CELL", 59, 69], ["Cr sodium chromate", "SIMPLE_CHEMICAL", 91, 109], ["cells", "CELL", 205, 210], ["T2 cells", "CELL_LINE", 3, 11], ["SW480 cells", "CELL_LINE", 44, 55], ["LoVo cells", "CELL_LINE", 59, 69], ["target cells", "CELL_TYPE", 198, 210], ["T2 cells", "TEST", 3, 11], ["CAP", "TEST", 24, 27], ["SSp", "TEST", 33, 36], ["SW480 cells", "PROBLEM", 44, 55], ["LoVo cells", "TEST", 59, 69], ["Cr sodium chromate", "TEST", 91, 109], ["SW480 cells", "OBSERVATION", 44, 55], ["LoVo cells", "OBSERVATION", 59, 69]]], ["Effector cells (DTH site-derived cells) were cocultured with target cells at a different ratio in a final volume of 200 \u03bcl for 4 hours.", [["Effector cells", "ANATOMY", 0, 14], ["DTH site-derived cells", "ANATOMY", 16, 38], ["cells", "ANATOMY", 68, 73], ["Effector cells", "CELL", 0, 14], ["DTH site-derived cells", "CELL", 16, 38], ["cells", "CELL", 68, 73], ["Effector cells", "CELL_TYPE", 0, 14], ["DTH site-derived cells", "CELL_LINE", 16, 38], ["target cells", "CELL_TYPE", 61, 73], ["Effector cells (DTH site-derived cells", "TREATMENT", 0, 38]]], ["Then 100 \u03bcl supernatants were harvested for measuring the chromate release.", [["supernatants", "ANATOMY", 12, 24], ["chromate", "CHEMICAL", 58, 66], ["chromate", "CHEMICAL", 58, 66], ["chromate", "SIMPLE_CHEMICAL", 58, 66], ["the chromate release", "TREATMENT", 54, 74]]], ["The proportion of specific cytotoxicity was determined according to formula: [(counts/minute of experimental 51 Cr releasecounts/minute of the spontaneous 51 Cr release)/(counts/minute of the maximal 51 Cr release -counts/minute of the spontaneous 51 Cr release)] \u00d7 100%.", [["Cr", "CHEMICAL", 112, 114], ["Cr", "CHEMICAL", 158, 160], ["Cr", "CHEMICAL", 203, 205], ["Cr", "CHEMICAL", 251, 253], ["specific cytotoxicity", "PROBLEM", 18, 39], ["Cr release", "TEST", 203, 213], ["cytotoxicity", "OBSERVATION", 27, 39]]], ["Counts from targets incubated with medium alone were cited as spontaneous release, and counts from targets incubated with 5% Triton X-100 were cited as maximal release.", [["Triton X-100", "CHEMICAL", 125, 137], ["Triton X-100", "SIMPLE_CHEMICAL", 125, 137], ["Counts", "TEST", 0, 6], ["spontaneous release", "PROBLEM", 62, 81], ["counts", "TEST", 87, 93], ["5% Triton", "TREATMENT", 122, 131]]], ["The spontaneous release was always <15% of maximal release.Statistical analysis.Results are expressed as the means \u00b1 SEM or the means \u00b1 SD.", [["Statistical analysis", "TEST", 59, 79]]], ["Comparisons between two groups were conducted by Student's t-test.", [["Student's t-test", "TEST", 49, 65]]], ["P values of \u22640.05 were considered significant.", [["P values", "TEST", 0, 8]]]], "2f99feff367379dafcebfa52837125d27f7fac28": [["IntroductionAs healthcare networks across USA brace for an influx of patients infected with COVID-19, it remains imperative that we consider how to prioritize surgical care delivery.", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["USA brace", "TREATMENT", 42, 51], ["COVID", "TREATMENT", 92, 97], ["surgical care delivery", "TREATMENT", 159, 181]]], ["Every hospital must, therefore, develop case-selection protocols based on clinical acuity and available resources in the context of an effective COVID-19 response strategy [1] .", [["case-selection protocols", "TREATMENT", 40, 64], ["an effective COVID", "TREATMENT", 132, 150]]], ["There is perhaps not a more relevant time for the deliberate allocation of medical resources through prioritization of high acuity and life-threatening cases than during the current COVID-19 pandemic [2, 3] .", [["high acuity", "PROBLEM", 119, 130], ["the current COVID", "TEST", 170, 187]]], ["The need to redistribute resources, healthcare personnel, and inpatient beds is common across all medical disciplines during times of disproportionate medical demand [2, [4] [5] [6] .", [["disproportionate medical demand", "TREATMENT", 134, 165]]], ["In surgical oncology and plastic surgery, where patients with extensive tumor burden or higher cancer stage may need to be prioritized for mastectomy, the decision of whether or not to perform breast reconstruction is Michelle Specht and Nikhil Sobti have equally contributed to the manuscript as co-first authors.Electronic supplementary materialThe online version of this article (https ://doi.org/10.1007/s1054 9-020-05739 -7) contains supplementary material, which is available to authorized users. an important consideration.", [["tumor", "ANATOMY", 72, 77], ["cancer", "ANATOMY", 95, 101], ["breast", "ANATOMY", 193, 199], ["tumor", "DISEASE", 72, 77], ["cancer", "DISEASE", 95, 101], ["patients", "ORGANISM", 48, 56], ["tumor", "CANCER", 72, 77], ["cancer", "CANCER", 95, 101], ["breast", "ORGANISM_SUBDIVISION", 193, 199], ["patients", "SPECIES", 48, 56], ["extensive tumor burden", "PROBLEM", 62, 84], ["higher cancer stage", "PROBLEM", 88, 107], ["mastectomy", "TREATMENT", 139, 149], ["breast reconstruction", "TREATMENT", 193, 214], ["Electronic supplementary material", "TREATMENT", 314, 347], ["extensive", "OBSERVATION_MODIFIER", 62, 71], ["tumor", "OBSERVATION", 72, 77], ["higher", "OBSERVATION_MODIFIER", 88, 94], ["cancer", "OBSERVATION", 95, 101], ["mastectomy", "OBSERVATION", 139, 149], ["breast", "ANATOMY", 193, 199], ["important consideration", "UNCERTAINTY", 506, 529]]], ["In fact, two weeks into March, as the USA began to broadly implement a COVID-19 emergency response plan, the American Society of Plastic Surgeons (ASPS) issued a position statement, acknowledging the significant resource utilization commanded by immediate breast reconstruction and the need for streamlining of operative technique to alleviate financial burden in such an unprecedented time [7] .Electronic supplementary materialAn effort to minimize resource utilization and improve surgical efficiency not only requires optimization of existing protocols, but also innovation of medical practice through implementation of telemedicine services and transition to same-day surgery, where patients are discharged on the day of surgery.", [["breast", "ANATOMY", 256, 262], ["breast", "ORGANISM_SUBDIVISION", 256, 262], ["patients", "ORGANISM", 688, 696], ["patients", "SPECIES", 688, 696], ["immediate breast reconstruction", "TREATMENT", 246, 277], ["streamlining of operative technique", "TREATMENT", 295, 330], ["financial burden", "PROBLEM", 344, 360], ["Electronic supplementary material", "TREATMENT", 396, 429], ["resource utilization", "TREATMENT", 451, 471], ["existing protocols", "TREATMENT", 538, 556], ["telemedicine services", "TREATMENT", 624, 645], ["surgery", "TREATMENT", 673, 680], ["surgery", "TREATMENT", 726, 733]]], ["[8] Previous studies have demonstrated the safety and efficacy of same-day mastectomy and breast reconstruction, largely relying on extensive perioperative planning and postoperative recovery protocols to simplify surgical course and minimize patient morbidity [9] [10] [11] .", [["breast", "ANATOMY", 90, 96], ["breast", "ORGAN", 90, 96], ["patient", "ORGANISM", 243, 250], ["patient", "SPECIES", 243, 250], ["Previous studies", "TEST", 4, 20], ["same-day mastectomy", "TREATMENT", 66, 85], ["breast reconstruction", "TREATMENT", 90, 111], ["extensive perioperative planning", "TREATMENT", 132, 164], ["postoperative recovery protocols", "TREATMENT", 169, 201], ["surgical course", "TREATMENT", 214, 229], ["mastectomy", "OBSERVATION", 75, 85], ["breast", "ANATOMY", 90, 96], ["reconstruction", "OBSERVATION", 97, 111]]], ["Prior implementation of an enhanced recovery protocol at our institution has decreased the need for opioid analgesia and length of hospital stay following mastectomy and implant-based breast reconstruction, thereby limiting the need for inpatient admission during the immediate postoperative period [12] .", [["breast", "ANATOMY", 184, 190], ["breast", "ORGAN", 184, 190], ["an enhanced recovery protocol", "TREATMENT", 24, 53], ["opioid analgesia", "TREATMENT", 100, 116], ["mastectomy", "TREATMENT", 155, 165], ["implant", "TREATMENT", 170, 177], ["based breast reconstruction", "TREATMENT", 178, 205], ["mastectomy", "OBSERVATION", 155, 165], ["breast", "ANATOMY", 184, 190]]], ["Similarly, Vuong et al. reported successful implementation of a pilot postmastectomy home recovery program, demonstrating low rates of emergency department visits or re-admission for discharged patients [13] .", [["patients", "ORGANISM", 194, 202], ["patients", "SPECIES", 194, 202], ["a pilot postmastectomy home recovery program", "TREATMENT", 62, 106]]], ["In a recent study conducted by Keehn et al., the authors reported the release of nearly 831 hospital beds across 13 hospitals in Alberta, Canada, per year due to their same-day surgery pathway, with no difference in postoperative complication or hospital re-admission when compared to those admitted overnight per traditional mastectomy protocol [14] .Electronic supplementary materialIn order to limit resource utilization during this crisis, we have operationalized a same-day mastectomy and breast reconstruction protocol.", [["breast", "ANATOMY", 494, 500], ["breast", "ORGANISM_SUBDIVISION", 494, 500], ["a recent study", "TEST", 3, 17], ["postoperative complication", "PROBLEM", 216, 242], ["traditional mastectomy protocol", "TREATMENT", 314, 345], ["Electronic supplementary material", "TREATMENT", 352, 385], ["a same-day mastectomy", "TREATMENT", 468, 489], ["breast reconstruction protocol", "TREATMENT", 494, 524], ["mastectomy", "OBSERVATION", 326, 336], ["mastectomy", "OBSERVATION", 479, 489], ["breast", "ANATOMY", 494, 500]]], ["Clearly, when a hospital is overwhelmed with COVID-19 demands, only life-threatening procedures will be carried out.", [["life-threatening procedures", "TREATMENT", 68, 95]]], ["During times of case surge, each team and hospital should observe local health board and national society guidance with regard to elective procedures such as breast reconstruction.", [["breast", "ANATOMY", 158, 164], ["breast", "ORGANISM_SUBDIVISION", 158, 164], ["elective procedures", "TREATMENT", 130, 149], ["breast reconstruction", "TREATMENT", 158, 179], ["breast", "ANATOMY", 158, 164]]], ["Breast reconstruction requires additional resources (personnel and PPE, extends the operating room time, increase risk of additional visits or operations in cases of complications).", [["Breast", "ANATOMY", 0, 6], ["Breast reconstruction", "TREATMENT", 0, 21], ["PPE", "TREATMENT", 67, 70], ["operations", "TREATMENT", 143, 153], ["complications", "PROBLEM", 166, 179]]], ["As we are observing in March 2020, hospitals across the country, even within the same state, can have very disparate experiences with regard to the acuity of COVID-19 surge.", [["COVID", "TEST", 158, 163]]], ["Therefore, preceding the surge or subsequently thereafter, as resource bandwidth permits performance of oncologic procedures, we propose that the use of a reduced resource mastectomy and breast reconstruction protocol may help to meet the demand for mastectomy and breast reconstruction procedures.", [["breast", "ANATOMY", 187, 193], ["breast", "ANATOMY", 265, 271], ["breast", "ORGAN", 187, 193], ["breast", "ORGANISM_SUBDIVISION", 265, 271], ["oncologic procedures", "TREATMENT", 104, 124], ["a reduced resource mastectomy", "TREATMENT", 153, 182], ["breast reconstruction protocol", "TREATMENT", 187, 217], ["mastectomy", "TREATMENT", 250, 260], ["breast reconstruction procedures", "TREATMENT", 265, 297], ["mastectomy", "OBSERVATION", 172, 182], ["breast", "ANATOMY", 187, 193], ["mastectomy", "OBSERVATION", 250, 260], ["breast", "ANATOMY", 265, 271]]], ["Preceding the COVID-19 crisis, we had assembled a multidisciplinary team at our institution to adapt a same-day surgery protocol, in an attempt to decrease healthcare expenditure, increase inpatient capacity, while maintaining a high level of care to patients undergoing mastectomy and immediate implantbased breast reconstruction.", [["breast", "ANATOMY", 309, 315], ["patients", "ORGANISM", 251, 259], ["breast", "ORGANISM_SUBDIVISION", 309, 315], ["patients", "SPECIES", 251, 259], ["a same-day surgery protocol", "TREATMENT", 101, 128], ["mastectomy", "TREATMENT", 271, 281], ["immediate implantbased breast reconstruction", "TREATMENT", 286, 330], ["mastectomy", "OBSERVATION", 271, 281], ["breast", "ANATOMY", 309, 315]]], ["This quality improvement project engaged the following stakeholders: surgical oncologist, plastic surgeons, anesthesiologists, operating room administrators, recovery room nursing staff, pre-operative care team, case managers, and patients.", [["patients", "ORGANISM", 231, 239], ["patients", "SPECIES", 231, 239]]], ["We refined this pathway to better address the challenges posed to hospital networks by the COVID-19 crisis, chief among them the minimization of viral exposure at the patient level and the reduction of resource utilization at the hospital level, by incorporating virtual patient portal and telehealth services for pre-operative and postoperative consultation and patient evaluation.", [["patient", "ORGANISM", 167, 174], ["patient", "ORGANISM", 271, 278], ["patient", "ORGANISM", 363, 370], ["patient", "SPECIES", 167, 174], ["patient", "SPECIES", 271, 278], ["patient", "SPECIES", 363, 370], ["this pathway", "TREATMENT", 11, 23], ["viral exposure", "PROBLEM", 145, 159], ["postoperative consultation", "TEST", 332, 358], ["patient evaluation", "TEST", 363, 381], ["viral exposure", "OBSERVATION", 145, 159], ["portal", "ANATOMY", 279, 285]]], ["Here, we describe our experience with this same-day mastectomy and immediate breast reconstruction to patients with breast cancer in the setting of the COVID-19 pandemic.", [["breast", "ANATOMY", 77, 83], ["breast cancer", "ANATOMY", 116, 129], ["breast cancer", "DISEASE", 116, 129], ["breast", "ORGANISM_SUBDIVISION", 77, 83], ["patients", "ORGANISM", 102, 110], ["breast cancer", "CANCER", 116, 129], ["patients", "SPECIES", 102, 110], ["mastectomy", "TREATMENT", 52, 62], ["immediate breast reconstruction", "TREATMENT", 67, 98], ["breast cancer", "PROBLEM", 116, 129], ["the COVID", "TEST", 148, 157], ["pandemic", "PROBLEM", 161, 169], ["mastectomy", "OBSERVATION", 52, 62], ["breast", "ANATOMY", 77, 83], ["breast", "ANATOMY", 116, 122], ["cancer", "OBSERVATION", 123, 129]]], ["We are motivated to share this simple playbook with the hope that this approach can be helpful to our community, so that we can continue to provide care to patients afflicted with breast cancer during this crisis.Study design and populationThe work presented here is a patient quality improvement initiative; therefore, review by an IRB was not necessary.", [["breast cancer", "ANATOMY", 180, 193], ["breast cancer", "DISEASE", 180, 193], ["patients", "ORGANISM", 156, 164], ["breast cancer", "CANCER", 180, 193], ["patient", "ORGANISM", 269, 276], ["patients", "SPECIES", 156, 164], ["patient", "SPECIES", 269, 276], ["breast cancer", "PROBLEM", 180, 193], ["this crisis", "PROBLEM", 201, 212], ["Study design", "TEST", 213, 225], ["an IRB", "TREATMENT", 330, 336], ["breast", "ANATOMY", 180, 186], ["cancer", "OBSERVATION", 187, 193]]], ["Consecutive patients having undergone mastectomy with immediate breast reconstruction via novel same-day surgery protocol were prospectively enrolled in the study between February and March of 2020 at Massachusetts General Hospital.", [["breast", "ANATOMY", 64, 70], ["patients", "ORGANISM", 12, 20], ["breast", "ORGAN", 64, 70], ["patients", "SPECIES", 12, 20], ["mastectomy", "TREATMENT", 38, 48], ["immediate breast reconstruction", "TREATMENT", 54, 85], ["novel same-day surgery protocol", "TREATMENT", 90, 121], ["mastectomy", "OBSERVATION", 38, 48], ["breast", "ANATOMY", 64, 70]]], ["Patients who underwent unilateral or bilateral mastectomy with subsequent tissue expander or direct-toimplant breast reconstruction were included.", [["tissue", "ANATOMY", 74, 80], ["breast", "ANATOMY", 110, 116], ["Patients", "ORGANISM", 0, 8], ["tissue", "TISSUE", 74, 80], ["Patients", "SPECIES", 0, 8], ["unilateral or bilateral mastectomy", "TREATMENT", 23, 57], ["subsequent tissue expander", "TREATMENT", 63, 89], ["direct-toimplant breast reconstruction", "TREATMENT", 93, 131], ["bilateral", "ANATOMY_MODIFIER", 37, 46], ["mastectomy", "OBSERVATION", 47, 57], ["expander", "OBSERVATION", 81, 89], ["breast", "ANATOMY", 110, 116]]], ["Importantly, only those patients who lived within 2-h of the hospital and had appropriate at-home support, as determined through shared decision making with the patient, were eligible for the same-day discharge protocol.", [["patients", "ORGANISM", 24, 32], ["patient", "ORGANISM", 161, 168], ["patients", "SPECIES", 24, 32], ["patient", "SPECIES", 161, 168]]], ["The remaining inclusion criteria are depicted in Fig. 1 .", [["Fig", "OBSERVATION_MODIFIER", 49, 52]]], ["Patient demographics, oncologic and clinical data, and operative metrics were extracted from the medical record.Prioritization of treatment by cancer stageDuring March 2020, our breast surgical oncology section was mandated to create guidelines for prioritization of breast cancer operations that should not be delayed, and those that could safely be postponed.", [["cancer", "ANATOMY", 143, 149], ["breast", "ANATOMY", 178, 184], ["breast cancer", "ANATOMY", 267, 280], ["cancer", "DISEASE", 143, 149], ["breast cancer", "DISEASE", 267, 280], ["cancer", "CANCER", 143, 149], ["breast cancer", "CANCER", 267, 280], ["Patient", "SPECIES", 0, 7], ["treatment", "TREATMENT", 130, 139], ["our breast surgical oncology section", "TREATMENT", 174, 210], ["prioritization of breast cancer operations", "TREATMENT", 249, 291], ["breast", "ANATOMY", 178, 184], ["breast", "ANATOMY", 267, 273], ["cancer", "OBSERVATION", 274, 280]]], ["All operations in our institutions after this date would require approval from our section chief and ultimately the chair of the department of surgery prior to being performed.", [["All operations", "TREATMENT", 0, 14], ["surgery", "TREATMENT", 143, 150]]], ["These guidelines required a collaborative effort with our multidisciplinary team -surgical oncology, plastic surgery, radiation oncology, medical oncology, breast imaging, and breast pathology.", [["breast", "ANATOMY", 156, 162], ["breast", "ANATOMY", 176, 182], ["breast", "ORGANISM_SUBDIVISION", 156, 162], ["breast pathology", "CANCER", 176, 192], ["breast imaging", "TEST", 156, 170], ["breast", "ANATOMY", 156, 162], ["breast", "ANATOMY", 176, 182], ["pathology", "OBSERVATION", 183, 192]]], ["See Supplemental Fig. 1 for the COVID guidelines that were used to approve the mastectomies that were performed during March 2020.", [["the COVID guidelines", "TREATMENT", 28, 48], ["the mastectomies", "TREATMENT", 75, 91], ["mastectomies", "OBSERVATION", 79, 91]]], ["There are 3 patients in our cohort whose operation was performed prior to implementation of our institution COVID-19-related prioritization of breast surgery operations.", [["breast", "ANATOMY", 143, 149], ["patients", "ORGANISM", 12, 20], ["breast", "ORGANISM_SUBDIVISION", 143, 149], ["patients", "SPECIES", 12, 20], ["our institution COVID", "TREATMENT", 92, 113], ["breast surgery operations", "TREATMENT", 143, 168], ["breast", "ANATOMY", 143, 149], ["surgery", "OBSERVATION", 150, 157]]], ["This study reports the results of a quality improvement project, and unlike a study protocol, there were no strict exclusion criteria.", [["This study", "TEST", 0, 10], ["a study protocol", "TEST", 76, 92]]], ["All consecutive patients during this window of time were offered the same-day option and the results are reported.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24]]], ["In our practice, patients with a known pre-operative positive node and a known indication for PMRT are counseled regarding increased risk of postoperative complications.", [["node", "ANATOMY", 62, 66], ["patients", "ORGANISM", 17, 25], ["node", "MULTI-TISSUE_STRUCTURE", 62, 66], ["patients", "SPECIES", 17, 25], ["a known pre-operative positive node", "PROBLEM", 31, 66], ["PMRT", "TREATMENT", 94, 98], ["postoperative complications", "PROBLEM", 141, 168], ["node", "OBSERVATION", 62, 66], ["postoperative complications", "OBSERVATION", 141, 168]]], ["As we continue to evolve surgical techniques, we found that muscle-sparing pre-pectoral implant placement can mitigate capsular contracture and decrease revision rates compared to subpectoral technique [15] .", [["muscle", "ANATOMY", 60, 66], ["pre-pectoral", "ANATOMY", 75, 87], ["capsular", "ANATOMY", 119, 127], ["contracture", "DISEASE", 128, 139], ["muscle", "ORGAN", 60, 66], ["surgical techniques", "TEST", 25, 44], ["muscle-sparing pre-pectoral implant placement", "TREATMENT", 60, 105], ["capsular contracture", "PROBLEM", 119, 139], ["decrease revision rates", "TREATMENT", 144, 167], ["subpectoral technique", "TEST", 180, 201], ["muscle", "ANATOMY", 60, 66], ["decrease", "OBSERVATION_MODIFIER", 144, 152], ["revision", "OBSERVATION", 153, 161]]], ["Patients who were not offered immediate reconstruction included those who were active smokers.Same-day surgery pathwayA perioperative pathway was developed in collaboration with a multidisciplinary team at Massachusetts General Hospital for same-day immediate implant-based breast reconstruction (Fig. 2) .", [["breast", "ANATOMY", 274, 280], ["Patients", "ORGANISM", 0, 8], ["breast", "ORGANISM_SUBDIVISION", 274, 280], ["Patients", "SPECIES", 0, 8], ["immediate reconstruction", "TREATMENT", 30, 54], ["same-day immediate implant", "TREATMENT", 241, 267], ["based breast reconstruction", "TREATMENT", 268, 295], ["breast", "ANATOMY", 274, 280]]], ["A concomitant enhanced recovery after surgery (ERAS) protocol was also conceived in conjunction with our anesthesia colleagues.", [["surgery (ERAS) protocol", "TREATMENT", 38, 61], ["concomitant", "OBSERVATION_MODIFIER", 2, 13], ["enhanced", "OBSERVATION_MODIFIER", 14, 22], ["recovery", "OBSERVATION_MODIFIER", 23, 31]]], ["The perioperative pathway focuses on three main areas of patient contact: preoperative, day of surgery, and postdischarge.", [["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["surgery", "TREATMENT", 95, 102]]], ["This pathway was adjusted in light of the COVID-19 outbreak in order to minimize patient visits to the hospital.Pre-operativePatients were initially seen in the surgical oncology clinic after diagnosis of breast cancer was confirmed.", [["breast cancer", "ANATOMY", 205, 218], ["breast cancer", "DISEASE", 205, 218], ["patient", "ORGANISM", 81, 88], ["breast cancer", "CANCER", 205, 218], ["patient", "SPECIES", 81, 88], ["the COVID", "TEST", 38, 47], ["breast cancer", "PROBLEM", 205, 218], ["breast", "ANATOMY", 205, 211], ["cancer", "OBSERVATION", 212, 218]]], ["Once it was determined that the patient would need a mastectomy for treatment of their breast cancer (unilateral or bilateral) they were educated by the surgical oncology team with regards to our perioperative pathway.", [["breast cancer", "ANATOMY", 87, 100], ["breast cancer", "DISEASE", 87, 100], ["patient", "ORGANISM", 32, 39], ["breast cancer", "CANCER", 87, 100], ["patient", "SPECIES", 32, 39], ["a mastectomy", "TREATMENT", 51, 63], ["treatment", "TREATMENT", 68, 77], ["their breast cancer", "PROBLEM", 81, 100], ["mastectomy", "OBSERVATION", 53, 63], ["breast", "ANATOMY", 87, 93], ["cancer", "OBSERVATION", 94, 100], ["bilateral", "ANATOMY_MODIFIER", 116, 125]]], ["This visit included information regarding the role of a paravertebral block to reduce postoperative nausea and vomiting, shorten time to oral pain medications, and decreased length of stay.", [["paravertebral", "ANATOMY", 56, 69], ["oral", "ANATOMY", 137, 141], ["paravertebral block", "DISEASE", 56, 75], ["postoperative nausea and vomiting", "DISEASE", 86, 119], ["pain", "DISEASE", 142, 146], ["oral", "ORGANISM_SUBDIVISION", 137, 141], ["a paravertebral block", "TREATMENT", 54, 75], ["postoperative nausea", "PROBLEM", 86, 106], ["vomiting", "PROBLEM", 111, 119], ["oral pain medications", "TREATMENT", 137, 158], ["paravertebral", "ANATOMY", 56, 69]]], ["Data regarding the efficacy of our ERAS protocol was reviewed and day surgery was offered to all patients who met inclusion criteria.", [["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["our ERAS protocol", "TREATMENT", 31, 48]]], ["Patients were then referred to plastic surgery for consultation regarding reconstruction.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["reconstruction", "TREATMENT", 74, 88]]], ["Given the current climate within the context of COVID-19 crisis, many patients underwent surgical oncology and plastic surgery consultation via video conferencing with patient pictures viewed by the plastic surgeon via a HIPAA approved secured system.", [["patients", "ORGANISM", 70, 78], ["patient", "ORGANISM", 168, 175], ["patients", "SPECIES", 70, 78], ["patient", "SPECIES", 168, 175], ["COVID-19 crisis", "PROBLEM", 48, 63]]], ["Patients were provided educational materials newly created by the multidisciplinary team to limit the need for in-person postoperative visits, including access to online videos to review wound and drain care.", [["wound", "ANATOMY", 187, 192], ["Patients", "ORGANISM", 0, 8], ["wound", "PATHOLOGICAL_FORMATION", 187, 192], ["Patients", "SPECIES", 0, 8], ["educational materials", "TREATMENT", 23, 44], ["wound and drain care", "TREATMENT", 187, 207], ["wound", "ANATOMY", 187, 192]]], ["Prescriptions for all medications needed postoperatively were sent electronically by the plastic surgery clinic to patient's pharmacy.", [["patient", "ORGANISM", 115, 122], ["patient", "SPECIES", 115, 122], ["all medications", "TREATMENT", 18, 33]]], ["Pre-operative medications (Gabapentin, Tylenol, and Celebrex) were ordered by the surgical oncology clinic to be given the day of surgery upon arrival to the pre-operative area.", [["Gabapentin", "CHEMICAL", 27, 37], ["Tylenol", "CHEMICAL", 39, 46], ["Gabapentin", "CHEMICAL", 27, 37], ["Tylenol", "CHEMICAL", 39, 46], ["Celebrex", "CHEMICAL", 52, 60], ["Gabapentin", "SIMPLE_CHEMICAL", 27, 37], ["Tylenol", "SIMPLE_CHEMICAL", 39, 46], ["Celebrex", "SIMPLE_CHEMICAL", 52, 60], ["Pre-operative medications", "TREATMENT", 0, 25], ["Gabapentin", "TREATMENT", 27, 37], ["Tylenol", "TREATMENT", 39, 46], ["Celebrex", "TREATMENT", 52, 60], ["surgery", "TREATMENT", 130, 137]]], ["All members of the Inclusion criteria for patients selected for same-day mastectomy and immediate breast reconstruction surgical team, anesthesia, peri-op nursing, and case managers were alerted to the upcoming cases and prepared to maximize likelihood of same-day discharge.Day of surgeryUpon arrival to the pre-operative area, routine evaluation was performed by the nursing staff and a patient checklist was made to ensure completion of perioperative tasks (Fig. 3) .", [["breast", "ANATOMY", 98, 104], ["patients", "ORGANISM", 42, 50], ["breast", "ORGANISM_SUBDIVISION", 98, 104], ["patient", "ORGANISM", 389, 396], ["patients", "SPECIES", 42, 50], ["patient", "SPECIES", 389, 396], ["same-day mastectomy", "TREATMENT", 64, 83], ["immediate breast reconstruction", "TREATMENT", 88, 119], ["surgery", "TREATMENT", 282, 289], ["routine evaluation", "TEST", 329, 347], ["perioperative tasks", "TEST", 440, 459], ["mastectomy", "OBSERVATION", 73, 83], ["breast", "ANATOMY", 98, 104], ["surgery", "OBSERVATION", 282, 289]]], ["Pre-operative medications were then administered.", [["Pre-operative medications", "TREATMENT", 0, 25]]], ["Paravertebral blocks are performed by the anesthesia pain team as part of the ERAS protocol.", [["pain", "DISEASE", 53, 57], ["Paravertebral blocks", "TREATMENT", 0, 20], ["the ERAS protocol", "TREATMENT", 74, 91], ["blocks", "OBSERVATION", 14, 20]]], ["Once in the operating room, the planned surgical procedures were performed by the surgical oncologist and plastic surgery teams.", [["the planned surgical procedures", "TEST", 28, 59]]], ["The tissue plane of implant placement was largely determined by the thickness of the mastectomy skin flap.", [["tissue", "ANATOMY", 4, 10], ["skin", "ANATOMY", 96, 100], ["tissue", "TISSUE", 4, 10], ["implant", "TISSUE", 20, 27], ["skin", "ORGAN", 96, 100], ["The tissue plane of implant placement", "TREATMENT", 0, 37], ["the mastectomy skin flap", "TREATMENT", 81, 105], ["implant", "OBSERVATION", 20, 27], ["mastectomy", "OBSERVATION", 85, 95], ["skin", "ANATOMY", 96, 100], ["flap", "OBSERVATION", 101, 105]]], ["In cases of robust mastectomy skin flaps with sufficient subcutaneous tissue thickness, the breast implant was placed in the pre-pectoral space and the reconstruction was usually carried out in a single-stage.", [["skin", "ANATOMY", 30, 34], ["subcutaneous tissue", "ANATOMY", 57, 76], ["breast", "ANATOMY", 92, 98], ["pre-pectoral space", "ANATOMY", 125, 143], ["skin", "ORGAN", 30, 34], ["subcutaneous tissue", "TISSUE", 57, 76], ["breast implant", "TISSUE", 92, 106], ["pre-pectoral space", "MULTI-TISSUE_STRUCTURE", 125, 143], ["robust mastectomy skin flaps", "TREATMENT", 12, 40], ["sufficient subcutaneous tissue thickness", "TREATMENT", 46, 86], ["the breast implant", "TREATMENT", 88, 106], ["the reconstruction", "TREATMENT", 148, 166], ["robust", "OBSERVATION_MODIFIER", 12, 18], ["mastectomy", "OBSERVATION", 19, 29], ["skin", "ANATOMY", 30, 34], ["flaps", "OBSERVATION", 35, 40], ["subcutaneous tissue", "ANATOMY", 57, 76], ["thickness", "OBSERVATION_MODIFIER", 77, 86], ["breast", "ANATOMY", 92, 98], ["implant", "OBSERVATION", 99, 106]]], ["If the mastectomy skin flap was thin or viability judged to be suboptimal clinically, a tissue expander was placed in the subpectoral plane.", [["skin", "ANATOMY", 18, 22], ["tissue", "ANATOMY", 88, 94], ["skin", "ORGAN", 18, 22], ["tissue", "TISSUE", 88, 94], ["the mastectomy skin flap", "TREATMENT", 3, 27], ["thin or viability", "PROBLEM", 32, 49], ["a tissue expander", "TREATMENT", 86, 103], ["mastectomy", "OBSERVATION", 7, 17], ["skin", "ANATOMY", 18, 22], ["flap", "OBSERVATION", 23, 27], ["subpectoral", "ANATOMY", 122, 133]]], ["Tumor size or oncologic characteristics did not influence the decision to perform pre-pectoral versus subpectoral reconstruction, the determinant of implant placement location and single versus staged approach is determined by mastectomy skin flap viability, which is supported by the literature [16, 17] .", [["Tumor", "ANATOMY", 0, 5], ["pre-pectoral", "ANATOMY", 82, 94], ["subpectoral", "ANATOMY", 102, 113], ["skin", "ANATOMY", 238, 242], ["Tumor", "CANCER", 0, 5], ["skin", "ORGAN", 238, 242], ["Tumor size", "PROBLEM", 0, 10], ["pre-pectoral versus subpectoral reconstruction", "TREATMENT", 82, 128], ["implant placement location", "TREATMENT", 149, 175], ["single versus staged approach", "TREATMENT", 180, 209], ["mastectomy skin flap viability", "TREATMENT", 227, 257], ["size", "OBSERVATION_MODIFIER", 6, 10], ["oncologic", "OBSERVATION", 14, 23], ["implant", "OBSERVATION", 149, 156], ["mastectomy", "OBSERVATION", 227, 237], ["skin", "ANATOMY", 238, 242], ["flap viability", "OBSERVATION", 243, 257]]], ["Anesthetic was administered using a strict total intravenous anesthesia (TIVA) protocol along with administration of at least two anti-emetics in order to maximize patient comfort and avoid postoperative nausea and vomiting.Day of surgeryAfter transfer to the recovery room, patients were eating, ambulating, and receiving oral medications for pain control.", [["intravenous", "ANATOMY", 49, 60], ["oral", "ANATOMY", 323, 327], ["postoperative nausea and vomiting", "DISEASE", 190, 223], ["pain", "DISEASE", 344, 348], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 49, 60], ["patient", "ORGANISM", 164, 171], ["patients", "ORGANISM", 275, 283], ["oral", "ORGANISM_SUBDIVISION", 323, 327], ["patient", "SPECIES", 164, 171], ["patients", "SPECIES", 275, 283], ["Anesthetic", "TREATMENT", 0, 10], ["a strict total intravenous anesthesia", "TREATMENT", 34, 71], ["TIVA) protocol", "TREATMENT", 73, 87], ["two anti-emetics", "TREATMENT", 126, 142], ["postoperative nausea", "PROBLEM", 190, 210], ["vomiting", "PROBLEM", 215, 223], ["surgery", "TREATMENT", 231, 238], ["oral medications", "TREATMENT", 323, 339], ["pain control", "TREATMENT", 344, 356], ["surgery", "OBSERVATION", 231, 238]]], ["They were monitored for four hours and ultimately assessed by a representative from the surgical team to evaluate for signs of hematoma and readiness to be discharged.", [["hematoma", "DISEASE", 127, 135], ["hematoma", "PROBLEM", 127, 135], ["hematoma", "OBSERVATION", 127, 135]]], ["At this point, a discharge order was written and nursing reviews discharge information and drain care.", [["drain care", "TREATMENT", 91, 101]]], ["Visiting nursing association (VNA) services are arranged prior to the day of surgery, with patients having already received their prescriptions, thereby simplifying discharge.Post dischargeAll patients were contacted through virtual patient portal by the plastic surgery clinic one day after discharge to ensure Peri-operative checklist for the same-day mastectomy and immediate breast reconstruction protocol that the patient was doing well and to answer any questions.", [["breast", "ANATOMY", 379, 385], ["patients", "ORGANISM", 91, 99], ["patients", "ORGANISM", 193, 201], ["patient", "ORGANISM", 233, 240], ["breast", "ORGAN", 379, 385], ["patient", "ORGANISM", 419, 426], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 193, 201], ["patient", "SPECIES", 233, 240], ["patient", "SPECIES", 419, 426], ["surgery", "TREATMENT", 77, 84], ["mastectomy", "TREATMENT", 354, 364], ["immediate breast reconstruction protocol", "TREATMENT", 369, 409], ["portal", "ANATOMY", 241, 247], ["mastectomy", "OBSERVATION", 354, 364], ["breast", "ANATOMY", 379, 385]]], ["Our standard before the crisis was to have a first postoperative appointment for three consecutive weeks, with one drain removed at week 1, last drain removed at week 2, and patient checked for seroma, and final healing at week 3.", [["seroma", "ANATOMY", 194, 200], ["seroma", "DISEASE", 194, 200], ["patient", "ORGANISM", 174, 181], ["seroma", "PATHOLOGICAL_FORMATION", 194, 200], ["patient", "SPECIES", 174, 181], ["one drain", "TREATMENT", 111, 120], ["last drain", "TREATMENT", 140, 150], ["seroma", "PROBLEM", 194, 200], ["seroma", "OBSERVATION", 194, 200]]], ["During the crisis, in an effort to minimize patient travel and limit nosocomial viral exposure, these visits were converted to virtual with visiting nurses performing drain removal at the patient's home or local hospital.Data collection and statistical analysisVariables recorded for each patient were age at surgery, laterality of cancer, type of mastectomy, neoadjuvant chemotherapy, mastectomy type (nipple-sparing v. skin-sparing), axillary management (axillary lymph node dissections and sentinel node biopsies), and reconstruction type (directto-implant or tissue expander reconstruction).", [["cancer", "ANATOMY", 332, 338], ["nipple", "ANATOMY", 403, 409], ["skin", "ANATOMY", 421, 425], ["axillary", "ANATOMY", 436, 444], ["axillary lymph node", "ANATOMY", 457, 476], ["sentinel node biopsies", "ANATOMY", 493, 515], ["tissue", "ANATOMY", 563, 569], ["cancer", "DISEASE", 332, 338], ["patient", "ORGANISM", 44, 51], ["patient", "ORGANISM", 188, 195], ["patient", "ORGANISM", 289, 296], ["cancer", "CANCER", 332, 338], ["nipple", "TISSUE", 403, 409], ["skin", "ORGAN", 421, 425], ["axillary", "MULTI-TISSUE_STRUCTURE", 436, 444], ["axillary lymph node", "MULTI-TISSUE_STRUCTURE", 457, 476], ["node biopsies", "MULTI-TISSUE_STRUCTURE", 502, 515], ["tissue", "TISSUE", 563, 569], ["patient", "SPECIES", 44, 51], ["patient", "SPECIES", 188, 195], ["patient", "SPECIES", 289, 296], ["the crisis", "PROBLEM", 7, 17], ["drain removal", "TREATMENT", 167, 180], ["Data collection", "TEST", 221, 236], ["statistical analysis", "TEST", 241, 261], ["cancer", "PROBLEM", 332, 338], ["mastectomy", "TREATMENT", 348, 358], ["neoadjuvant chemotherapy", "TREATMENT", 360, 384], ["mastectomy type (nipple-sparing v. skin-sparing", "TREATMENT", 386, 433], ["axillary management", "TREATMENT", 436, 455], ["axillary lymph node dissections", "TREATMENT", 457, 488], ["sentinel node biopsies", "TREATMENT", 493, 515], ["reconstruction type (directto-implant", "TREATMENT", 522, 559], ["tissue expander reconstruction", "TREATMENT", 563, 593], ["cancer", "OBSERVATION", 332, 338], ["mastectomy", "OBSERVATION", 348, 358], ["neoadjuvant chemotherapy", "OBSERVATION", 360, 384], ["mastectomy", "OBSERVATION", 386, 396], ["skin", "ANATOMY", 421, 425], ["axillary", "ANATOMY", 436, 444], ["axillary", "ANATOMY", 457, 465], ["lymph node dissections", "OBSERVATION", 466, 488], ["sentinel node", "OBSERVATION", 493, 506]]], ["Primary endpoints of interest include operating time, disposition (admission vs. discharge), time interval between surgical closure and discharge, re-admission rate, and emergency department presentation.", [["surgical closure", "TREATMENT", 115, 131]]], ["The following postoperative complications were identified: hematoma requiring a return trip to the operating room, infection requiring a return trip to the operating room.Data collection and statistical analysisData was analyzed using SPSS 25 (IBM Corp., Armonk, NY).", [["hematoma", "DISEASE", 59, 67], ["infection", "DISEASE", 115, 124], ["hematoma", "PROBLEM", 59, 67], ["infection", "PROBLEM", 115, 124], ["Data collection", "TEST", 171, 186], ["statistical analysisData", "TEST", 191, 215], ["SPSS", "TEST", 235, 239], ["hematoma", "OBSERVATION", 59, 67], ["infection", "OBSERVATION", 115, 124]]], ["Summary statistics were calculated for patient demographics, clinical and surgical characteristics, and primary and secondary endpoints.", [["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46]]], ["Patient demographics (age and BMI) were compared to those reported in prior publications from our institution using a two-sided unpaired t-test test for continuous variables.Patient demographic and clinical characteristicsWe enrolled a total of 15 patients.", [["patients", "ORGANISM", 248, 256], ["Patient", "SPECIES", 0, 7], ["Patient", "SPECIES", 174, 181], ["patients", "SPECIES", 248, 256], ["t-test test", "TEST", 137, 148]]], ["The mean age of the women at the time of surgery was 45.38 \u00b1 6.86 years.", [["women", "ORGANISM", 20, 25], ["women", "SPECIES", 20, 25], ["surgery", "TREATMENT", 41, 48], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["Eleven patients underwent unilateral mastectomy while four patients underwent bilateral mastectomy.", [["patients", "ORGANISM", 7, 15], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 7, 15], ["patients", "SPECIES", 59, 67], ["unilateral mastectomy", "TREATMENT", 26, 47], ["bilateral mastectomy", "TREATMENT", 78, 98], ["unilateral", "OBSERVATION_MODIFIER", 26, 36], ["mastectomy", "OBSERVATION", 37, 47], ["bilateral", "ANATOMY_MODIFIER", 78, 87], ["mastectomy", "OBSERVATION", 88, 98]]], ["Eleven patients underwent mastectomy with sentinel lymph node biopsy compared with three patients who underwent mastectomy with axillary lymph node dissection.", [["lymph node", "ANATOMY", 51, 61], ["axillary lymph node", "ANATOMY", 128, 147], ["patients", "ORGANISM", 7, 15], ["lymph node", "MULTI-TISSUE_STRUCTURE", 51, 61], ["biopsy", "MULTI-TISSUE_STRUCTURE", 62, 68], ["patients", "ORGANISM", 89, 97], ["axillary lymph node", "MULTI-TISSUE_STRUCTURE", 128, 147], ["patients", "SPECIES", 7, 15], ["patients", "SPECIES", 89, 97], ["mastectomy", "TREATMENT", 26, 36], ["sentinel lymph node biopsy", "TREATMENT", 42, 68], ["mastectomy", "TREATMENT", 112, 122], ["axillary lymph node dissection", "TREATMENT", 128, 158], ["mastectomy", "OBSERVATION", 26, 36], ["sentinel", "OBSERVATION", 42, 50], ["lymph node", "OBSERVATION", 51, 61], ["mastectomy", "OBSERVATION", 112, 122], ["axillary", "ANATOMY", 128, 136], ["lymph node dissection", "OBSERVATION", 137, 158]]], ["Nipple-sparing mastectomy was performed in 11 (73.33%) patients, while skin-sparing mastectomy was performed in 4 (26.67%).", [["skin", "ANATOMY", 71, 75], ["patients", "ORGANISM", 55, 63], ["skin", "ORGAN", 71, 75], ["patients", "SPECIES", 55, 63], ["Nipple-sparing mastectomy", "TREATMENT", 0, 25], ["skin-sparing mastectomy", "TREATMENT", 71, 94], ["sparing", "OBSERVATION_MODIFIER", 7, 14], ["mastectomy", "OBSERVATION", 15, 25], ["skin", "ANATOMY", 71, 75], ["mastectomy", "OBSERVATION", 84, 94]]], ["Direct-toimplant immediate breast reconstruction was performed in 11 breasts and tissue-expander-based reconstruction in 8 breasts.", [["breast", "ANATOMY", 27, 33], ["breasts", "ANATOMY", 69, 76], ["tissue", "ANATOMY", 81, 87], ["breasts", "ANATOMY", 123, 130], ["breast", "ORGAN", 27, 33], ["breasts", "PATHOLOGICAL_FORMATION", 69, 76], ["tissue", "TISSUE", 81, 87], ["breasts", "MULTI-TISSUE_STRUCTURE", 123, 130], ["Direct-toimplant immediate breast reconstruction", "TREATMENT", 0, 48], ["tissue-expander-based reconstruction in 8 breasts", "TREATMENT", 81, 130], ["breast", "ANATOMY", 27, 33], ["breasts", "ANATOMY", 69, 76], ["breasts", "ANATOMY", 123, 130]]], ["In addition, implant placement in the pre-pectoral plane (n = 11, 57.90%) outpaced submuscular reconstruction (n = 8, 42.10%).", [["pre-pectoral plane", "ANATOMY", 38, 56], ["submuscular", "ANATOMY", 83, 94], ["implant placement in the pre-pectoral plane", "TREATMENT", 13, 56], ["submuscular reconstruction", "TREATMENT", 83, 109], ["implant", "OBSERVATION", 13, 20], ["submuscular", "ANATOMY", 83, 94]]], ["Importantly, the decision for adjuvant chemotherapy and postmastectomy radiation is dependent on evaluation of tumor oncotype, the results of which often return weeks after mastectomy.", [["tumor", "ANATOMY", 111, 116], ["tumor", "DISEASE", 111, 116], ["tumor", "CANCER", 111, 116], ["adjuvant chemotherapy", "TREATMENT", 30, 51], ["postmastectomy radiation", "TREATMENT", 56, 80], ["evaluation", "TEST", 97, 107], ["tumor oncotype", "PROBLEM", 111, 125], ["mastectomy", "TREATMENT", 173, 183], ["tumor", "OBSERVATION", 111, 116], ["mastectomy", "OBSERVATION", 173, 183]]], ["As such, data regarding oncologic management is largely incomplete.", [["oncologic management", "TREATMENT", 24, 44]]], ["Importantly, four breasts demonstrated simultaneous DCIS and IDC pathologies.", [["breasts", "ANATOMY", 18, 25], ["DCIS", "ANATOMY", 52, 56], ["IDC", "ANATOMY", 61, 64], ["DCIS", "DISEASE", 52, 56], ["breasts", "CANCER", 18, 25], ["DCIS", "CANCER", 52, 56], ["IDC", "CANCER", 61, 64], ["simultaneous DCIS", "PROBLEM", 39, 56], ["IDC pathologies", "PROBLEM", 61, 76], ["breasts", "ANATOMY", 18, 25], ["simultaneous", "OBSERVATION_MODIFIER", 39, 51], ["DCIS", "OBSERVATION", 52, 56]]], ["The remaining oncologic characteristics are detailed in Table 1 .", [["remaining", "OBSERVATION_MODIFIER", 4, 13], ["oncologic", "OBSERVATION", 14, 23]]], ["Further, reconstruction at the time of mastectomy is not dependent on whether the patient will need adjuvant chemotherapy or adjuvant radiation therapy.", [["patient", "ORGANISM", 82, 89], ["patient", "SPECIES", 82, 89], ["reconstruction", "TREATMENT", 9, 23], ["mastectomy", "TREATMENT", 39, 49], ["adjuvant chemotherapy", "TREATMENT", 100, 121], ["adjuvant radiation therapy", "TREATMENT", 125, 151], ["mastectomy", "OBSERVATION", 39, 49]]], ["The rate of prior irradiation in our patient population was 6.67% (n = 1), with four patients having undergone neoadjuvant chemotherapy (26.67%).", [["patient", "ORGANISM", 37, 44], ["patients", "ORGANISM", 85, 93], ["patient", "SPECIES", 37, 44], ["patients", "SPECIES", 85, 93], ["prior irradiation", "TREATMENT", 12, 29], ["our patient population", "TEST", 33, 55], ["neoadjuvant chemotherapy", "TREATMENT", 111, 135]]], ["Patient demographics are presented in Table 1 .", [["Patient", "SPECIES", 0, 7]]], ["Of note, when comparing patient demographics to patient cohorts in previous publications from our institution, we could not identify a statistically significant difference in age (p = 0.60) and BMI (p = 0.94).Evaluation of efficacy endpointsThe mean operative time for mastectomy with immediate breast reconstruction was 151.27 \u00b1 33.14 min (2.52 \u00b1 0.55 h).", [["breast", "ANATOMY", 295, 301], ["patient", "ORGANISM", 24, 31], ["patient", "ORGANISM", 48, 55], ["breast", "ORGAN", 295, 301], ["patient", "SPECIES", 24, 31], ["patient", "SPECIES", 48, 55], ["BMI", "TEST", 194, 197], ["Evaluation", "TEST", 209, 219], ["efficacy endpoints", "PROBLEM", 223, 241], ["mastectomy", "TREATMENT", 269, 279], ["immediate breast reconstruction", "TREATMENT", 285, 316], ["mastectomy", "OBSERVATION", 269, 279], ["breast", "ANATOMY", 295, 301]]], ["In contrast, the average time of mastectomy without reconstruction was 80.54 \u00b1 24.34 min (1.34 \u00b1 0.41 h) (n = 13).", [["mastectomy", "TREATMENT", 33, 43], ["reconstruction", "TREATMENT", 52, 66], ["mastectomy", "OBSERVATION", 33, 43]]], ["The time interval from surgical closure to discharge for patients that underwent mastectomy and reconstruction was 301.27 \u00b1 77.13 min (5.02 \u00b1 1.29 h) and time to discharge without reconstruction was 249.29 \u00b1 113.58 min (4.15 \u00b1 1.89 h), where 6 patients were excluded from this comparison as they were admitted due to associated comorbid conditions.", [["patients", "ORGANISM", 57, 65], ["patients", "ORGANISM", 244, 252], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 244, 252], ["surgical closure", "TREATMENT", 23, 39], ["mastectomy", "TREATMENT", 81, 91], ["reconstruction", "TREATMENT", 96, 110], ["reconstruction", "TEST", 180, 194], ["associated comorbid conditions", "PROBLEM", 317, 347], ["mastectomy", "OBSERVATION", 81, 91]]], ["Patients without reconstruction were older, more likely to have undergo chemotherapy and have comorbid medical conditions.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["reconstruction", "TREATMENT", 17, 31], ["chemotherapy", "TREATMENT", 72, 84], ["comorbid medical conditions", "PROBLEM", 94, 121]]], ["Therefore, reconstruction added 1 h and 20 min to the total case time and less than 1 h to the time interval from surgical closure to discharge.", [["reconstruction", "TREATMENT", 11, 25], ["surgical closure", "TREATMENT", 114, 130]]], ["In bilateral cases, the plastic surgeon begins reconstruction after one breast is removed to work concurrently with the surgical oncologist in order to minimize operative time.", [["breast", "ANATOMY", 72, 78], ["breast", "ORGAN", 72, 78], ["reconstruction", "TREATMENT", 47, 61], ["bilateral", "ANATOMY_MODIFIER", 3, 12], ["breast", "ANATOMY", 72, 78]]], ["All patients enrolled in the same-day immediate breast reconstruction protocol were discharged home, with no re-admission or emergency department visits ( Table 2) .", [["breast", "ANATOMY", 48, 54], ["patients", "ORGANISM", 4, 12], ["breast", "ORGAN", 48, 54], ["patients", "SPECIES", 4, 12], ["immediate breast reconstruction protocol", "TREATMENT", 38, 78], ["breast", "ANATOMY", 48, 54]]], ["During virtual visits, patients were questioned about any local emergency room visits for postoperative complications and these responses were corroborated by independent review of external medical records.Evaluation of safety endpointsNo postoperative complications were observed for patients undergoing same-day immediate breast reconstruction with 30-day postoperative follow-up.", [["breast", "ANATOMY", 324, 330], ["patients", "ORGANISM", 23, 31], ["patients", "ORGANISM", 285, 293], ["breast", "ORGAN", 324, 330], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 285, 293], ["postoperative complications", "PROBLEM", 90, 117], ["Evaluation of safety endpoints", "TEST", 206, 236], ["postoperative complications", "PROBLEM", 239, 266], ["same-day immediate breast reconstruction", "TREATMENT", 305, 345], ["postoperative", "OBSERVATION_MODIFIER", 239, 252], ["complications", "OBSERVATION", 253, 266], ["breast", "ANATOMY", 324, 330]]], ["Importantly, incidence of hematoma was not observed in the 24-h postoperative period, during which time a patient would otherwise have been admitted and monitored for development of early complication.", [["hematoma", "ANATOMY", 26, 34], ["hematoma", "DISEASE", 26, 34], ["hematoma", "PATHOLOGICAL_FORMATION", 26, 34], ["patient", "ORGANISM", 106, 113], ["patient", "SPECIES", 106, 113], ["hematoma", "PROBLEM", 26, 34], ["early complication", "PROBLEM", 182, 200], ["hematoma", "OBSERVATION", 26, 34], ["early", "OBSERVATION_MODIFIER", 182, 187], ["complication", "OBSERVATION", 188, 200]]], ["All of our patients were seen by a visiting nurse on either POD #1 or POD #2.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19]]], ["Drains were removed without difficulty either by VNA or qualified healthcare provider locally without requiring the patient to return to our hospital.", [["patient", "ORGANISM", 116, 123], ["patient", "SPECIES", 116, 123], ["Drains", "TREATMENT", 0, 6], ["difficulty", "PROBLEM", 28, 38]]], ["We reduced the number of postoperative visits from 2 visits per patient, which was standard protocol prior to same-day surgery implementation, to 0 visits per patient postimplementation.DiscussionGiven the rapid spread of COVID-19 and the need for deliberate resource prioritization, the implementation of a resource-limited operative protocol for immediate implantbased breast reconstruction is of critical importance.", [["breast", "ANATOMY", 371, 377], ["patient", "ORGANISM", 64, 71], ["patient", "ORGANISM", 159, 166], ["breast", "ORGANISM_SUBDIVISION", 371, 377], ["patient", "SPECIES", 64, 71], ["patient", "SPECIES", 159, 166], ["COVID", "TEST", 222, 227], ["limited operative protocol", "TREATMENT", 317, 343], ["immediate implantbased breast reconstruction", "TREATMENT", 348, 392]]], ["Sameday mastectomy and immediate breast reconstruction have been proposed as safe, economic methods of conferring oncologic and reconstructive treatment, while reducing resources and inpatient volume on hospital systems [18, 19] .", [["breast", "ANATOMY", 33, 39], ["breast", "ORGAN", 33, 39], ["Sameday mastectomy", "TREATMENT", 0, 18], ["immediate breast reconstruction", "TREATMENT", 23, 54], ["conferring oncologic", "TREATMENT", 103, 123], ["reconstructive treatment", "TREATMENT", 128, 152], ["mastectomy", "OBSERVATION", 8, 18], ["breast", "ANATOMY", 33, 39], ["reconstruction", "OBSERVATION", 40, 54]]], ["These protocols have yet to be widely implemented, and few studies have been conducted to demonstrate reliability of technique.", [["few studies", "TEST", 55, 66]]], ["The present study serves as a pilot, demonstrating the safety and efficacy of a novel same-day surgery pathway for immediate breast reconstruction at our hospital using virtual and telehealth operative consultation and evaluation during the growing COVID-19 crisis.", [["breast", "ANATOMY", 125, 131], ["breast", "ORGANISM_SUBDIVISION", 125, 131], ["The present study", "TEST", 0, 17], ["immediate breast reconstruction", "TREATMENT", 115, 146], ["telehealth operative consultation", "TEST", 181, 214], ["evaluation", "TEST", 219, 229], ["the growing COVID", "TEST", 237, 254], ["breast", "ANATOMY", 125, 131]]], ["At the time of writing, Massachusetts ranks fourth in the USA in the number of COVID-19 cases, with our hospital currently treating over 40 COVID-19 patients in the ICU.", [["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157]]], ["We are not yet overwhelmed by the surge of patients and, as such, are still able to carry out operations for symptomatic and high stage cancer patients at this time.", [["cancer", "ANATOMY", 136, 142], ["cancer", "DISEASE", 136, 142], ["patients", "ORGANISM", 43, 51], ["high stage cancer", "CANCER", 125, 142], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 143, 151], ["symptomatic and high stage cancer", "PROBLEM", 109, 142], ["high stage", "OBSERVATION_MODIFIER", 125, 135], ["cancer", "OBSERVATION", 136, 142]]], ["By performing essential postoperative assessments through remote telemedicine or at-home visits, we hope to reserve availability of inpatient beds for COVID-19 cases and decrease the risk of transmission to patients recovering from immediate breast reconstruction.DiscussionDevelopment and implementation of a same-day surgery protocol requires extensive communication and collaboration among primary stakeholders, in an effort to target areas of traditional operative course that can be consolidated or made remote.", [["breast", "ANATOMY", 242, 248], ["patients", "ORGANISM", 207, 215], ["breast", "ORGANISM_SUBDIVISION", 242, 248], ["patients", "SPECIES", 207, 215], ["postoperative assessments", "TEST", 24, 49], ["COVID", "TREATMENT", 151, 156], ["immediate breast reconstruction", "TREATMENT", 232, 263], ["a same-day surgery protocol", "TREATMENT", 308, 335], ["traditional operative course", "TREATMENT", 447, 475], ["breast", "ANATOMY", 242, 248]]], ["In light of the COVID-19 pandemic, in-person pre-operative visits were foregone in favor of online evaluation, providing patients with access to educational videos and informative documents to facilitate shared decision making.", [["patients", "ORGANISM", 121, 129], ["person", "SPECIES", 38, 44], ["patients", "SPECIES", 121, 129], ["online evaluation", "TEST", 92, 109]]], ["Importantly, postoperative management was conducted via telemedicine, with the plastic surgeon assessing for immediate complication or the need for in-person evaluation within 24 h of reconstruction.", [["immediate complication", "PROBLEM", 109, 131], ["person evaluation", "TEST", 151, 168], ["reconstruction", "TREATMENT", 184, 198]]], ["Subsequent 1-week and 2-week visits were conducted virtually, with VNA services utilized for drain removal.", [["VNA services", "TREATMENT", 67, 79], ["drain removal", "TREATMENT", 93, 106]]], ["These modifications to the existing sameday surgery protocol minimized risk of viral exposure to patients recovering from surgery, particularly important in this patient population that may need to undergo immune compromising chemotherapy [20, 21] .", [["patients", "ORGANISM", 97, 105], ["patient", "ORGANISM", 162, 169], ["patients", "SPECIES", 97, 105], ["patient", "SPECIES", 162, 169], ["the existing sameday surgery protocol", "TREATMENT", 23, 60], ["viral exposure", "PROBLEM", 79, 93], ["surgery", "TREATMENT", 122, 129], ["immune compromising chemotherapy", "TREATMENT", 206, 238], ["viral exposure", "OBSERVATION", 79, 93]]], ["In this report, the average time interval between operation and discharge was 5.02 \u00b1 1.29 h, with no re-admissions or emergency department visits, which is significantly lower than the national average of overnight admission in hospitals employing traditional postmastectomy protocols [22, 23] .", [["traditional postmastectomy protocols", "TREATMENT", 248, 284]]], ["Our institution performs an estimated 350-400 immediate breast reconstructions annually.", [["breast", "ANATOMY", 56, 62], ["breast", "ORGAN", 56, 62], ["breast", "ANATOMY", 56, 62]]], ["The implementation of a same-day surgery pathway could save the hospital an equivalent number of inpatient bed days, thereby significantly reducing cost and increasing capacity.", [["a same-day surgery", "TREATMENT", 22, 40], ["increasing capacity", "PROBLEM", 157, 176]]], ["We recognize that the number of patients in our pilot study is small and our median follow up was 8 days.", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["our pilot study", "TEST", 44, 59], ["small", "OBSERVATION_MODIFIER", 63, 68]]], ["However, none of the patients experienced complication, demonstrating same-day immediate breast reconstruction to be a safe alternative to conventional treatment paradigm [24] [25] [26] [27] [28] [29] .DiscussionEssential in the development of a successful perioperative pathway is the use of appropriate patient selection criteria.", [["breast", "ANATOMY", 89, 95], ["[24] [25] [26] [27] [28]", "CHEMICAL", 171, 195], ["patients", "ORGANISM", 21, 29], ["breast", "ORGAN", 89, 95], ["[24] [25] [26] [27] [28] [29]", "SIMPLE_CHEMICAL", 171, 200], ["patient", "ORGANISM", 305, 312], ["patients", "SPECIES", 21, 29], ["patient", "SPECIES", 305, 312], ["complication", "PROBLEM", 42, 54], ["same-day immediate breast reconstruction", "TREATMENT", 70, 110], ["a safe alternative to conventional treatment paradigm", "TREATMENT", 117, 170], ["breast", "ANATOMY", 89, 95]]], ["In the case of COVID-19, resource allocation should be prioritized based on tumor burden and cancer grade, thereby providing timely oncologic treatment and breast reconstruction to those with the most immediate need.", [["tumor", "ANATOMY", 76, 81], ["cancer", "ANATOMY", 93, 99], ["breast", "ANATOMY", 156, 162], ["tumor", "DISEASE", 76, 81], ["cancer", "DISEASE", 93, 99], ["tumor", "CANCER", 76, 81], ["cancer", "CANCER", 93, 99], ["breast", "ORGANISM_SUBDIVISION", 156, 162], ["COVID", "TEST", 15, 20], ["resource allocation", "TREATMENT", 25, 44], ["tumor burden", "PROBLEM", 76, 88], ["cancer grade", "PROBLEM", 93, 105], ["timely oncologic treatment", "TREATMENT", 125, 151], ["breast reconstruction", "TREATMENT", 156, 177], ["tumor", "OBSERVATION", 76, 81]]], ["Non-essential procedures that may provide modest psychologic and physiologic benefit, such as contralateral prophylactic mastectomy, can be avoided in favor of decreasing complications associated with the contralateral breast, which could strain limited medical resources during the postoperative period [30] [31] [32] .", [["breast", "ANATOMY", 219, 225], ["breast", "ORGAN", 219, 225], ["Non-essential procedures", "TREATMENT", 0, 24], ["modest psychologic and physiologic benefit", "PROBLEM", 42, 84], ["contralateral prophylactic mastectomy", "TREATMENT", 94, 131], ["decreasing complications", "PROBLEM", 160, 184], ["mastectomy", "OBSERVATION", 121, 131], ["decreasing", "OBSERVATION_MODIFIER", 160, 170], ["complications", "OBSERVATION", 171, 184], ["contralateral", "ANATOMY_MODIFIER", 205, 218], ["breast", "ANATOMY", 219, 225]]], ["Recent studies from our group have demonstrated comparable safety profile between direct-to-implant prepectoral reconstruction and traditional subpectoral reconstruction [33] .", [["prepectoral", "ANATOMY", 100, 111], ["subpectoral", "ANATOMY", 143, 154], ["Recent studies", "TEST", 0, 14], ["direct-to-implant prepectoral reconstruction", "TREATMENT", 82, 126], ["traditional subpectoral reconstruction", "TREATMENT", 131, 169], ["subpectoral", "ANATOMY", 143, 154]]], ["For patients with PMRT, pre-pectoral breast reconstruction is associated with lower rates of capsular contracture and need for revision compared with subpectoral implant placement [15] .", [["pre-pectoral breast", "ANATOMY", 24, 43], ["capsular", "ANATOMY", 93, 101], ["contracture", "DISEASE", 102, 113], ["patients", "ORGANISM", 4, 12], ["breast", "ORGAN", 37, 43], ["patients", "SPECIES", 4, 12], ["PMRT", "TREATMENT", 18, 22], ["pre-pectoral breast reconstruction", "TREATMENT", 24, 58], ["capsular contracture", "PROBLEM", 93, 113], ["revision", "TREATMENT", 127, 135], ["subpectoral implant placement", "TREATMENT", 150, 179], ["breast", "ANATOMY", 37, 43], ["reconstruction", "OBSERVATION", 44, 58], ["capsular contracture", "OBSERVATION", 93, 113]]], ["In addition, for cases where autologous breast reconstruction is planned, immediate implant placement within the pre-pectoral space can be used as a \"space-holder\" during the time of crisis as a bridge to subsequent autologous reconstruction when feasible.", [["breast", "ANATOMY", 40, 46], ["pre-pectoral space", "ANATOMY", 113, 131], ["breast", "ORGAN", 40, 46], ["autologous breast reconstruction", "TREATMENT", 29, 61], ["immediate implant placement within the pre-pectoral space", "TREATMENT", 74, 131], ["a \"space-holder", "TREATMENT", 147, 162], ["crisis", "PROBLEM", 183, 189], ["subsequent autologous reconstruction", "TREATMENT", 205, 241], ["breast", "ANATOMY", 40, 46]]], ["Since prepectoral breast reconstruction is far less resource intensive than autologous free tissue breast reconstruction, a larger number of patients can be treated with this \"space-holder,\" complete adjunctive chemotherapy or radiation, then complete autologous free tissue transfer at a later date.DiscussionPrioritization of patients with high-grade cancer may uniformly increase the baseline operative risk of the entire patient cohort, with greater pre-operative morbidity associated with tumor burden and the tendency toward axillary lymph node dissection, which have previously been demonstrated to be independent risk factors for infection [34] [35] [36] .", [["prepectoral breast", "ANATOMY", 6, 24], ["tissue breast", "ANATOMY", 92, 105], ["tissue", "ANATOMY", 268, 274], ["high-grade cancer", "ANATOMY", 342, 359], ["tumor", "ANATOMY", 494, 499], ["axillary lymph node", "ANATOMY", 531, 550], ["cancer", "DISEASE", 353, 359], ["tumor", "DISEASE", 494, 499], ["infection", "DISEASE", 638, 647], ["breast", "ORGAN", 18, 24], ["tissue breast", "MULTI-TISSUE_STRUCTURE", 92, 105], ["patients", "ORGANISM", 141, 149], ["tissue", "TISSUE", 268, 274], ["patients", "ORGANISM", 328, 336], ["high-grade cancer", "CANCER", 342, 359], ["patient", "ORGANISM", 425, 432], ["tumor", "CANCER", 494, 499], ["axillary lymph node", "MULTI-TISSUE_STRUCTURE", 531, 550], ["patients", "SPECIES", 141, 149], ["patients", "SPECIES", 328, 336], ["patient", "SPECIES", 425, 432], ["prepectoral breast reconstruction", "TREATMENT", 6, 39], ["autologous free tissue breast reconstruction", "TREATMENT", 76, 120], ["this \"space-holder", "TREATMENT", 170, 188], ["complete adjunctive chemotherapy", "TREATMENT", 191, 223], ["radiation", "TREATMENT", 227, 236], ["high-grade cancer", "PROBLEM", 342, 359], ["greater pre-operative morbidity", "PROBLEM", 446, 477], ["tumor burden", "PROBLEM", 494, 506], ["the tendency toward axillary lymph node dissection", "PROBLEM", 511, 561], ["infection", "PROBLEM", 638, 647], ["breast", "ANATOMY", 18, 24], ["reconstruction", "OBSERVATION", 25, 39], ["breast", "ANATOMY", 99, 105], ["larger", "OBSERVATION_MODIFIER", 124, 130], ["cancer", "OBSERVATION", 353, 359], ["increase", "OBSERVATION_MODIFIER", 374, 382], ["tumor", "OBSERVATION", 494, 499], ["axillary", "ANATOMY", 531, 539], ["lymph node dissection", "OBSERVATION", 540, 561]]], ["It is important to consider the relative benefit of immediate implant placement versus primary closure and delayed reconstruction.", [["immediate implant placement", "TREATMENT", 52, 79], ["primary closure", "TREATMENT", 87, 102], ["delayed reconstruction", "TREATMENT", 107, 129]]], ["Infection in a patient without prosthesis placement can be successfully treated with oral or intravenous antibiotics.", [["oral", "ANATOMY", 85, 89], ["intravenous", "ANATOMY", 93, 104], ["Infection", "DISEASE", 0, 9], ["patient", "ORGANISM", 15, 22], ["oral", "ORGANISM_SUBDIVISION", 85, 89], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 93, 104], ["patient", "SPECIES", 15, 22], ["Infection", "PROBLEM", 0, 9], ["prosthesis placement", "TREATMENT", 31, 51], ["oral or intravenous antibiotics", "TREATMENT", 85, 116]]], ["In contrast, infection in those with immediate reconstruction will almost certainly require unplanned return to the operating room resulting in higher resource utilization in the already limited setting of the COVID-19 crisis.DiscussionThe success of implant-based breast reconstruction is contingent on the viability of the mastectomy skin flap.", [["breast", "ANATOMY", 265, 271], ["skin", "ANATOMY", 336, 340], ["infection", "DISEASE", 13, 22], ["breast", "ORGAN", 265, 271], ["skin", "ORGAN", 336, 340], ["infection", "PROBLEM", 13, 22], ["immediate reconstruction", "TREATMENT", 37, 61], ["the COVID", "TEST", 206, 215], ["implant-based breast reconstruction", "TREATMENT", 251, 286], ["the mastectomy skin flap", "TREATMENT", 321, 345], ["infection", "OBSERVATION", 13, 22], ["implant", "OBSERVATION", 251, 258], ["breast", "ANATOMY", 265, 271], ["mastectomy", "OBSERVATION", 325, 335], ["skin", "ANATOMY", 336, 340], ["flap", "OBSERVATION", 341, 345]]], ["Patients were counseled that if during surgery the mastectomy skin flap was judged to have viability issues clinically, the implant will not be placed, and the skin flap will be closed after excision of the ischemic area of concern.", [["skin", "ANATOMY", 62, 66], ["skin flap", "ANATOMY", 160, 169], ["Patients", "ORGANISM", 0, 8], ["skin", "ORGAN", 62, 66], ["skin", "ORGAN", 160, 164], ["Patients", "SPECIES", 0, 8], ["surgery", "TREATMENT", 39, 46], ["the mastectomy skin flap", "TREATMENT", 47, 71], ["viability issues", "PROBLEM", 91, 107], ["the implant", "TREATMENT", 120, 131], ["the skin flap", "TREATMENT", 156, 169], ["excision", "TREATMENT", 191, 199], ["the ischemic area", "PROBLEM", 203, 220], ["mastectomy", "OBSERVATION", 51, 61], ["skin", "ANATOMY", 62, 66], ["flap", "OBSERVATION", 67, 71], ["skin", "ANATOMY", 160, 164], ["flap", "OBSERVATION", 165, 169], ["ischemic", "OBSERVATION_MODIFIER", 207, 215]]], ["In all the cases examined, we did not abort implant placement.", [["abort implant placement", "TREATMENT", 38, 61]]], ["While autologous reconstruction may improve the viability of the overlying mastectomy skin flap in some instances, the additional resources required for autologous reconstruction renders it difficult to apply during the COVID-19 surge when capacity and resources are limiting factors.DiscussionInvariably, the need for resource conservation will continue to rise as cases of COVID-19 increase.", [["skin", "ANATOMY", 86, 90], ["skin", "ORGAN", 86, 90], ["autologous reconstruction", "TREATMENT", 6, 31], ["the overlying mastectomy skin flap", "TREATMENT", 61, 95], ["autologous reconstruction", "TREATMENT", 153, 178], ["the COVID-19 surge", "TREATMENT", 216, 234], ["resource conservation", "TREATMENT", 319, 340], ["COVID", "TEST", 375, 380], ["overlying", "OBSERVATION_MODIFIER", 65, 74], ["mastectomy", "OBSERVATION", 75, 85], ["skin", "ANATOMY", 86, 90], ["flap", "OBSERVATION", 91, 95]]], ["For example, the utilization of personal protective equipment (PPE) during COVID-19 for elective operations can be a source of concern for many hospitals around the country.", [["COVID-19", "CHEMICAL", 75, 83], ["personal protective equipment", "TREATMENT", 32, 61], ["COVID", "TREATMENT", 75, 80], ["elective operations", "TREATMENT", 88, 107]]], ["At the time of writing, many hospitals have implemented N95 recycling programs and PPE does not appear to be limiting necessary procedures.", [["N95 recycling programs", "TREATMENT", 56, 78], ["PPE", "TREATMENT", 83, 86]]], ["Additionally, this pathway of same-day mastectomy and reconstruction is proposed to also be useful during emergence from the COVID-19 surge, where capacity is still under strain as hospitals work through the backlog of patients awaiting oncologic operations.DiscussionIn the event that patient demand far exceeds supply, hospital networks will need to scale-back on the number of mastectomy and breast reconstruction cases performed, instead diverting resources to treatment efforts for COVID-19.", [["breast", "ANATOMY", 395, 401], ["patients", "ORGANISM", 219, 227], ["patient", "ORGANISM", 286, 293], ["breast", "ORGAN", 395, 401], ["patients", "SPECIES", 219, 227], ["patient", "SPECIES", 286, 293], ["mastectomy", "TREATMENT", 39, 49], ["reconstruction", "TREATMENT", 54, 68], ["oncologic operations", "TREATMENT", 237, 257], ["mastectomy", "TREATMENT", 380, 390], ["breast reconstruction cases", "TREATMENT", 395, 422], ["diverting resources", "TREATMENT", 442, 461], ["treatment efforts", "TREATMENT", 465, 482], ["COVID", "TEST", 487, 492], ["mastectomy", "OBSERVATION", 39, 49], ["mastectomy", "OBSERVATION", 380, 390], ["breast", "ANATOMY", 395, 401]]], ["However, in the time interval before or after the peak incidence of COVID-19 surge, we anticipate a tenable need for efficient surgical practice to alleviate the expected backlog of breast cancer cases resulting from the re-allocation of resources toward COVID-19.", [["breast cancer", "ANATOMY", 182, 195], ["breast cancer", "DISEASE", 182, 195], ["breast cancer", "CANCER", 182, 195], ["COVID", "TEST", 68, 73], ["efficient surgical practice", "TREATMENT", 117, 144], ["breast cancer", "PROBLEM", 182, 195], ["COVID", "TEST", 255, 260], ["breast", "ANATOMY", 182, 188], ["cancer", "OBSERVATION", 189, 195]]], ["The merit of this same-day surgery protocol is the ability to safely and efficiently decrease resource utilization, while implementing virtual patient visits to meet the challenges posed by COVID-19.", [["COVID-19", "CHEMICAL", 190, 198], ["patient", "ORGANISM", 143, 150], ["patient", "SPECIES", 143, 150], ["surgery protocol", "TREATMENT", 27, 43]]], ["We acknowledge the limitation of the small sample size and short follow-up duration in the present study.", [["the small sample size", "PROBLEM", 33, 54], ["the present study", "TEST", 87, 104], ["small", "OBSERVATION_MODIFIER", 37, 42], ["sample", "OBSERVATION_MODIFIER", 43, 49], ["size", "OBSERVATION_MODIFIER", 50, 54], ["short follow-up duration", "OBSERVATION_MODIFIER", 59, 83]]], ["However, this patient cohort was well matched compared to those in previous publications from our institution, namely in age and BMI, suggesting that these patients are representative of the patient cohort that normally undergoes mastectomy and immediate breast reconstruction [37] .", [["breast", "ANATOMY", 255, 261], ["patient", "ORGANISM", 14, 21], ["patients", "ORGANISM", 156, 164], ["patient", "ORGANISM", 191, 198], ["breast", "ORGANISM_SUBDIVISION", 255, 261], ["patient", "SPECIES", 14, 21], ["patients", "SPECIES", 156, 164], ["patient", "SPECIES", 191, 198], ["mastectomy", "TREATMENT", 230, 240], ["immediate breast reconstruction", "TREATMENT", 245, 276], ["mastectomy", "OBSERVATION", 230, 240], ["breast", "ANATOMY", 255, 261]]], ["In addition, immediate postoperative complications that require hospital re-admission and operative management, namely hematoma, tend to occur within 3 days of breast reconstruction [38] .", [["breast", "ANATOMY", 160, 166], ["hematoma", "DISEASE", 119, 127], ["breast", "ORGANISM_SUBDIVISION", 160, 166], ["immediate postoperative complications", "PROBLEM", 13, 50], ["hospital re-admission", "TREATMENT", 64, 85], ["operative management", "TREATMENT", 90, 110], ["hematoma", "PROBLEM", 119, 127], ["breast reconstruction", "TREATMENT", 160, 181], ["postoperative complications", "OBSERVATION", 23, 50], ["hematoma", "OBSERVATION", 119, 127], ["breast", "ANATOMY", 160, 166]]], ["As such, nearly one week of follow-up should be sufficient to identify postoperative hematoma in patients at risk for implant loss and in need of salvage procedures.", [["hematoma", "DISEASE", 85, 93], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["postoperative hematoma", "PROBLEM", 71, 93], ["implant loss", "PROBLEM", 118, 130], ["salvage procedures", "TREATMENT", 146, 164], ["hematoma", "OBSERVATION", 85, 93], ["implant loss", "OBSERVATION", 118, 130]]], ["Therefore, we felt it necessary to disseminate this information in a timely manner given the escalation of the COVID-19 crisis, especially if this protocol can be helpful to our community.", [["the COVID", "TEST", 107, 116], ["this protocol", "TREATMENT", 142, 155]]], ["Additionally, it stands to reason that this same-day surgery pathway may not be generalizable across all institutions given likely limitations in accessibility, resource funding, and telemedicine capabilities.", [["surgery", "TREATMENT", 53, 60], ["telemedicine capabilities", "TEST", 183, 208]]], ["The success of this same-day protocol does demonstrate that a transition to outpatient surgical facilities for breast reconstruction may be feasible in the near future, given appropriate patient selection, pre-operative counseling, surgical planning, and resource optimization.", [["breast", "ANATOMY", 111, 117], ["breast", "ORGANISM_SUBDIVISION", 111, 117], ["patient", "ORGANISM", 187, 194], ["patient", "SPECIES", 187, 194], ["outpatient surgical facilities", "TREATMENT", 76, 106], ["breast reconstruction", "TREATMENT", 111, 132], ["pre-operative counseling", "TREATMENT", 206, 230], ["surgical planning", "TREATMENT", 232, 249], ["resource optimization", "TREATMENT", 255, 276], ["breast", "ANATOMY", 111, 117]]], ["We hope that this successful implementation of a same-day protocol for immediate breast reconstruction will serve as a framework for other institutions to incorporate techniques or develop efficient, cost-effective pathways for immediate breast reconstruction during these unprecedented times.ConclusionThis early experience demonstrates that an efficient mastectomy and immediate breast reconstruction can be operationalized to meet acute constraints of hospital capacity and resources.", [["breast", "ANATOMY", 81, 87], ["breast", "ANATOMY", 238, 244], ["breast", "ANATOMY", 381, 387], ["breast", "ORGANISM_SUBDIVISION", 81, 87], ["breast", "ORGANISM_SUBDIVISION", 238, 244], ["breast", "ORGAN", 381, 387], ["a same-day protocol", "TREATMENT", 47, 66], ["immediate breast reconstruction", "TREATMENT", 71, 102], ["immediate breast reconstruction", "TREATMENT", 228, 259], ["an efficient mastectomy", "TREATMENT", 343, 366], ["immediate breast reconstruction", "TREATMENT", 371, 402], ["breast", "ANATOMY", 81, 87], ["efficient", "OBSERVATION_MODIFIER", 346, 355], ["mastectomy", "OBSERVATION", 356, 366], ["breast", "ANATOMY", 381, 387]]], ["This perioperative pathway can be readily modified to utilize virtual patient visits in the setting of the COVID-19 crisis to conserve resources, increase inpatient capacity, and minimize viral exposure for patients recovering from surgery.", [["patient", "ORGANISM", 70, 77], ["patients", "ORGANISM", 207, 215], ["patient", "SPECIES", 70, 77], ["patients", "SPECIES", 207, 215], ["the COVID", "TEST", 103, 112], ["surgery", "TREATMENT", 232, 239]]], ["This work is particularly timely given the acute need for well-defined protocols for oncologic and reconstructive procedures during the COVID-19 pandemic.", [["well-defined protocols", "TREATMENT", 58, 80], ["oncologic and reconstructive procedures", "TREATMENT", 85, 124], ["the COVID", "TEST", 132, 141], ["pandemic", "PROBLEM", 145, 153], ["acute", "OBSERVATION_MODIFIER", 43, 48]]], ["Marianne Turner, and Shin Hae Yoon.", [["Shin", "ANATOMY", 21, 25]]], ["No additional funding supported this work.ConclusionAuthor contributions NS-Author made substantial contributions to the acquisition of data, interpretation of data, drafting of the work, substantively revised draft of work, approved the submitted version and agreed to be both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work.", [["additional", "OBSERVATION_MODIFIER", 3, 13], ["funding", "OBSERVATION", 14, 21]]], ["MS-Author made substantial contributions to the conception and design of the work, interpretation of data, substantively revised draft of work, approved the submitted version and agreed to be both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work.ConclusionFunding No funds were received for this study.Compliance with ethical standardsConflict of interest Author ECL has consultant agreements with, but is explicitly not a speaker for, Musculoskeletal Transplant Foundation and Allergan Inc., manufacturers of FlexHD and AlloDerm, respectively.", [["this study", "TEST", 396, 406], ["ethical standards", "TREATMENT", 423, 440], ["Allergan Inc.", "TREATMENT", 583, 596], ["FlexHD and AlloDerm", "TREATMENT", 615, 634], ["Musculoskeletal", "ANATOMY", 541, 556], ["Transplant", "OBSERVATION", 557, 567]]], ["Author NS declares that she has no conflict of interest.", [["Author NS", "TREATMENT", 0, 9]]], ["Author MS declares that she has no conflict of interest.Compliance with ethical standardsEthical approval This work is a clinical quality improvement, patients were followed prospectively.", [["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["ethical standards", "TREATMENT", 72, 89], ["Ethical approval", "TREATMENT", 89, 105]]], ["No IRB review is needed for clinical quality improvement that meets standard of care.", [["IRB review", "TEST", 3, 13]]], ["All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.Compliance with ethical standardsInformed consent This work is a clinical quality improvement, patients were followed prospectively.", [["human", "ORGANISM", 46, 51], ["patients", "ORGANISM", 358, 366], ["human", "SPECIES", 46, 51], ["participants", "SPECIES", 52, 64], ["patients", "SPECIES", 358, 366], ["human", "SPECIES", 46, 51], ["All procedures", "TREATMENT", 0, 14], ["ethical standards", "TREATMENT", 279, 296]]]], "PMC5737525": [], "PMC7429913": [["Several months earlier, a novel coronavirus infection in Wuhan, China, set off a chain reaction of events internationally that became the most impactful global disruption in living memory.1 On March 11, 2020, the World Health Organization (WHO) declared a global pandemic, triggering global population-wide lockdowns affecting billions of people.2 The magnitude of the COVID-19 crisis truly defied imagination\u2014or preplanning\u2014yet despite the scale and impact of the situation, community pharmacies across Canada remained open and continued to provide service and care to their patients.", [["coronavirus infection", "DISEASE", 32, 53], ["coronavirus", "ORGANISM", 32, 43], ["people", "ORGANISM", 339, 345], ["patients", "ORGANISM", 576, 584], ["people", "SPECIES", 339, 345], ["patients", "SPECIES", 576, 584], ["a novel coronavirus infection", "PROBLEM", 24, 53], ["a global pandemic", "PROBLEM", 254, 271], ["the COVID", "TEST", 365, 374], ["coronavirus", "OBSERVATION_MODIFIER", 32, 43], ["infection", "OBSERVATION", 44, 53], ["impactful", "OBSERVATION_MODIFIER", 143, 152], ["global", "OBSERVATION_MODIFIER", 153, 159], ["disruption", "OBSERVATION", 160, 170], ["global", "OBSERVATION_MODIFIER", 284, 290], ["population", "OBSERVATION_MODIFIER", 291, 301], ["wide", "OBSERVATION_MODIFIER", 302, 306]]], ["At the time this article was written, the full story of COVID-19 was still not known, nor is there any clarity as to whether or when any return to a discernible prepandemic \u201cnormal\u201d will be possible.BackgroundIn 2007, we published research examining previously unimaginable public health crises.3 This article focused on the ways in which community pharmacists in Ontario coped with severe acute respiratory syndrome (SARS) in 2003 and the massive disruption of the electrical transmission grid across eastern North America in 2005.", [["acute respiratory syndrome", "DISEASE", 390, 416], ["SARS", "DISEASE", 418, 422], ["COVID", "TEST", 56, 61], ["severe acute respiratory syndrome", "PROBLEM", 383, 416], ["SARS", "PROBLEM", 418, 422], ["the massive disruption", "PROBLEM", 436, 458], ["severe", "OBSERVATION_MODIFIER", 383, 389], ["acute", "OBSERVATION_MODIFIER", 390, 395], ["respiratory syndrome", "OBSERVATION", 396, 416], ["massive", "OBSERVATION_MODIFIER", 440, 447], ["disruption", "OBSERVATION", 448, 458]]], ["The focus of this research was on the adaptation strategies community pharmacies used to maintain service despite the collapse of basic infrastructure (electricity, primary health care) and concluded that the profession needed to plan for and expect similar situations in the future because \u201cemergencies and civil crises will continue to occur.\u201d3BackgroundPandemic planning has been in place across provincial health systems for many years; a globally influential study by Cox, Tamblyn and Tam4 (who eventually went on to become Canada\u2019s chief public health officer during the COVID-19 pandemic) described principles for system responsiveness, drawing upon lessons learned during SARS, particularly in Toronto.", [["SARS", "DISEASE", 680, 684], ["the collapse of basic infrastructure", "PROBLEM", 114, 150], ["civil crises", "PROBLEM", 308, 320], ["SARS", "PROBLEM", 680, 684], ["collapse", "OBSERVATION", 118, 126]]], ["In particular, this study focused on the need to coordinate health care screening and delivery activities across diverse agencies, but with scant attention paid to the potential role and importance of community pharmacy.", [["this study", "TEST", 15, 25], ["health care screening", "TEST", 60, 81], ["delivery activities", "TREATMENT", 86, 105]]], ["Fitzgerald et al.6 examined promising practices in pandemic planning with respect to optimization of the role of community pharmacies: at that time, they noted that, despite ongoing discussions and formal commitments, there were few effective examples of how to integrate privately owned pharmacies into a broader public health agenda.", [["pandemic planning", "TREATMENT", 51, 68]]], ["Nationally and globally, pharmacy organizations have developed statements and toolkits to provide guidance to community pharmacists during pandemics.", [["pandemics", "PROBLEM", 139, 148]]], ["FIP (the International Pharmacy Federation) recently published guidelines for pharmacists and the pharmacy workforce to manage COVID-19, highlighting core responsibilities associated with stewardship of the drug supply chain, patient education and provision of public health services where scope of practice permits.7 Initially produced in 2009, the Canadian Pharmacists Association\u2019s \u201cPharmacists\u2019 Guide to Pandemic Preparedness\u201d focused on pragmatic issues, including strategies for safeguarding personal health and safety, initiation of infection control programs within retail environments and guidance for managing surges in patient demand and store-based traffic.8 Similar guidance documents have been produced by the Royal Pharmaceutical Society (United Kingdom)9 and the American Pharmacists Association,10 reflecting their unique national and local health system needs and resources.BackgroundWhile important and helpful, such documents and previous research could simply not predict the magnitude of what occurred in the late winter/early spring of 2020.", [["FIP", "DISEASE", 0, 3], ["Pandemic", "DISEASE", 408, 416], ["infection", "DISEASE", 540, 549], ["patient", "ORGANISM", 226, 233], ["patient", "ORGANISM", 630, 637], ["patient", "SPECIES", 226, 233], ["patient", "SPECIES", 630, 637], ["COVID", "TEST", 127, 132], ["infection control programs", "TREATMENT", 540, 566], ["managing surges", "TREATMENT", 611, 626]]], ["Currently, there is general consensus that the evolution of COVID-19 will involve successive \u201cwaves\u201d or cycles of peak infection followed by trough periods.11 In order to prepare better for what may be several years of disruption in society and professional practice, it is valuable to generate early data regarding how community pharmacists managed the first wave of COVID-19 in order to better support forward planning and preparation.Research objectiveThe objective of this research was to describe the experience of community pharmacies during the early first phase (mid-March to mid-May 2020) of the COVID-19 pandemic in Ontario, Canada.", [["infection", "DISEASE", 119, 128], ["COVID-19", "CHEMICAL", 368, 376], ["COVID", "TEST", 60, 65], ["successive \u201cwaves", "TREATMENT", 82, 99], ["peak infection", "PROBLEM", 114, 128], ["COVID", "TEST", 368, 373], ["the COVID", "TEST", 601, 610], ["peak", "OBSERVATION_MODIFIER", 114, 118], ["infection", "OBSERVATION", 119, 128]]], ["For the purpose of this research, the unit of study was the pharmacy as an organization, rather than individual pharmacists, technicians or other staff members.MethodsThe highly unusual circumstances of the COVID-19 pandemic, coupled with the magnitude of its societal impact, introduced significant challenges and opportunities for addressing the research objective.", [["the COVID", "TEST", 203, 212]]], ["Given the fast-changing nature of the situation and the absence of any real precedent for this kind of world-changing event, a qualitative, exploratory research method was selected in order to provide a starting point for future research.", [["exploratory research method", "TEST", 140, 167]]], ["No guiding principles or theoretical framework currently in existence was sufficiently robust to apply to this pandemic situation, given its breadth and dimensions.12 Equally importantly, this unprecedented situation provided the researchers with an opportunity to engage in real-time research\u2014actively engaging with participants as the pandemic situation itself was evolving rather than waiting for it to end and then retrospectively examining how pharmacists responded.13 The value of rapid-response real-time research in this context was significant, as it could potentially inform practice and policy decisions related to subsequent follow-up waves or surges of COVID-19 in the months or years ahead.14 As a result, a combination of convenience, snowballing and purposive sampling methods was used to recruit participants, using a method described by Yin.15MethodsFor convenience purposes, sites for this study were community pharmacies involved in the University of Toronto\u2019s experiential education program.", [["participants", "SPECIES", 317, 329], ["participants", "SPECIES", 813, 825], ["The value", "TEST", 474, 483], ["COVID", "TEST", 666, 671], ["purposive sampling methods", "TREATMENT", 766, 792], ["a method", "TREATMENT", 833, 841], ["this study", "TEST", 904, 914]]], ["Purposive sampling was used to identify potential research sites across the province of Ontario (urban [city or town], rural, suburban) representing different geographical locations and business types (independent, chain, grocery, etc.).", [["Purposive sampling", "TREATMENT", 0, 18], ["potential research sites", "PROBLEM", 40, 64]]], ["The unit of analysis for this study was the pharmacy itself, rather than individual staff members: as a result, participation was limited to pharmacies where 3 or more staff members representing different job types (pharmacist, manager, owner, regulated technician, unregulated technician, assistant, etc.) agreed to participate.MethodsSnowball sampling was also used for participant recruitment; all participants in this study were invited to nominate or recommend another colleague or friend in another pharmacy who they thought might be interested in participating in this study\u2014a research team member would then follow up to provide this individual/group with further information and an invitation to participate.", [["participants", "SPECIES", 401, 413], ["analysis", "TEST", 12, 20], ["this study", "TEST", 25, 35], ["MethodsSnowball sampling", "TREATMENT", 329, 353], ["this study", "TEST", 417, 427]]], ["Snowball sampling is useful for rapid expansion of the potential pool of research participants but can lead to overrepresentation of similar kinds of individuals, as research participants (in general) are more likely to recommend colleagues who are similar demographically or with respect to practice type to themselves.15MethodsTo optimize the value of this snowballing technique, purposive sampling was also applied to the participant pool.", [["participants", "SPECIES", 82, 94], ["participants", "SPECIES", 175, 187], ["Snowball sampling", "TEST", 0, 17], ["this snowballing technique", "TREATMENT", 354, 380], ["purposive sampling", "TREATMENT", 382, 400]]], ["Purposive sampling provided the research team with a more direct opportunity to filter potential participants based on core demographic characteristics, such as location of practice (urban, suburban, rural, small town), nature of practice (chain, independent, grocery, big-box retailer) and prescription volume (low [<250/day], medium [250-500/day] or high [>500 day]), in an effort to more broadly align the participant pool with practice demographics of the profession in Ontario.", [["participants", "SPECIES", 97, 109]]], ["Inclusion criteria for this study were 1) working a minimum of 24 hours/week within the pharmacy for a minimum of 3 years; 2) working in a patient-facing role within the dispensary (rather than front shop); 3) pharmacist, regulated pharmacy technician or dispensary assistant only (no students/learners); and 4) English speaking.", [["patient", "ORGANISM", 139, 146], ["patient", "SPECIES", 139, 146], ["this study", "TEST", 23, 33]]], ["The combination of these 3 forms of sampling allowed for rapid assembly of a sample that was approximate (although not necessarily statistically representative) of the profession in Ontario.MethodsSince the unit of analysis for this study was the pharmacy\u2014rather than the individual employee within the pharmacy\u2014a focus group method was selected that involved simultaneous interviews of all participants within the pharmacy followed by open-forum discussion.", [["participants", "SPECIES", 391, 403], ["this study", "TEST", 228, 238]]], ["The Teams platform also supported generation of transcripts of recorded meetings, which facilitated rapid analysis and coding of data.", [["rapid analysis", "TEST", 100, 114]]], ["Importantly, the Teams platform stores video and transcript data in an encrypted format that is not possible for the research team to fully control.", [["transcript data", "TEST", 49, 64]]], ["As a result, absolute security and confidentiality were not possible in this study.", [["this study", "TEST", 72, 82], ["not possible", "UNCERTAINTY", 56, 68]]], ["This study was deemed low risk through institutional ethics review, and this information was fully disclosed to all participants.MethodsFocus group interview sessions were conducted pursuant to a semistructured interview protocol that evolved during the course of the study (see online Appendix 1 for the final version used).", [["participants", "SPECIES", 116, 128], ["This study", "TEST", 0, 10], ["a semistructured interview protocol", "TEST", 194, 229], ["the study", "TEST", 264, 273]]], ["As the focus of this project was on rapid research, there was no pilot testing of the protocol.", [["pilot testing", "TEST", 65, 78], ["the protocol", "TREATMENT", 82, 94]]], ["Similarly, given the extraordinary and unprecedented circumstances associated with the COVID-19 pandemic, there were no available previously validated instruments that were useful in this research context, nor was there any relevant theoretical framework to guide its development.", [["the COVID", "TEST", 83, 92]]], ["The semistructured nature of the protocol facilitated significant opportunities to customize questions and approaches to the unique experiences of the pharmacy team being interviewed in order to capture the broadest and deepest data possible.MethodsAll transcripts were independently reviewed by 2 members of the research team, who then met to reconcile coding and analysis after each interview.", [["the protocol", "TREATMENT", 29, 41]]], ["Interviews were all conducted by the same person (PAMG) to enhance consistency of data collection.", [["person", "SPECIES", 42, 48]]], ["Interviews proceeded to the point of thematic saturation, the point at which no additional new information was being adduced from participants.", [["participants", "SPECIES", 130, 142], ["thematic saturation", "TEST", 37, 56]]], ["No compensation was available for participants in this study.", [["participants", "SPECIES", 34, 46], ["compensation", "PROBLEM", 3, 15], ["this study", "TEST", 50, 60], ["compensation", "OBSERVATION", 3, 15]]], ["The study received expedited approval from institutional ethics review, in recognition of its potential value and importance to the pharmacy community in anticipation of the next wave of COVID.1.", [["The study", "TEST", 0, 9], ["institutional ethics review", "TEST", 43, 70], ["the next wave of COVID", "TREATMENT", 170, 192]]], ["What happened? ::: Findings and DiscussionThe speed and magnitude of practice change that was experienced in community pharmacy was the dominant theme across all participants.", [["participants", "SPECIES", 162, 174]]], ["Across all pharmacy teams, the following practice changes were highlighted: 1) surges in volumes of patients seeking renewals of prescriptions, health advice/counselling and nonprescription medications; 2) increases in drug shortages and increases in unpredictability of short supply items; 3) increased workload with respect to dispensing as policies designed to prevent stockpiling or worsening shortages reduced allowable dispensing quantities; 4) significant decrease/complete collapse in provision of documented and remunerated clinical services such as vaccinations and MedsChecks; 5) increase in unremunerated clinical interventions (such as prescription modifications and waived fees for prescription renewals); 6) significant decrease in patient-facing activities related to education/counselling; and 7) significant increase in nonclinical customer service activities such as explanation of drug shortage issues or changes in prescription renewal policies.1.", [["patients", "ORGANISM", 100, 108], ["patient", "ORGANISM", 747, 754], ["patients", "SPECIES", 100, 108], ["patient", "SPECIES", 747, 754], ["nonprescription medications", "TREATMENT", 174, 201], ["short supply items", "PROBLEM", 271, 289], ["stockpiling", "PROBLEM", 372, 383], ["worsening shortages reduced allowable dispensing quantities", "PROBLEM", 387, 446], ["significant decrease/complete collapse", "PROBLEM", 451, 489], ["vaccinations and MedsChecks", "TREATMENT", 559, 586], ["unremunerated clinical interventions", "TREATMENT", 603, 639], ["prescription modifications", "TREATMENT", 649, 675], ["prescription renewals", "TREATMENT", 696, 717], ["significant decrease in patient-facing activities", "PROBLEM", 723, 772], ["drug shortage issues", "PROBLEM", 901, 921], ["worsening", "OBSERVATION_MODIFIER", 387, 396], ["collapse", "OBSERVATION", 481, 489], ["significant", "OBSERVATION_MODIFIER", 723, 734], ["decrease", "OBSERVATION_MODIFIER", 735, 743], ["significant", "OBSERVATION_MODIFIER", 814, 825], ["increase", "OBSERVATION_MODIFIER", 826, 834]]], ["What happened? ::: Findings and DiscussionIt was nonstop and just like a tidal wave.", [["tidal wave", "OBSERVATION", 73, 83]]], ["Sure, a lot of the things we used to do\u2014MedsChecks . . . you just couldn\u2019t any more, even basic counselling.", [["Meds", "TREATMENT", 40, 44]]], ["But at the end of the day people needed to get drugs in their hands\u2014or delivered at home!\u2014and that\u2019s the priority and we got that done so everyone should be proud we stepped up and made it happen.", [["people", "ORGANISM", 26, 32], ["people", "SPECIES", 26, 32]]], ["What happened? ::: Findings and DiscussionAcross participants in this study, there was consensus on the experience of practice during pandemic: prioritization of dispensing and drug distribution activities over virtually all other, particularly remunerated clinical activities.", [["participants", "SPECIES", 49, 61], ["this study", "TEST", 65, 75], ["dispensing", "TREATMENT", 162, 172]]], ["There was no consensus, however, on the significance of this common experience: some participants lamented this \u201cbacksliding\u201d away from clinical work, while others expressed pride that they were able to provide what they thought to be the most essential of pharmacy services with minimal disruption to patients.", [["patients", "ORGANISM", 302, 310], ["participants", "SPECIES", 85, 97], ["patients", "SPECIES", 302, 310], ["no", "UNCERTAINTY", 10, 12]]], ["It is unclear whether this situation is unique to Ontario (which was particularly hard-hit by the COVID-19 pandemic).", [["the COVID", "TEST", 94, 103], ["unclear whether", "UNCERTAINTY", 6, 21]]], ["How did we respond? ::: Findings and DiscussionAcross all participants, there was broad agreement that the first 2 to 3 weeks following the WHO declaration of a global pandemic were the most challenging in their professional experience, given the lack of preplanning at the pharmacy or organizational level.", [["participants", "SPECIES", 58, 70], ["a global pandemic", "PROBLEM", 159, 176]]], ["Participants vividly described personal and professional fears associated with lack of information regarding the pandemic and in particular issues related to personal safety, lack of personal protective equipment (PPE) and lack of clear policies or practices to guide daily work.", [["Participants", "SPECIES", 0, 12], ["the pandemic", "PROBLEM", 109, 121]]], ["For example, when information regarding the potential value of hydroxychloroquine in reducing risk associated with COVID-19 was being promoted by some individuals, or when questions regarding the role of ibuprofen in worsening COVID-19 symptoms arose, pharmacists needed rapid access to high-quality information and found this difficult to find, highlighting a potential opportunity for future development.2.", [["hydroxychloroquine", "CHEMICAL", 63, 81], ["ibuprofen", "CHEMICAL", 204, 213], ["COVID", "DISEASE", 227, 232], ["hydroxychloroquine", "CHEMICAL", 63, 81], ["COVID-19", "CHEMICAL", 115, 123], ["ibuprofen", "CHEMICAL", 204, 213], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 63, 81], ["ibuprofen", "SIMPLE_CHEMICAL", 204, 213], ["hydroxychloroquine", "TREATMENT", 63, 81], ["ibuprofen", "TREATMENT", 204, 213], ["worsening COVID-19 symptoms", "PROBLEM", 217, 244]]], ["We need something, otherwise it\u2019s every man for himself, there\u2019s no consistency and it . . . well, you saw what happened, it was disorganization and chaos.", [["man", "ORGANISM", 40, 43], ["man", "SPECIES", 40, 43]]], ["Lack of awareness of this important repository of information by pharmacists in this study suggests that further work in either communicating or disseminating the availability of such information, or further training of pharmacists to locate credible available evidence, may be required.2.", [["this study", "TEST", 80, 90]]], ["How did we respond? ::: Findings and DiscussionAnother common theme across all participants was the need to enhance pharmacy-based security, navigation and PPE practices.", [["participants", "SPECIES", 79, 91], ["navigation and PPE practices", "TREATMENT", 141, 169]]], ["In particular, given high levels of public anxiety and uncertainty regarding the integrity of the drug supply chain in Canada, many participants reported difficult, sometimes frightening, interactions with members of the public and their desire for dedicated security to provide support and conflict management.", [["anxiety", "DISEASE", 43, 50], ["participants", "SPECIES", 132, 144], ["public anxiety", "PROBLEM", 36, 50], ["support", "TREATMENT", 279, 286], ["conflict management", "TREATMENT", 291, 310]]], ["The additional stress of these issues further heightened workplace pressures and reduced the capacity of all pharmacy team members to manage increasing demands.", [["increasing demands", "PROBLEM", 141, 159], ["pressures", "OBSERVATION_MODIFIER", 67, 76]]], ["Most participants also highlighted the impact of inconsistent guidance and practices regarding PPE in the workplace\u2014for staff and for customers/patients.", [["patients", "ORGANISM", 144, 152], ["participants", "SPECIES", 5, 17], ["patients", "SPECIES", 144, 152]]], ["While scientific consensus on the importance of masks or gloves had been inconsistent and changing, virtually all participants in this research reported a high level of anxiety around interactions with unprotected patients and customers and other staff, as well as a strong desire for greater clarity and leadership from employers and organizations around PPE and security issues.", [["anxiety", "DISEASE", 169, 176], ["patients", "ORGANISM", 214, 222], ["participants", "SPECIES", 114, 126], ["patients", "SPECIES", 214, 222], ["gloves", "TREATMENT", 57, 63], ["anxiety", "PROBLEM", 169, 176]]], ["While pharmacy-based navigation (e.g., \u201csafety bubbles\u201d on floors to indicate a safe 2-metre zone, or directional wayfinding arrows to prevent bunching of people in aisles) became commonplace retail strategies in the second and third months of the pandemic, they were not widely used in the first few weeks, and this increased anxiety and concerns for pharmacy staff.2.", [["anxiety", "DISEASE", 327, 334], ["people", "ORGANISM", 155, 161], ["people", "SPECIES", 155, 161], ["this increased anxiety", "PROBLEM", 312, 334]]], ["I mean here we all are, the pharmacists, the team, and we\u2019re stressed and we\u2019re scared, we don\u2019t have the right [PPE], the customers are freaked out with drug shortages and things.", [["right", "ANATOMY_MODIFIER", 106, 111]]], ["I know how to handle patients when they are upset or angry but this was way beyond that.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29]]], ["I don\u2019t understand\u2014I mean, it would have been so simple and yes maybe cost a bit of money\u2014but having a dedicated security guard or someone who could help when things got heated, so the pharmacy staff aren\u2019t feeling threatened or afraid, especially because, well, who knows if the person shouting or crying has COVID?", [["person", "SPECIES", 280, 286]]], ["How did we respond? ::: Findings and DiscussionA final common theme across all participants related to the central role of workplace/employer support in enhancing personal resilience strategies.", [["participants", "SPECIES", 79, 91], ["employer support", "TREATMENT", 133, 149]]], ["Participants in this study ranged considerably in terms of their years in practice, yet all were \u201cexperienced\u201d and had developed strategies for managing time and interpersonal pressures associated with pre-COVID-19 pharmacy practice.", [["Participants", "SPECIES", 0, 12], ["this study", "TEST", 16, 26], ["interpersonal pressures", "TEST", 162, 185]]], ["Most participants noted that, despite this experience and a personal repertoire of effective coping and adaptation resources, the dimensions of the pandemic clearly meant that resilience was more than a personal issue: workplace policies were substantially more meaningful and integral to the ability of the pharmacy to actually function and for individuals employed within that environment to personally cope.2.", [["participants", "SPECIES", 5, 17], ["adaptation resources", "TREATMENT", 104, 124]]], ["But at the end of the day, what I learned was the most important thing is the way the whole operation manages, the way the whole store, or organization gets itself ready.", [["the whole operation", "TREATMENT", 82, 101]]], ["These things . . . well, even if there never is a second wave or cycle, these changes in the way pharmacies run should just become routine because in the end, that\u2019s going to make the pharmacy run better, be more efficient and actually have a greater impact for patients.", [["patients", "ORGANISM", 262, 270], ["patients", "SPECIES", 262, 270]]], ["What worked\u2014and what didn\u2019t work? ::: Findings and DiscussionParticipants in this study were unanimous in noting that the length of time spent in the pharmacy in a patient-facing role was of considerable importance in predicting operational success and supporting personal resilience.", [["patient", "ORGANISM", 164, 171], ["patient", "SPECIES", 164, 171], ["this study", "TEST", 77, 87]]], ["Longer shifts (12, 14, or even longer consecutive hours worked) produced cognitive and emotional overload, which led to knock-on effects and delayed recovery.", [["cognitive and emotional overload", "DISEASE", 73, 105], ["cognitive and emotional overload", "PROBLEM", 73, 105], ["overload", "OBSERVATION", 97, 105]]], ["While historically some pharmacists may have preferred longer but fewer worked shifts per week for personal or family reasons, from an operational and psychological perspective, there was consensus among participants in this study that this was problematic.", [["participants", "SPECIES", 204, 216], ["this study", "TEST", 220, 230]]], ["The need for recovery time following a shift, coupled with the physical and emotional exhaustion associated with such long shifts, was considerably exacerbated due to pandemic-related demand surges.B. Scheduling patterns ::: 3.", [["pandemic", "DISEASE", 167, 175], ["the physical and emotional exhaustion", "PROBLEM", 59, 96], ["pandemic", "PROBLEM", 167, 175]]], ["What worked\u2014and what didn\u2019t work? ::: Findings and DiscussionParticipants in this study highlighted the value of scheduling practices that focused on teams of pharmacists, regulated technicians and assistants, rather than on each person as an individual.", [["person", "SPECIES", 230, 236], ["this study", "TEST", 77, 87], ["scheduling practices", "TREATMENT", 113, 133]]], ["Historically, many pharmacies have defined the individual worker as the unit of scheduling, rather than a team or line-based approach.", [["line-based approach", "TREATMENT", 114, 133]]], ["The advantages of scheduling the same people to work in as consistent a manner as possible included greater efficiency in communication and interaction among team members (as there was no learning curve for collaboration at the start of each shift), as well as greater social comfort.", [["people", "ORGANISM", 38, 44], ["people", "SPECIES", 38, 44]]], ["Importantly during the pandemic, consistent scheduling also reduced the number of different people individual staff members would interact with over the course of a week or month of work, and this provided significant comfort.", [["people", "ORGANISM", 92, 98], ["people", "SPECIES", 92, 98]]], ["Finally, working with the same team consistently also made it easier for individuals within that team to provide social and psychosocial support for one another and to notice if any individual within that line/team was experiencing problems.C. Reduction of multitasking ::: 3.", [["C.", "SPECIES", 241, 243], ["C.", "SPECIES", 241, 243], ["problems", "PROBLEM", 232, 240]]], ["What worked\u2014and what didn\u2019t work? ::: Findings and DiscussionIn an effort to reduce crowding in tight dispensary spaces, some participants noted their workplaces modified existing practices during the pandemic to support greater focus and specialization of work.", [["participants", "SPECIES", 126, 138], ["crowding in tight dispensary spaces", "PROBLEM", 84, 119], ["tight", "OBSERVATION_MODIFIER", 96, 101], ["dispensary spaces", "OBSERVATION", 102, 119]]], ["For example, small counselling rooms (which were not used due to social distancing concerns) became separated office space the pharmacist could use to focus on a series of tasks (e.g., follow-up calls with patients or prescription verification) without the usual interruptions that occur within a dispensary environment.", [["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 206, 214], ["small", "OBSERVATION_MODIFIER", 13, 18]]], ["The positive effects of focus and reduction of multitasking were described as immediate and significant: the reduction in cognitive load associated with task focus was seen as not only important from a personal resilience perspective but also from a quality of care and clinical outcome perspective.", [["the reduction in cognitive load", "PROBLEM", 105, 136], ["positive effects", "OBSERVATION_MODIFIER", 4, 20], ["reduction", "OBSERVATION_MODIFIER", 34, 43], ["significant", "OBSERVATION_MODIFIER", 92, 103], ["reduction", "OBSERVATION_MODIFIER", 109, 118]]], ["Regulated technicians noted that the physical separation of the pharmacist from the dispensary not only allowed them to practise to a fuller scope, but it also permitted greater division of responsibilities that enhanced overall operational efficiency, while allowing the pharmacy team as a whole to actually enhance productivity, quality and workplace satisfaction.D. Enhanced use of technology ::: 3.", [["a fuller scope", "TEST", 132, 146], ["operational efficiency", "OBSERVATION", 229, 251]]], ["Participants in this study, regardless of their role, noted that pharmacies that had embraced and integrated technologies more fully into daily practice prior to the pandemic were much better placed to respond and be resilient as the pandemic evolved.", [["Participants", "SPECIES", 0, 12], ["this study", "TEST", 16, 26]]], ["They noted that, while the learning curve to use such technologies can be challenging and steep, once learned, such technologies provided pharmacy team members with much greater control over day-to-day tasks.", [["such technologies", "TREATMENT", 49, 66]]], ["Technology provided pharmacy team members with options for contacting patients and prescribers and for prioritizing and managing workflow more effectively.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78]]], ["Pharmacies that had not adopted technologies prior to the pandemic reported struggling with conventional routes of communication and interaction as demand surges peaked and as anxiety rose for patients; trying to integrate new technologies (e.g., Zoom) in the midst of the pandemic was also described negatively due to cognitive overload.", [["anxiety", "DISEASE", 176, 183], ["cognitive overload", "DISEASE", 319, 337], ["patients", "ORGANISM", 193, 201], ["patients", "SPECIES", 193, 201], ["anxiety", "PROBLEM", 176, 183], ["cognitive overload", "PROBLEM", 319, 337]]], ["Participants in this study noted that a desired outcome following the first wave of the pandemic would be greater investment in and more wholesale integration of diverse communications, monitoring and documentation technologies into their practices, which could further reinforce division of labour between pharmacists and regulated technicians, support greater task focus and provide more control over day-to-day work.E. The need for more nonprofessional support staff ::: 3.", [["Participants", "SPECIES", 0, 12], ["E.", "SPECIES", 419, 421], ["this study", "TEST", 16, 26]]], ["What worked\u2014and what didn\u2019t work? ::: Findings and DiscussionA final common theme was the problem of being \u201cpenny-wise, pound-foolish\u201d during the pandemic with respect to staffing levels and staffing mix.", [["staffing levels", "TEST", 171, 186]]], ["Pandemic-triggered demand surges produced extraordinary levels of stress and increased workload, some of which could have been alleviated through additional hiring of casual staff members to perform nonregulated work, ranging from deliveries to inventory receiving to pharmacy-based security and wayfinding.", [["Pandemic", "PROBLEM", 0, 8], ["stress", "PROBLEM", 66, 72], ["increased workload", "PROBLEM", 77, 95], ["increased workload", "OBSERVATION", 77, 95]]], ["Participants reported that many pharmacies appeared slow or hesitant to bring in additional staff or increase existing staffing hours, and as a result, professional staff were required to absorb increased nonprofessional workload, which further compounded workplace stress (e.g., regulated technicians driving around town delivering medications when they could be more useful managing refills, or pharmacists instructing customers on which way to walk down aisles to support social distancing).", [["Participants", "SPECIES", 0, 12], ["medications", "TREATMENT", 333, 344]]], ["Much of the pandemic-induced demand surge was caused by nonpharmacy-related issues, and without additional nonprofessional support staff (e.g., drivers, receivers, greeters to hand out PPE or do front-door COVID-19 screening), this was simply added work that increased stress for everyone.E. The need for more nonprofessional support staff ::: 3.", [["E.", "SPECIES", 289, 291]]], ["Simple things like, you can\u2019t ask people to work 12-hour days when they have kids doing home schooling, or let\u2019s schedule a group to work together so they can work as a team instead of individuals.", [["people", "ORGANISM", 34, 40], ["people", "SPECIES", 34, 40]]], ["What worked\u2014and what didn\u2019t work? ::: Findings and DiscussionAt the time this article was written, the first wave of the pandemic appears to be subsiding in many (but not all) parts of Canada.", [["the pandemic", "PROBLEM", 117, 129], ["appears to be", "UNCERTAINTY", 130, 143], ["subsiding", "OBSERVATION", 144, 153]]], ["Public health officials caution us that this is not only premature, but it may be unlikely and unrealistic.", [["may be unlikely", "UNCERTAINTY", 75, 90]]], ["Findings from this study suggest that personal resiliency in times of a pandemic is built upon a foundation of organizational support and managerial strategies that help the workforce manage surge demands, unpredictability and stress.", [["this study", "TEST", 14, 24], ["organizational support", "TREATMENT", 111, 133], ["managerial strategies", "TREATMENT", 138, 159], ["stress", "PROBLEM", 227, 233]]], ["A shift away from multitasking towards task focus and more rapid integration of communication and medication management technologies in practice can help reduce cognitive overload that compromises both quality care and workplace satisfaction.", [["cognitive overload", "DISEASE", 161, 179], ["medication management technologies", "TREATMENT", 98, 132], ["cognitive overload", "PROBLEM", 161, 179]]], ["Pharmacy owners and managers have the opportunity to materially impact the efficiency and effectiveness of their practices by shifting away from a traditional multitasking dispensing focus towards one that more fully embraces division of labour and supports regulated technician scope of practice.Limitations ::: Findings and DiscussionIt is important to note that the findings of this study must be interpreted with caution.", [["this study", "TEST", 381, 391]]], ["As rapid response research designed to capture a fast-changing event in real time, the use of purposive, convenience and snowball sampling methods means the participant pool for this study was neither representative of the profession, nor can findings be considered generalizable beyond the sample frame.", [["snowball sampling methods", "TEST", 121, 146], ["this study", "TEST", 178, 188]]], ["Rapid response research design also means triangulation and confirmation of participants\u2019 statements and claims were not undertaken beyond the thematic saturation process previously described.", [["participants", "SPECIES", 76, 88]]], ["Further, the focus group method, while useful in conceptualizing pharmacy staffing as a team, rather than individual, process, introduces social bias issues, which means individual participants may not have been as honest or forthcoming as they might have been in individual interviews.", [["participants", "SPECIES", 181, 193]]], ["Despite these limitations and as a first approximation of examining community pharmacies\u2019 response to a pandemic crisis, this study provides a useful starting point for discussion and reflection on preparation for an uncertain future.ConclusionIt is reasonable to believe that no one could have predicted the speed, severity, depth and magnitude of the COVID-19 pandemic.", [["a pandemic crisis", "PROBLEM", 102, 119], ["this study", "TEST", 121, 131], ["the COVID", "TEST", 349, 358], ["pandemic", "PROBLEM", 362, 370]]], ["These stories need to be promoted to reinforce public perception of pharmacy as an essential service during times of mass disruption events.", [["mass disruption events", "PROBLEM", 117, 139], ["mass", "OBSERVATION", 117, 121]]], ["By conceptualizing resilience as both a personal and organizational process and highlighting specific strategies that may in the future help community pharmacy adapt more rapidly to the unexpected, findings of this study also help us to identify important opportunities to simply enhance the quality of practice and workplace satisfaction for employees within the profession. \u25a0", [["this study", "TEST", 210, 220]]]], "365386dca7d40b3994d92218bb5ee633cab5f1f1": [["In particular, rituximab should be considered 43 for patients with severe disease and without active COVID-19 illness after discussion of specific 44 individual-level risks (age, comorbidities, occupation) and benefits of rituximab.", [["rituximab", "CHEMICAL", 15, 24], ["illness", "DISEASE", 110, 117], ["rituximab", "CHEMICAL", 222, 231], ["rituximab", "SIMPLE_CHEMICAL", 15, 24], ["patients", "ORGANISM", 53, 61], ["rituximab", "SIMPLE_CHEMICAL", 222, 231], ["patients", "SPECIES", 53, 61], ["rituximab", "TREATMENT", 15, 24], ["severe disease", "PROBLEM", 67, 81], ["active COVID-19 illness", "PROBLEM", 94, 117], ["rituximab", "TREATMENT", 222, 231], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["disease", "OBSERVATION", 74, 81], ["without", "UNCERTAINTY", 86, 93]]], ["We would also 45 consider rituximab for younger patients without comorbidities and with less severe disease.", [["rituximab", "CHEMICAL", 26, 35], ["rituximab", "SIMPLE_CHEMICAL", 26, 35], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["rituximab", "TREATMENT", 26, 35], ["comorbidities", "PROBLEM", 65, 78], ["less severe disease", "PROBLEM", 88, 107], ["less severe", "OBSERVATION_MODIFIER", 88, 99], ["disease", "OBSERVATION", 100, 107]]], ["46 First, rituximab is an effective and targeted therapy for pemphigus.", [["rituximab", "CHEMICAL", 10, 19], ["pemphigus", "DISEASE", 61, 70], ["rituximab", "SIMPLE_CHEMICAL", 10, 19], ["rituximab", "TREATMENT", 10, 19], ["targeted therapy", "TREATMENT", 40, 56], ["pemphigus", "PROBLEM", 61, 70]]], ["We have limited data directly 47 comparing adverse events in those treated with rituximab versus other therapies but compared to 48 prednisone alone, individuals treated with rituximab plus short-term prednisone had decreased 49 cumulative exposure to prednisone and fewer adverse effects, 2 including known risk factors for Conversely, physicians should discuss that rituximab may reduce immune response to 63 vaccination, 5 which may decrease the ability of patients to effectively receive a COVID-19 64 vaccine.", [["rituximab", "CHEMICAL", 80, 89], ["prednisone", "CHEMICAL", 132, 142], ["rituximab", "CHEMICAL", 175, 184], ["prednisone", "CHEMICAL", 201, 211], ["prednisone", "CHEMICAL", 252, 262], ["rituximab", "CHEMICAL", 368, 377], ["COVID-19 64", "CHEMICAL", 494, 505], ["prednisone", "CHEMICAL", 132, 142], ["prednisone", "CHEMICAL", 201, 211], ["prednisone", "CHEMICAL", 252, 262], ["rituximab", "SIMPLE_CHEMICAL", 80, 89], ["prednisone", "SIMPLE_CHEMICAL", 132, 142], ["rituximab", "SIMPLE_CHEMICAL", 175, 184], ["prednisone", "SIMPLE_CHEMICAL", 201, 211], ["prednisone", "SIMPLE_CHEMICAL", 252, 262], ["rituximab", "SIMPLE_CHEMICAL", 368, 377], ["patients", "ORGANISM", 460, 468], ["patients", "SPECIES", 460, 468], ["rituximab", "TREATMENT", 80, 89], ["other therapies", "TREATMENT", 97, 112], ["prednisone", "TREATMENT", 132, 142], ["rituximab", "TREATMENT", 175, 184], ["short-term prednisone", "TREATMENT", 190, 211], ["prednisone", "TREATMENT", 252, 262], ["fewer adverse effects", "PROBLEM", 267, 288], ["rituximab", "TREATMENT", 368, 377], ["immune response", "PROBLEM", 389, 404], ["a COVID", "TREATMENT", 492, 499]]], ["The response to vaccination appears to improve when given 6 months or more after 65 rituximab dosing.", [["rituximab", "CHEMICAL", 84, 93], ["rituximab", "SIMPLE_CHEMICAL", 84, 93], ["vaccination", "TREATMENT", 16, 27], ["65 rituximab dosing", "TREATMENT", 81, 100]]], ["5 Immune response to infection itself may similarly be blunted, theoretically 66 leading to risk of re-infection.", [["infection", "DISEASE", 21, 30], ["infection", "PROBLEM", 21, 30], ["blunted", "PROBLEM", 55, 62], ["re-infection", "PROBLEM", 100, 112], ["infection", "OBSERVATION", 21, 30], ["re-infection", "OBSERVATION", 100, 112]]], ["67 In summary, we agree with careful consideration of rituximab for patients during the COVID-19 68 pandemic.", [["rituximab", "CHEMICAL", 54, 63], ["rituximab", "SIMPLE_CHEMICAL", 54, 63], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["rituximab", "TREATMENT", 54, 63], ["the COVID", "TEST", 84, 93], ["pandemic", "PROBLEM", 100, 108]]], ["However, with an unknown peak of COVID-19, it may not be feasible or beneficial to 69 delay rituximab.", [["rituximab", "CHEMICAL", 92, 101], ["COVID-19", "CHEMICAL", 33, 41], ["rituximab", "SIMPLE_CHEMICAL", 92, 101], ["COVID", "TEST", 33, 38], ["rituximab", "TREATMENT", 92, 101]]], ["On an individualized basis through shared decision making, dermatologists 70 should consider rituximab for select patients.", [["rituximab", "CHEMICAL", 93, 102], ["rituximab", "SIMPLE_CHEMICAL", 93, 102], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["rituximab", "TREATMENT", 93, 102]]], ["Our approach is to discuss rituximab in patients 71 with severe disease, who might otherwise require high doses of prednisone or more broadly 72 immunosuppressive agents over an extended time period, and those with less severe disease but 73 fewer comorbidities and younger age.", [["rituximab", "CHEMICAL", 27, 36], ["prednisone", "CHEMICAL", 115, 125], ["prednisone", "CHEMICAL", 115, 125], ["rituximab", "SIMPLE_CHEMICAL", 27, 36], ["patients", "ORGANISM", 40, 48], ["prednisone", "SIMPLE_CHEMICAL", 115, 125], ["patients", "SPECIES", 40, 48], ["rituximab", "TREATMENT", 27, 36], ["severe disease", "PROBLEM", 57, 71], ["prednisone", "TREATMENT", 115, 125], ["broadly 72 immunosuppressive agents", "TREATMENT", 134, 169], ["less severe disease", "PROBLEM", 215, 234], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["disease", "OBSERVATION", 64, 71]]], ["Rheumatologic dosing of rituximab, rather than 74 hematologic, can be considered to decrease healthcare exposures, and we would recommend 75 against maintenance dosing in stable patients where the risk of disease flare is deemed low.", [["rituximab", "CHEMICAL", 24, 33], ["rituximab", "SIMPLE_CHEMICAL", 24, 33], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["rituximab", "TREATMENT", 24, 33], ["disease flare", "PROBLEM", 205, 218], ["disease", "OBSERVATION", 205, 212], ["low", "OBSERVATION_MODIFIER", 229, 232]]], ["2 76 Prior to rituximab, we recommend discussing vaccination concerns and general infection control 77 guidance, including social distancing, frequent hand-washing, and use of masks.", [["hand", "ANATOMY", 151, 155], ["rituximab", "CHEMICAL", 14, 23], ["infection", "DISEASE", 82, 91], ["rituximab", "SIMPLE_CHEMICAL", 14, 23], ["rituximab", "TREATMENT", 14, 23], ["vaccination concerns", "TREATMENT", 49, 69], ["general infection control", "TREATMENT", 74, 99], ["frequent hand-washing", "TREATMENT", 142, 163], ["masks", "TREATMENT", 176, 181]]]], "891e5d871c4b4ce18cf85c9ac5b4265c5ab65f5a": [["Para el diagn\u00f3stico virol\u00f3gico se realiz\u00f3 inmunofluorescencia y reacci\u00f3n en cadena de la polimerasa (PCR) en aspirado nasofar\u00edngeo.", [["Para el", "TEST", 0, 7]]], ["El rinovirus fue el segundo agente viral identificado tras el virus respiratorio sincitial (29,9 % de los hospitalizados).", [["El rinovirus", "TEST", 0, 12]]], ["Los diagn\u00f3sticos m\u00e1s frecuentes fueron sibilancias recurrentes en el 60,5 %, bronquiolitis en 23,7 %, neumon\u00eda en el 7,9 % e infecci\u00f3n respiratoria de v\u00edas altas en el 5,3 %.", [["Los diagn\u00f3sticos", "TEST", 0, 16], ["fueron", "TEST", 32, 38], ["sibilancias", "TEST", 39, 50], ["bronquiolitis", "TEST", 77, 90], ["neumon\u00eda", "TEST", 102, 110], ["respiratoria", "TEST", 135, 147]]], ["Presentaron fiebre de m\u00e1s de 38\u00b0C el 57,9 % de los ni\u00f1os e infiltrado radiol\u00f3gico el 23,7 %.", [["radiol\u00f3gico el", "TEST", 70, 84]]], ["En ni\u00f1os mayores de 2 a\u00f1os el diagn\u00f3stico fue crisis asm\u00e1tica en 21 de los 22 casos.ConclusionesLos rinovirus se detectaron en un importante porcentaje de los ni\u00f1os hospitalizados a consecuencia de infecci\u00f3n respiratoria, siendo precedidos en frecuencia s\u00f3lo por el virus respiratorio sincitial.", [["siendo precedidos", "PROBLEM", 222, 239]]], ["Infecci\u00f3n respiratoria.", [["Infecci\u00f3n respiratoria", "SPECIES", 0, 22]]], ["Rinovirus.", [["Rinovirus", "PROBLEM", 0, 9]]], ["Sibilancias recurrentes.ROLE OF RHINOVIRUS IN RESPIRATORY TRACT INFECTIONS IN HOSPITALIZED CHILDREN BackgroundRhinovirus is a recognized cause of common cold and has been shown to cause asthma exacerbations in adults and children.", [["asthma exacerbations", "DISEASE", 186, 206], ["children", "ORGANISM", 221, 229], ["children", "SPECIES", 221, 229], ["Sibilancias recurrentes", "PROBLEM", 0, 23], ["RHINOVIRUS", "PROBLEM", 32, 42], ["Rhinovirus", "PROBLEM", 110, 120], ["common cold", "PROBLEM", 146, 157], ["asthma exacerbations", "PROBLEM", 186, 206], ["RHINOVIRUS", "OBSERVATION", 32, 42], ["RESPIRATORY TRACT", "ANATOMY", 46, 63], ["Rhinovirus", "OBSERVATION", 110, 120]]], ["The burden of rhinovirus infections in hospitalized children has not been described in Spain.ObjectiveTo describe confirmed rhinovirus infections in children hospitalized for respiratory tract infection in a secondary public hospital.INTRODUCCI\u00d3NEs bien conocido que el rinovirus es el agente causal m\u00e1s com\u00fan de las infecciones respiratorias de v\u00edas altas tanto en ni\u00f1os como en adultos.", [["respiratory tract", "ANATOMY", 175, 192], ["rhinovirus infections", "DISEASE", 14, 35], ["rhinovirus infections", "DISEASE", 124, 145], ["respiratory tract infection", "DISEASE", 175, 202], ["rhinovirus", "ORGANISM", 14, 24], ["children", "ORGANISM", 52, 60], ["rhinovirus", "ORGANISM", 124, 134], ["children", "ORGANISM", 149, 157], ["tract", "ORGANISM_SUBDIVISION", 187, 192], ["children", "SPECIES", 52, 60], ["children", "SPECIES", 149, 157], ["rhinovirus infections", "PROBLEM", 14, 35], ["rhinovirus infections", "PROBLEM", 124, 145], ["respiratory tract infection", "PROBLEM", 175, 202], ["INTRODUCCI\u00d3NEs", "TREATMENT", 234, 248], ["burden", "OBSERVATION_MODIFIER", 4, 10], ["rhinovirus", "OBSERVATION_MODIFIER", 14, 24], ["infections", "OBSERVATION", 25, 35], ["rhinovirus", "OBSERVATION", 124, 134], ["respiratory tract", "ANATOMY", 175, 192], ["infection", "OBSERVATION", 193, 202]]], ["En los ni\u00f1os las infecciones por rinovirus son incluso m\u00e1s frecuentes que en los adultos y pr\u00e1cticamente todos los ni\u00f1os han experimentado al menos un catarro por rinovirus a los 2 a\u00f1os 3 .INTRODUCCI\u00d3NSin embargo, ha sido en los \u00faltimos a\u00f1os, desde la introducci\u00f3n de las t\u00e9cnicas de reacci\u00f3n en cadena de la polimerasa (PCR), cuando se ha empezado a conocer la importancia de las infecciones por rinovirus en otros \u00e1mbitos, como causante de infecciones de v\u00edas bajas en lactantes 4 , o como desencadenante de exacerbaciones de asma en escolares 5,6 , en adultos 7, 8 , o en pacientes afectados de enfermedad pulmonar obstructiva cr\u00f3nica 9 .INTRODUCCI\u00d3NEn nuestro pa\u00eds no hemos encontrado datos acerca de las infecciones por rinovirus en ni\u00f1os hospitalizados y su posible papel como inductor de crisis asm\u00e1ticas o episodios de sibilancias recurrentes.", [["En los ni\u00f1os las infecciones", "TREATMENT", 0, 28], ["PCR", "TEST", 321, 324], ["a conocer la importancia", "TREATMENT", 349, 373], ["cr\u00f3nica", "TEST", 630, 637], ["hemos", "PROBLEM", 672, 677]]], ["El objetivo de nuestro trabajo ha sido describir de forma prospectiva las infecciones por rinovirus acontecidas en los ni\u00f1os hospitalizados por patolog\u00eda respiratoria durante una temporada epidemiol\u00f3gica en nuestro centro.MATERIAL Y M\u00c9TODOSEstudio descriptivo prospectivo de las infecciones por rinovirus en ni\u00f1os de 0 a 14 a\u00f1os hospitalizados por in-fecci\u00f3n respiratoria en el Hospital Severo Ochoa (Legan\u00e9s, Madrid) durante los meses de septiembre de 2004 a julio de 2005.", [["respiratoria", "TEST", 154, 166]]], ["Se solicit\u00f3 consentimiento informado verbal a los pacientes para su inclusi\u00f3n en el estudio.MATERIAL Y M\u00c9TODOSDe los 352 ni\u00f1os ingresados por infecci\u00f3n respiratoria, fiebre o crisis asm\u00e1tica, se obtuvo muestra de aspirado nasofar\u00edngeo y consentimiento para participar en el estudio en 304 casos, que fueron los incluidos finalmente en este an\u00e1lisis.", [["respiratoria", "PROBLEM", 152, 164], ["crisis", "PROBLEM", 175, 181]]], ["Se analizaron prospectivamente las variables epidemiol\u00f3gicas de edad, sexo y estacionalidad y las caracter\u00edsticas cl\u00ednicas de los pacientes entre las que se incluyeron la presencia de fiebre, la saturaci\u00f3n transcut\u00e1nea de ox\u00edgeno, la leucocitosis, la prote\u00edna C reactiva s\u00e9rica, el resultado de la radiograf\u00eda de t\u00f3rax, el diagn\u00f3stico cl\u00ednico y la duraci\u00f3n del ingreso.", [["la leucocitosis", "PROBLEM", 231, 246], ["la prote\u00edna C reactiva s\u00e9rica", "PROBLEM", 248, 277], ["la leucocitosis", "ANATOMY", 231, 246], ["la prote\u00edna", "ANATOMY", 248, 259]]], ["Los diagn\u00f3sticos finales fueron definidos como: a) bronquiolitis: primer episodio de broncospasmo asociado a catarro de v\u00edas altas en ni\u00f1os menores de 24 meses, o presencia de hipoxia (saturaci\u00f3n de ox\u00edgeno < 95 % determinado por pulsioximetr\u00eda) e hiperinsuflaci\u00f3n en la radiograf\u00eda de t\u00f3rax en ausencia de broncospasmo (Criterios de McConnochie 10 ); b) episodio recurrente de sibilancias: infecci\u00f3n respiratoria con sibilancias habiendo presentado alg\u00fan episodio similar previo, en ni\u00f1os menores de 2 a\u00f1os; c) neumon\u00eda: infiltrado focal con consolidaci\u00f3n en la radiograf\u00eda de t\u00f3rax en ausencia de sibilancias; d) s\u00edndrome febril en el que se descarta otra etiolog\u00eda infecciosa; e) infecci\u00f3n respiratoria de v\u00edas altas (IRVA): s\u00edntomas catarrales, sin broncospasmo asociado, acompa\u00f1ados o no de fiebre; f) laringitis aguda: obstrucci\u00f3n de la v\u00eda a\u00e9rea superior acompa\u00f1ada de estridor inspiratorio, y g) crisis asm\u00e1tica: episodio de dificultad respiratoria y sibilancias espiratorias en ni\u00f1os mayores de 2 a\u00f1os.MATERIAL Y M\u00c9TODOSLas variables cuantitativas se expresan como media \u00b1 desviaci\u00f3n est\u00e1ndar y las variables cualitativas como proporciones.", [["proporciones", "CHEMICAL", 1136, 1148], ["proporciones", "CHEMICAL", 1136, 1148], ["a catarro de v\u00edas", "TREATMENT", 107, 124], ["pulsioximetr\u00eda", "TEST", 230, 244], ["e hiperinsuflaci\u00f3n en la radiograf\u00eda", "TREATMENT", 246, 282], ["infecci\u00f3n", "PROBLEM", 391, 400], ["respiratoria", "PROBLEM", 401, 413], ["habiendo", "TEST", 430, 438], ["presentado", "TEST", 439, 449], ["episodio", "PROBLEM", 456, 464], ["infiltrado", "PROBLEM", 522, 532], ["focal con consolidaci\u00f3n", "PROBLEM", 533, 556], ["en la radiograf\u00eda", "TREATMENT", 557, 574], ["d) s\u00edndrome febril", "PROBLEM", 612, 630], ["s\u00edntomas catarrales", "PROBLEM", 728, 747], ["crisis", "PROBLEM", 904, 910]]], ["Todo el an\u00e1lisis fue realizado empleando el Statistical Package of Social Science (SPSS), Versi\u00f3n 10.0.Estudio virol\u00f3gicoA todos los pacientes se les recogi\u00f3 una muestra de secreciones respiratorias obtenidas mediante aspirado nasofar\u00edngeo, que se remitieron en medio de transporte vi-ral al Servicio de Virolog\u00eda del Centro Nacional de Microbiolog\u00eda, Instituto de Salud Carlos III de Madrid, donde se procesaron en las 24 h siguientes a su recogida.", [["Versi\u00f3n", "TEST", 90, 97]]], ["El estudio virol\u00f3gico se realiz\u00f3 empleando una parte de cada muestra y realizando en ella inmunofluorescencia, congelando a continuaci\u00f3n el resto de la muestra a -70\u00b0C.Estudio virol\u00f3gicoSe realiz\u00f3 inmunofluorescencia y PCR para virus respiratorio sincitial tipos A y B (VRS-A y B), adenovirus, influenza A, B y C, y parainfluenza 1, 2, 3 y 4, y coronavirus seg\u00fan nuestro grupo ha descrito previamente 11 en todas las muestras de aspirado nasofar\u00edngeo.", [["adenovirus", "ORGANISM", 282, 292], ["Estudio", "TEST", 168, 175], ["virol\u00f3gicoSe", "TEST", 176, 188], ["adenovirus", "PROBLEM", 282, 292], ["influenza", "PROBLEM", 294, 303]]], ["Adem\u00e1s se ha estudiado la presencia de metapneumovirus humano, mediante dos ensayos independientes de reacci\u00f3n en cadena de la polimerasa en tiempo real (RT-PCR) seg\u00fan se detalla en una publicaci\u00f3n previa de nuestro grupo 12 .", [["metapneumovirus humano", "DISEASE", 39, 61], ["metapneumovirus", "ORGANISM", 39, 54], ["PCR", "TEST", 157, 160]]], ["Para el diagn\u00f3stico de la infecci\u00f3n por rinovirus se emple\u00f3 RT-PCR m\u00faltiple que ha sido previamente descrita tambi\u00e9n por nuestro grupo 13 .RESULTADOSSe estudiaron durante la temporada epidemiol\u00f3gica 2004/2005 un total de 352 ni\u00f1os de 11 d\u00edas a 10 a\u00f1os con infecci\u00f3n respiratoria, siendo el 59 % varones (208).", [["RESULTADOSSe estudiaron durante la temporada epidemiol\u00f3gica 2004/2005 un total de 352 ni\u00f1os", "SPECIES", 139, 230], ["Para el diagn\u00f3stico", "TEST", 0, 19], ["rinovirus", "TEST", 40, 49], ["PCR", "TEST", 63, 66], ["respiratoria", "TEST", 266, 278]]], ["Se identificaron 76 muestras positivas para rinovirus correspondientes a 76 episodios de 72 ni\u00f1os, lo que supone un 25 % de los pacientes hospitalizados.", [["Se identificaron", "TEST", 0, 16]]], ["El virus m\u00e1s frecuentemente identificado fue el VRS que supuso el 41,5 % de los aislamientos (tabla 1).RESULTADOSDe los 76 casos con infecci\u00f3n por rinovirus, 54 fueron de 2 a\u00f1os o menores (71,1 %) con una edad media de 266,2 \u00b1 185 d\u00edas y 22 mayores de 2 a\u00f1os con una edad media de 1.660,9 \u00b1 787,4 d\u00edas (4,5 \u00b1 2 a\u00f1os).", [["El virus m\u00e1s", "TEST", 0, 12], ["d\u00edas", "TEST", 297, 301]]], ["El 69,7 % de los pacientes fueron varones.", [["fueron varones", "SIMPLE_CHEMICAL", 27, 41], ["El", "TEST", 0, 2]]], ["Se detectaron coinfecciones en 30 de los 76 casos (39,5 %), siendo el adenovirus el agente m\u00e1s frecuente (tabla 2).", [["siendo el adenovirus", "TREATMENT", 60, 80]]], ["Los aislamientos de rinovirus se obtuvieron en dos picos de mayor frecuencia el primero de ellos en septiembre y el segundo en febrero-marzo ( fig. 1) .RESULTADOSLos diagn\u00f3sticos finales del total de los pacientes con infecci\u00f3n por rinovirus fueron sibilancias recurrentes o crisis de asma en el 60,5 % de los casos, bronquiolitis en el 23,7 %, neumon\u00eda en el 7,9 % e IRVA en el 5,3 %.", [["Los aislamientos de rinovirus se obtuvieron en dos picos", "TREATMENT", 0, 56], ["neumon\u00eda", "TEST", 345, 353]]], ["Los ni\u00f1os con infecci\u00f3n \u00fanica por rinovirus tuvieron como diagn\u00f3stico sibilancias de repetici\u00f3n o crisis asm\u00e1tica de forma m\u00e1s frecuente (28/33, 84,8 %) que los ni\u00f1os con infecciones mixtas (17/31, 54,8 %) de forma significativa (p = 0,009), no encontr\u00e1ndose diferencias en el resto de variables analizadas.RESULTADOSPara intentar establecer el papel del rinovirus como desencadenante de sibilancias recurrentes o crisis asm\u00e1ticas en la infancia, se analiz\u00f3 el agente viral detectado en el total de los pacientes ingresados durante la temporada 2004/2005 con estos diagn\u00f3sticos, detect\u00e1ndose rinovirus en el 31 % de los casos, seguido por el VRS que caus\u00f3 el 23,6 % de las exacerbaciones de asma.", [["Los ni\u00f1os con infecci\u00f3n", "TREATMENT", 0, 23], ["mixtas", "TEST", 183, 189], ["crisis", "PROBLEM", 414, 420], ["diagn\u00f3sticos", "TEST", 565, 577]]], ["En el 29,7 % de estos episodios no se detect\u00f3 ning\u00fan agente viral (tabla 5).DISCUSI\u00d3NA la luz de nuestros resultados, el rinovirus en nuestro medio, es globalmente el agente viral que con m\u00e1s frecuencia se detecta en pacientes con sibilancias de repetici\u00f3n o crisis asm\u00e1ticas en la infancia y uno de los agentes m\u00e1s frecuentemente implicados en infecciones respiratorias de la suficiente consideraci\u00f3n para precisar ingreso hospitalario.DISCUSI\u00d3NEl VRS es el pat\u00f3geno responsable con mayor frecuencia de bronquiolitis en los lactantes y tambi\u00e9n de episodios de sibilancias recurrentes, pero la importancia del rinovirus ha sido infraestimada por la ausencia de m\u00e9todos diagn\u00f3sticos suficientemente sensibles.", [["En el", "TEST", 0, 5], ["crisis", "PROBLEM", 259, 265]]], ["Desde la introducci\u00f3n de las t\u00e9cnicas de PCR viral 14, 15 , el rinovirus se perfila como el segundo agente en importancia en los lactantes tanto como causante de bronquiolitis 16 , como de 17 , han valorado el papel del rinovirus en el desarrollo posterior de asma en ni\u00f1os en edad escolar, encontrando que el padecer una hospitalizaci\u00f3n por infecci\u00f3n respiratoria por rinovirus en la lactancia, confiere un riesgo relativo de padecer asma cuatro veces superior al de los ni\u00f1os que sufrieron un ingreso de similares caracter\u00edsticas por VRS.", [["viral", "TEST", 45, 50], ["el rinovirus", "TEST", 60, 72], ["han valorado el papel del rinovirus", "TREATMENT", 194, 229], ["respiratoria", "PROBLEM", 352, 364]]], ["En nuestra serie, el rinovirus es el segundo agente en frecuencia en las infecciones respiratorias en lactantes (25 %), siendo un importante causante de bronquiolitis y tambi\u00e9n de episodios de sibilancias recurrentes.TABLA 3.", [["TABLA 3", "CHEMICAL", 217, 224], ["TABLA 3", "GENE_OR_GENE_PRODUCT", 217, 224], ["TABLA 3", "PROTEIN", 217, 224]]], ["Porcentaje de diagn\u00f3sticos en el total de los pacientes hospitalizados y analizados en la temporada 2004-2005 y en los ni\u00f1os en los que se identific\u00f3 rinovirus (RV) tanto como agente viral \u00fanico como en coinfecci\u00f3n con otro virusEn cuanto a los ni\u00f1os mayores de 2 a\u00f1os, son cada vez m\u00e1s los trabajos que definen al rinovirus como el agente causal del 60-70 % de las exacerbaciones asm\u00e1ticas 5, 18, 19 , fundamentalmente en pacientes hospitalizados 20 .", [["RV", "ANATOMY", 161, 163]]], ["Cuando se analizan temporadas epidemiol\u00f3gicas completas, como es nuestro caso, las exacerbaciones de asma relacionadas con rinovirus se detectan fuera de la \u00e9poca invernal, en oto\u00f1o y en la primavera, que es la \u00e9poca de circulaci\u00f3n del rinovirus.", [["del rinovirus", "OBSERVATION", 232, 245]]], ["En nuestra serie, el rinovirus fue el agente identificado en el 43,8 % de las crisis asm\u00e1ticas de los ni\u00f1os mayores de 2 a\u00f1os y se detect\u00f3 fundamentalmente en septiembre y en febrero y marzo.TABLA 3.", [["TABLA 3", "CHEMICAL", 191, 198], ["TABLA 3", "GENE_OR_GENE_PRODUCT", 191, 198], ["TABLA 3", "PROTEIN", 191, 198]]], ["Porcentaje de diagn\u00f3sticos en el total de los pacientes hospitalizados y analizados en la temporada 2004-2005 y en los ni\u00f1os en los que se identific\u00f3 rinovirus (RV) tanto como agente viral \u00fanico como en coinfecci\u00f3n con otro virusJartti et al 21 en una serie reciente de ni\u00f1os finlandeses con sibilancias, de todas las edades, cubriendo dos temporadas epidemiol\u00f3gicas casi completas, sientan en nuestra opini\u00f3n el papel de los diferentes virus como agentes desencadenantes de asma.", [["rinovirus", "TEST", 150, 159], ["viral \u00fanico como en coinfecci\u00f3n", "TREATMENT", 183, 214], ["RV", "ANATOMY", 161, 163]]], ["En su experiencia el VRS es el virus detectado con mayor frecuencia en ni\u00f1os menores de un a\u00f1o, pero despu\u00e9s los picornavirus (enterovirus y rinovirus) pasan a ocupar el primer lugar sobre todo en los ni\u00f1os mayores de 3 a\u00f1os llegando a involucrarse en el 82 % de las crisis asm\u00e1ticas.", [["enterovirus y rinovirus", "DISEASE", 127, 150], ["picornavirus", "PROBLEM", 113, 125]]], ["Ellos encuentran un 4 % de infecciones por metapneumovirus, siendo el 11 % en los menores de un a\u00f1o.", [["metapneumovirus", "ORGANISM", 43, 58], ["metapneumovirus", "PROBLEM", 43, 58]]], ["Los resultados de estos autores son muy parecidos a los encontrados en nuestra serie.TABLA 3.", [["TABLA 3", "CHEMICAL", 85, 92], ["TABLA 3", "GENE_OR_GENE_PRODUCT", 85, 92], ["TABLA 3", "PROTEIN", 85, 92]]], ["Porcentaje de diagn\u00f3sticos en el total de los pacientes hospitalizados y analizados en la temporada 2004-2005 y en los ni\u00f1os en los que se identific\u00f3 rinovirus (RV) tanto como agente viral \u00fanico como en coinfecci\u00f3n con otro virusCuando las t\u00e9cnicas de diagn\u00f3stico virol\u00f3gico empleadas en las infecciones respiratorias incluyen un amplio repertorio de virus (PCR m\u00faltiple), las infecciones virales m\u00faltiples representan un importante porcentaje de casos (19,5 % en la serie de Papadopoulus et al 16 ) , siendo el rinovirus uno de los agentes m\u00e1s frecuentemente implicados y al que se atribuye incluso conferir una mayor severidad cl\u00ednica.", [["rinovirus", "TEST", 150, 159], ["otro virus", "TEST", 219, 229], ["respiratorias", "TEST", 304, 317], ["un amplio repertorio de virus", "PROBLEM", 327, 356], ["las infecciones virales", "PROBLEM", 373, 396], ["% en la serie de Papadopoulus et al", "TREATMENT", 459, 494], ["RV", "ANATOMY", 161, 163]]], ["En nuestra casu\u00edstica, las infecciones m\u00faltiples asociadas con rinovirus son muy elevadas (39,5 %), por encima de otras series publicadas, lo que seguramente es atribuible a que no es habitual encontrar en la literatura m\u00e9dica trabajos que realicen una bater\u00eda tan completa de diagn\u00f3stico virol\u00f3gico en todas las muestras.TABLA 3.", [["TABLA 3", "CHEMICAL", 322, 329], ["TABLA 3", "GENE_OR_GENE_PRODUCT", 322, 329], ["TABLA 3", "PROTEIN", 322, 329]]], ["Porcentaje de diagn\u00f3sticos en el total de los pacientes hospitalizados y analizados en la temporada 2004-2005 y en los ni\u00f1os en los que se identific\u00f3 rinovirus (RV) tanto como agente viral \u00fanico como en coinfecci\u00f3n con otro virusEl papel de las coinfecciones virales es dif\u00edcil de establecer.", [["viral \u00fanico como en coinfecci\u00f3n", "TREATMENT", 183, 214], ["otro virusEl papel", "TREATMENT", 219, 237], ["RV", "ANATOMY", 161, 163]]], ["Mientras algunos autores encuentran que confieren mayor severidad al cuadro, o al menos que influyen en el curso natural de las infecciones, otros creen que no aportan una mayor gravedad 22 .", [["Mientras", "TEST", 0, 8]]], ["En este sentido, Nokso-Koivisto et al 23 realizaron un estudio en 107 ni\u00f1os de un mes a 16 a\u00f1os sanos, que iban a ser sometidos a cirug\u00eda, en busca de picornavirus y coronavirus en el aspirado nasofar\u00edngeo.", [["Nokso", "TEST", 17, 22]]], ["En esta misma direcci\u00f3n, van Benten et al 24 en una cohorte de ni\u00f1os seguidos desde el nacimiento a los 2 a\u00f1os de forma ambulatoria, encuentran que el rinovirus es el agente causal de infecciones respiratorias m\u00e1s frecuente a esta edad (60 %), aunque hasta en un 20 % de los ni\u00f1os con aspirado nasofar\u00edngeo positivo para rinovirus no encuentran patolog\u00eda concomitante.TABLA 3.", [["TABLA 3", "CHEMICAL", 368, 375], ["TABLA 3", "GENE_OR_GENE_PRODUCT", 368, 375], ["TABLA 3", "PROTEIN", 368, 375], ["a esta edad", "TEST", 224, 235]]], ["Porcentaje de diagn\u00f3sticos en el total de los pacientes hospitalizados y analizados en la temporada 2004-2005 y en los ni\u00f1os en los que se identific\u00f3 rinovirus (RV) tanto como agente viral \u00fanico como en coinfecci\u00f3n con otro virusRakes et al 19 estudian episodios de crisis asm\u00e1ticas en ni\u00f1os de 2 meses a 16 a\u00f1os en urgencias y les realizan determinaci\u00f3n viral en aspirado nasofar\u00edngeo, empleando adem\u00e1s un grupo control de ni\u00f1os valorados por otras patolog\u00edas.", [["viral \u00fanico como en coinfecci\u00f3n con otro virus", "TREATMENT", 183, 229], ["viral en aspirado nasofar\u00edngeo", "TREATMENT", 355, 385], ["RV", "ANATOMY", 161, 163]]], ["Ellos encuentran hasta un 40 % de rinovirus en los controles asintom\u00e1ticos, pero en estos pacientes no se valor\u00f3 si hab\u00edan pasado un catarro de v\u00edas altas los d\u00edas previos ni si desarrollaron despu\u00e9s una infecci\u00f3n respiratoria como lo hizo el grupo de Nokso-Koivisto et al 23 .", [["una infecci\u00f3n", "PROBLEM", 200, 213]]], ["Nosotros no disponemos en nuestro trabajo de un grupo control de pacientes hospitalizados por otras patolog\u00edas para conocer el porcentaje de ni\u00f1os ingresados con detecci\u00f3n asintom\u00e1tica de rinovirus.TABLA 3.", [["TABLA 3", "CHEMICAL", 198, 205], ["TABLA 3", "GENE_OR_GENE_PRODUCT", 198, 205], ["TABLA 3", "PROTEIN", 198, 205]]], ["Porcentaje de diagn\u00f3sticos en el total de los pacientes hospitalizados y analizados en la temporada 2004-2005 y en los ni\u00f1os en los que se identific\u00f3 rinovirus (RV) tanto como agente viral \u00fanico como en coinfecci\u00f3n con otro virusEn nuestra serie, un 7,9 % de los pacientes con infecci\u00f3n por rinovirus fueron diagnosticados de neumon\u00eda.", [["RV", "ANATOMY", 161, 163]]], ["El ri-", [["El ri-", "CHEMICAL", 0, 6]]]], "64022ee1166bb1462744e24162b4b833a198200e": [["1 Prime minister Hashimoto sought ASEAN's support for Japan's crisis-hit economy in face of China's increasing economic and political power.", [["Japan's crisis", "PROBLEM", 54, 68]]], ["3 The fi nal compromise reached by ASEAN countries resulted in holding three separate summits attended by each country of the North, and, separately, one common EAS (the decision was made at the Second ASEAN Informal Summit held from 14 to 16 December 1997) .", [["The fi nal compromise", "PROBLEM", 2, 23], ["nal compromise", "OBSERVATION", 9, 23]]], ["It can be concluded that Hashimoto's doctrine-as planned by its creator-led to establishing ASEAN\u2212Japan Summits, but it also resulted in the APT First Summit (Tanaka 2007 ).", [["Hashimoto's doctrine", "DISEASE", 25, 45], ["Hashimoto's doctrine", "TREATMENT", 25, 45]]], ["4 In this context, it is worth mentioning that ASEAN leaders decided to develop an outline for the structure of ASEAN+3 before the outbreak of the Asian fi nancial crisis.", [["Asian fi nancial", "SPECIES", 147, 163], ["nancial crisis", "OBSERVATION", 156, 170]]], ["However, the Asian crisis had a major impact on intensifying intraregional cooperation, justifying this form of mutual contacts.", [["the Asian crisis", "PROBLEM", 9, 25]]], ["Consequently, in the context of the failure to establish the AMF (right after the outbreak of the crisis), and contrary to the original plans to focus the summit debates on diplomatic issues, the First APT Summit was dominated by discussions related to the rapidly deteriorating fi nancial crisis.", [["the failure", "PROBLEM", 32, 43], ["the AMF", "PROBLEM", 57, 64], ["diplomatic issues", "PROBLEM", 173, 190], ["the rapidly deteriorating fi nancial crisis", "PROBLEM", 253, 296], ["failure", "OBSERVATION", 36, 43], ["nancial crisis", "OBSERVATION", 282, 296]]], ["However, apart from the fact that the Second Informal ASEAN Summit in Kuala Lumpur proposed the ASEAN Vision 2020, it did not lead to any signifi cant resolutions or agreements adopted by a larger composition of participants extended by the ASEAN+3 structure.", [["ASEAN", "PROTEIN", 241, 246], ["participants", "SPECIES", 212, 224]]], ["It was a breakthrough event in terms of APT's institutionalisation process.", [["a breakthrough event", "PROBLEM", 7, 27]]], ["The participants decided to establish regular ASEAN+3 Summits, accompanying all ASEAN summits (offi cial and informal).", [["participants", "SPECIES", 4, 16]]], ["In addition to that, Kim Dae-jung proposed establishing the East Asia Vision Group (EAVG)-a group composed of outstanding intellectuals from APT countries, acting as an ASEAN+3 group of advisors for creating long-term visions for the region's revitalisation and mutual economic cooperation.", [["creating long-term visions", "TREATMENT", 199, 225]]], ["Another step in the process of ASEAN+3's institutionalisation was a proposal made by Hu Jintao to hold meetings of East Asian fi nancial experts.", [["ASEAN+3's institutionalisation", "TREATMENT", 31, 61]]], ["7 Simultaneously, Japan proposed establishing the New Miyazawa Initiative-fi nancial support offered to crisis-hit countries in the amount of USD 30 billion (see Sect.", [["the New Miyazawa Initiative-fi nancial support", "TREATMENT", 46, 92]]]]}